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dose for an adult to that of a child based on the child’s bodyweight. This oversimplification 
of pediatric physiology commonly resulted in drug plasma concentrations either 
below	 or	 above	 adult	 reference	 concentrations.	 Then,	 a	 series	 of	 reports	 of	 children	
who experienced either severe drug toxicity or lack of effect raised awareness on this 
oversimplification. A classic example is the case of toxic exposure to chloramphenicol 
with fatal cardiovascular collapse (grey baby syndrome) in neonates as a result.4 This 
was ascribed to underdevelopment of drug metabolism in neonates. But even recently 
there have been cases of serious adverse events in pediatric drug treatment partly 
explained	by	ontogeny.	To	illustrate	this,	in	2017	the	US	Food	and	Drug	Administration	
(FDA)	restricted	the	use	of	codeine	and	tramadol	as	the	risk	of	apnea	appears	greater	in	
children younger than 12 years.5,6 Another example is the precipitation of ceftriaxone 
with	calcium-containing	products,	which	resulted	in	fatal	cases	in	neonates	only.7
Regulations on pediatric drug development
Well,	 why	 did	 we	 have	 limited	 information	 on	 drug	 therapy	 in	 pediatrics	 when	 the	
drug development processes carried out by pharmaceutical companies are extremely 
regulated? Wasn’t there any pediatric data when the drugs entered the market? Pediatric 
drug development is challenged by ethical concerns and logistical issues. In the earlier 
days,	 pharmaceutical	 companies	 were	 not	 obliged	 to	 study	 their	 compounds	 in	
children,	and	excluded	children	from	experimental	trials	because	they	were	considered	
vulnerable as developing humans. Serious adverse event such as sketched above 
brought	realization	that	 it	 is	actually	unethical	 to	not	conduct	studies	 in	children.	For	
example,	 the	 drugs	 that	 could	 be	 valuable	 for	 certain	 disease	 conditions	 in	 children	
were	made	available	‘off-label’,	but	an	appropriate	benefit-risk	analysis,	including	dose	
finding,	 as	 is	 mandatory	 for	 adults,	 was	 lacking.	 Therefore,	 over	 the	 years,	 specific	
regulations for pediatric drug development have been established (see Table 1 for an 
overview of the key landmarks). These regulations mandated pediatric research and 
have greatly increased expertise and activity in pediatric drug development.
Ontogeny of drug metabolism and membrane transport




Cytochrome	 P450s	 (CYPs)	 and	 phase	 2	 enzymes	 like	 UDP-glucuronosyltransferase	
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(UGTs).	These	drug	metabolizing	enzymes	biotransform	the	parent	drug	into	active	and/







not yet expressed or differentially expressed during fetal life. Hence ontogeny of drug 
metabolizing	 enzymes	 and	 transporters	 occurs,	 influencing	 the	 disposition	 of	 their	
endogenous and exogenous substrates over age.2,3	Drug	metabolizing	enzymes	work	
together with membrane transporters located in various organs to detoxify the body 
from	exogenous	compounds,	like	drugs	and	food	toxins,	and	to	maintain	homeostasis	





to pediatrics are necessary.
Innovation in developmental pharmacology
Better understanding of the underlying processes involved in drug disposition may aid to 
better	predict	drug	disposition	and	create	age-appropriate	dosing	guidelines	for	use	in	
Table 1 Key	landmarks	in	pediatric	medicines	regulation.	Adapted	from	Germovsek et al.8
Year Regulation Impact
1997 US	FDA	Modernization	Act	(FDAMA) This act presented the financial incentive of an additional 
6 months	of	market	exclusivity	to	companies	undertaking	
required pediatric studies








Sponsors required to undertake clinical studies in children for 
new medicines and biological products
2006 EU	Pediatric	Regulation Introduction	of	new	legislation	in	the	European	Union	mandating	










The latter is specifically important for pediatric research where tissues are scarcely 
available.	 Second,	 innovative	 study	 designs	 using	 radioactive	 labelled	 microtracers	
allowed	 to	 study	 –	without	 risk	 for	 the	 child	 –	 the	 oral	 bioavailability	 of	 compounds	
used	as	a	marker	for	certain	drug	metabolism	pathways.	Feasibility	of	these	designs	to	
assess	 age-associated	changes	metabolism	was	 shown	 for	paracetamol.10,11	Third,	 the	
use of modeling and simulation to support dosing recommendations in a pediatric trial 
or even to substitute a pediatric trial in children is supported by both the EMA and the 
US	FDA.12,13	As	a	result,	physiologically	based	PK	(PBPK)	models,	that	include	age-specific	
physiologic	 information,	 are	 increasingly	 being	 used,	 not	 only	 to	 aid	 pediatric	 drug	
development but also to improve drug therapy of existing compounds.
Mind the gaps and try to close them
Although the knowledge on ontogeny of drug metabolism and transport has increased 
over	time,	important	knowledge	gaps	remain,	some	of	which	are	explained	below.
Membrane transporter ontogeny in the liver and kidney
The importance of membrane transporters in drug disposition and effect has received 
increasing attention in recent years.14-17	 In	 light	 of	 this,	 ex vivo transporter gene and 
protein	expression	studies	using	pediatric	tissues	allow	to	learn	whether	there	are	age-
related changes in the expression of these membrane transporters. These studies are 
dependent	on	the	availability	of	pediatric	tissues,	which	is	rather	an	exception	than	the	
rule,	but	these	tissues	may	be	obtained	from	unique	biobanks.
Recently,	 the	hepatic	protein	expression	 levels	of	10	clinically	 relevant	transporters	 in	






CYP3A ontogeny in the intestine and liver
The	 drug	metabolizing	 enzyme	CYP3A	 is	well	 known	 for	 its	 involvement	 in	 >50%	of	
metabolized	drugs,	and	is	abundantly	present	in	the	intestine	and	liver.	CYP3A	consists	
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of	 the	 three	 main	 isoforms	 CYP3A4,	 -3A5	 and	 -3A7,	 for	 which	 substrate	 specificity	
differs.19,20 In vitro	 studies	 have	 shown	 that	 hepatic	 CYP3A7	 abundance	 decreases	
rapidly	 after	birth,	 and	 that	hepatic	 and	 intestinal	CYP3A4	abundance	 increases	with	
increasing age.21-23	CYP3A5	is	polymorphically	expressed	with	a	stable	expression	from	






reflecting	 CYP3A	 in	 the	 intestine	 and	 liver.	 In	 preterm	 infants	 (gestational	 age	 26-31	
weeks	and	postnatal	age	3-13	days),	the	oral	midazolam	clearance	was	markedly	lower	
(0.16	 L/h/kg	 vs	 3.0	 L/h/kg),	 and	 the	 oral	 bioavailability	 higher	 than	 those	 in	 children	
beyond	1	year	of	age	(49-92%	vs	21%)	and	in	adults	(49-92%	vs	37%).33-35 These findings 
suggest	 developmentally	 lower	 intestinal	 and/or	 hepatic	 CYP3A	 activity	 in	 preterm	
neonates.
Although the oral bioavailability of midazolam has been studied in children31,33-36,	there	
is a distinct knowledge gap for term neonates to children <1 year old. This knowledge 
gap	hampers	dose	predictions	 for	oral	CYP3A	substrates	 to	be	prescribed	 to	 this	age	
group.
The	classical	study	design	to	obtain	data	on	oral	bioavailability	entails	a	cross-over	study	
in	which	an	oral	 and	 IV	dose	of	 a	drug	are	administered	alternately,	with	a	wash-out	
period in between. This design is ethically and practically challenging as children are 
exposed twice to therapeutic drug doses with extensive blood sampling. An interesting 
alternative	 is	a	microtracer	study	with	a	 [14C]-labelled	drug.	A	microdose	 is	defined	as	
‘<1/100th	 of	 the	 no	 observed	 adverse	 effect	 level	 (NOAEL)	 or	 <100	 µg’.37,38	The	 [14C]-
label allows quantification of extremely low plasma concentrations by accelerator 
mass	 spectrometry	 (AMS)	 in	 only	 10-15µl	 plasma.39,40 A microdose can be used in an 
elegant	 design	 as	 a	 microtracer	 in	 which	 an	 oral	 [14C]-labelled	 drug	 is	 administered	
simultaneously	 with	 therapeutic	 IV	 doses	 of	 the	 same	 unlabeled	 drug	 or	 vice versa. 
This	allows	simultaneous	measurement	of	both	the	oral	and	IV	disposition	in	the	same	
subject	and,	with	 that,	quantification	of	 the	oral	bioavailability.10,11 This approach has 
been shown practically and ethically feasible to study developmental changes in 
pharmacokinetics in children.10,11,41
Importantly,	 for	direct	extrapolation	of	exposure	from	microdose	to	therapeutic	dose,	
the	PK	of	the	microdose	must	be	linear	to	the	PK	of	the	therapeutic	dose.42,43 This may 
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1not	 be	 the	 case,	 for	 example,	 when	 a	 therapeutic	 dose	 saturates	 drug	 metabolism	
pathways,	plasma	protein	binding	and/or	active	transporters.43	Dose-linearity	of	the	PK	




Pediatric metabolite in safety testing (MIST) study
Due	 to	 ontogeny	 of	 processes	 involved	 in	 drug	 disposition,	 predicting	 parent	 and	
metabolite exposure of compounds with a complex metabolism is challenging in 
children.46	In	adults,	a	general	approach	to	study	the	parent	and	metabolite	exposures	
of	 a	 drug	 during	 the	 drug	 development	 process,	 is	 performing	 a	 mass	 balance	 and	
metabolite in safety testing (MIST) study to create metabolite profiles.
Just	recently,	advances	mainly	in	analytical	technology	have	enabled	new	approaches	to	
MIST studies with less radioactivity exposure.47,48	By	using	[14C]microtracers	concurrently	
administered	with	a	therapeutic	dose,	metabolites	can	be	identified	and	quantified	with	





to create complete metabolic profiles have not yet been conducted in children.
Ontogeny data in literature
The accuracy of predicting pediatric drug exposure is highly dependent on the available 
ontogeny profiles of drug metabolizing enzymes and transporters. While increasing 
pediatric	data	become	available	in	literature,	results	are	often	limited	in	age	range	and	
fragmented	 in	 several	 publications.	 Therefore,	 new	 data	 are	 needed,	 in	 combination	
with better accessibility of all the available in vitro and ex vivo	data.	Moreover,	creating	
high-resolution	quantitative	ontogeny	profiles	will	aid	to	improve	existing	models	and	
to specify remaining information gaps.
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AIMS AND OUTLINE OF THIS THESIS
Based	on	the	above-mentioned	knowledge	gaps,	the	aims	of	this	thesis	are:
•	 To	 review	 the	 current	 literature	 and	 quantitatively	 describe	 ontogeny	 of	 hepatic	
membrane transporters and drug metabolizing enzymes.
•	 To	study	the	ontogeny	of	relevant	human	membrane	transporters	gene	and	protein	









From literature to bench to clinical research
The outline of this thesis is tailored to the common approach in research; starting with 
literature	research	(Part	I),	going	to	fundamental	(ex vivo)	research	on	the	bench	(Part	II),	
and taking it into clinical research (Part III).
First,	in	Part	I	the	hepatic	ontogeny	of	drug	transporters	and	drug	metabolizing	enzymes	
is captured in a quantitative review in chapter 2. A review of the ontogeny of drug 
transporters in all major organs is presented in chapter 3.
Part II focuses on our ex vivo studies. Chapter 4 and chapter 5	 address	 age-related	
changes in gene and protein expression of clinically relevant hepatic and renal 
transporters.	To	better	understand	observed	age-related	variation	in	transporter	protein	
expression,	in	chapter 6 alternative splicing of the OATP1B1 transporter as a mechanism 
for developmentally regulated expression is explored.
Part III presents the results of two clinical pediatric studies. Chapter 7 shows the dose 
linearity	of	an	intravenous	[14C]midazolam	microdose	in	children.	The	oral	bioavailability	
of	midazolam	in	children	0-6	years	as	determined	by	a	[14C]midazolam	microtracer	study	
is described in chapter 8. Chapter 9 presents the pilot results of the first pediatric MIST 
study with midazolam as an example compound.
Part	IV	puts	the	results	of	the	studies	in	a	broader	perspective,	and	areas	of	current	and	
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clearance	 in	pediatric	patients.	 Physiologically-based	pharmacokinetic	 (PBPK)	models	




modeling	 in	 the	drug	application	 review	process.	Yet,	 significant	 knowledge	gaps	on	
developmental	biology	still	exist,	which	must	be	addressed	to	increase	the	confidence	
of	 prediction.	 Recently,	 more	 data	 on	 ontogeny	 of	 transporters	 have	 emerged	 and	
supplied a missing piece of the puzzle. This review highlights the recent findings on the 
ontogeny	of	transporters	specifically	 in	the	intestine,	 liver	and	kidney.	 It	also	provides	
a	case	study,	which	illustrates	the	utility	of	incorporating	this	information	in	predicting	
drug	 exposure	 in	 children	 using	 a	 PBPK	 approach.	 Collaborative	 work	 has	 greatly	
improved the understanding of the interplay between developmental physiology and 
drug disposition. Such efforts will continually be needed to address the remaining 






medicine.1 This is mainly because drug development for treatment in pediatric patients 
is challenged by ethical concerns and logistical issues.2 As children widely differ from 
adults due to developmental changes in the biological processes involved in the 
disposition	 of	 drugs,	 this	 leaves	 them	 at	 risk	 for	 subtherapeutic	 or	 toxic	 exposures.	 3 
The	establishment	of	the	Best	Pharmaceuticals	for	Children	Act	(BPCA)	in	2002	and	the	
Pediatric	Research	Equity	Act	 (PREA)	 in	2003,	which	were	made	permanent	under	the	
Food	 and	 Drug	 Administration	 Safety	 and	 Innovation	 Act	 (FDASIA)	 in	 2012,	 and	 the	
European	‘Paediatric	Regulation’	(regulation	no	1901-2/2006)	in	2006	have	highlighted	
the	 commitment	 of	 the	 U.S.	 Food	 and	 Drug	 Administration	 (FDA)	 and	 the	 European	
parliament	 and	 council	 to	 conduct	 studies	 in	 pediatric	 patients,	 and	 thereby	 fill	 the	
pediatric gaps in drug development to increase the safety and efficacy of pediatric drug 
therapy.4-6
With the advancement of in silico	 technologies,	novel	methodologies	 such	as	model-
informed	drug	development	(MIDD)	can	leverage	our	existing	understanding	of	pediatric	
physiology,	 disease	 states	 and	 pharmacology.	 This	 provides	 quantitative	 information	
to	 streamline	decision-making	 in	drug	development,	 such	 as	 clinical	 trial	 design	 and	
dose	optimization,	which	can	increase	the	success	of	pediatric	clinical	trials.7 To support 
this,	 FDA	has	 committed	 to	 advance	MIDD	under	 the	Prescription	Drug	User	 Fee	Act	
(PDUFA)	VI,	with	approaches	that	 include	convening	a	series	of	workshops	to	 identify	





to	support	submissions	to	the	FDA	and	European	Medicines	Agency	(EMA).9,10 Of all the 
PBPK	analyses	that	were	included	in	the	New	Drug	Application	(NDA)	submissions	to	the	
FDA	between	2008	and	2017,	60%	were	utilized	to	assess	enzyme-mediated	drug-drug	
interactions	 (DDIs).	This	was	 followed	by	 15%	of	 the	 submissions	 that	 supported	 the	
evaluation	of	pediatric-related	 issues	such	as	 initial	dose	 recommendation	 for	clinical	
trials,	 and	 7%	 that	 analyzed	 transporter-mediated	 DDIs.9	 During	 the	 FDA	 Advisory	




gaps	 in	 areas	 such	as	 the	ontogeny	of	membrane	 transporters,	 and	 thereby	may	not	
predict drug exposure well.11
Given	 that	 new	data	 on	 the	 ontogeny	 of	membrane	 transporters	 has	 emerged	 since	
2012,	 the	 objective	 of	 this	 article	 is	 to	 review	findings	 from	 recent	 studies	 that	 have	
evaluated pediatric developmental changes in the membrane transporters.
ONTOGENY OF MEMBRANE TRANSPORTERS
Membrane transporters facilitate the active movement of drug molecules and 
endogenous	 compounds	 into	 and	 out	 of	 cells	 of	 various	 organs,	 affecting	 drug	
absorption,	distribution	 and	excretion.12	Hence,	 they	have	 a	 critical	 role	 in	 impacting	
pharmacokinetics	(PK)	and	pharmacodynamics	(PD)	of	drugs,	and	should	be	considered	
and	assessed	carefully	during	drug	development.	 In	 the	2017	FDA’s	draft	 in vitro	DDI	
guidance,	 FDA	 recommended	 the	evaluation	of	DDI	potential	by	 studying	whether	 a	
Table 1. The	full	name,	protein	names	and	gene	names	of	the	membrane	transporters	that	are	discussed	
in this review
Full name Protein name Gene name
P-glycoprotein P-gp ABCB1
Breast	Cancer	Resistance	Protein BCRP ABCG2
Multidrug and Toxin Extrusion 1 MATE1 SLC47A1
Multidrug	and	Toxin	Extrusion	2-K MATE2-K SLC47A2
Organic Anion Transporting Polypeptide 1B1 OATP1B1 SLCO1B1
Organic Anion Transporting Polypeptide 1B3 OATP1B3 SLCO1B3
Organic Anion Transporter 1 OAT1 SLC22A6




Peptide Transporter 1 PEPT1 SLC15A1
Sodium/taurocholate	Cotransporting	Polypeptide NTCP SLC10A1
Bile salt export pump BSEP ABCB11
Glucose	transporter	1 GLUT1 SLC2A1
Glucose	transporter	2 GLUT2 SLC2A2




new drug is a potential substrate or inhibitor of the following nine transporters (see 







on the data available for the ontogeny of clinically relevant membrane transporters.14 
Further,	the	working	group	also	provided	recommendations	to	address	and	overcome	
some of the challenges in filling the pediatric knowledge.14 These include building 
multidisciplinary	 and	 international	 collaborative	 networks	 to	 facilitate	 data	 sharing,	
increasing awareness of clinicians about the importance of transporters in pediatric 
drug disposition and identifying biomarkers for transporter activity in children. In the 
following discussion and in Table 2,	human	data	presented	in	that	review	are	highlighted,	
and updated information from recent literature is provided. Figure	1 also depicts the 
human	membrane	transporters	in	the	intestine,	liver	and	kidneys	that	are	mentioned	in	
this article.
Ontogeny of intestinal transporters
Most drugs prescribed to children are administered orally.37 The intestine is a major 
absorption site of drugs that are administered via oral route. Transporters that are 
present in the enterocytes on the gut wall mucosa govern the initial access into the 




intestinal absorption of drugs in human.40	 Further,	 peptide	 transporter	 (PEPT)1	 is	 a	
major	uptake	transporter	that	facilitates	absorption	of	peptide-like	drugs	in	the	systemic	
circulation	such	as	β-lactam	antibiotics.38,41	Therefore,	drug	absorption	 in	children	will	
be highly dependent on the expression and activity of these intestinal transporters.
P-gp, BCRP, MRPs, OATP2B1 and PEPT1:	 In	 their	 review,	 Brouwer	 et	 al	 noted	 that	
ontogeny of intestinal transporters was mainly revealed by mRNA expression and 
localization data using immunohistochemistry.14	 P-gp	 and	 MRP2	 mRNA	 expression	
levels in neonates and infants appeared to be comparable to adults.17-24	 Localization	
data	suggested	that	BCRP	and	MRP1	distribution	was	similar	in	adult	and	fetal	samples	




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1 Summary	 of	 the	 human	 membrane	 transporters	 in	 the	 intestine,	 liver	 and	 kidneys	 that	 are	
mentioned in this review. 
Transporters with only mRNA or limited data are depicted in brown circles; whereas those that have both gene 
expression and protein abundance data are depicted in green circles. (adapted/modifi ed from Brouwer et al and 
Chu et al)15,16 Noteworthy, the localization of OATP2B1 remains questionable. Future investigation would also be 
needed to characterize if its localization is subject to developmental changes.
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intestinal	transporters,	OATP2B1	gene	expression	levels	were	much	higher	in	neonates	
than in adults.23	 Noteworthy,	 the	 localization	 of	 OATP2B1	 remains	 questionable;	
while two studies observed localization of the transporter to the apical membrane of 
human	enterocytes,	another	research	group,	which	studied	mainly	pediatric	 intestinal	
tissue	samples,	detected	OATP2B1	 in	 the	basolateral	membrane.25,42-44 This basolateral 
localization was also reported by another independent group using six healthy human 




changes in PEPT1 mRNA expression and localization.25 While PEPT1 expression appeared 
to	be	slightly	lower	in	neonates	than	in	their	older	counterparts,	the	tissue	distribution	
was relatively stable among all the samples studied.
While changes in the gene expression and localization of these transporters during 
development	 were	 stressed	 in	 various	 published	 studies,	 data	 on	 their	 protein	
expression	 levels	are	still	missing.	 In	addition,	 the	ontogeny	patterns	of	other	human	
intestinal	transporters,	such	as	OATP1A2	and	MCT1,	remain	uncertain.	Since	many	drugs	
are	administered	orally,	 it	 is	crucial	 to	fill	 this	knowledge	gap	 in	 intestinal	 transporter	
ontogeny.
Ontogeny of liver transporters
In	 comparison	 to	 intestinal	 transporters,	 data	 on	 developmental	 changes	 in	 hepatic	
transporters	 have	 grown	quite	 rapidly	 recently.	 Classic	 analytical	 approaches	 include	




utilized	 to	 measure	 the	 absolute	 protein	 abundance	 of	 these	 transporters,	 allowing	
the quantification of many transporters in only a small amount of tissue. Proteomics 
data generated from two independent laboratories complemented each other in 
terms of age range of the samples and provided a more complete picture of the 




adult	 samples	 (>	16	years	old).29	 In	another	 study,	 the	absolute	protein	expression	of	





samples from adults).28 The findings in these two studies and other previous studies are 
discussed below.
OCT1:	 As	 previously	 reported,	 OCT1	mRNA	 levels	 in	 pediatric	 livers	 appeared	 to	 be	
comparable to that in adult livers.14,26	 Nonetheless,	 OCT1	 protein	 levels	 have	 shown	
to	 undergo	 age-dependent	 increase.27-29 This was supported by a recently published 
clinical study in neonates who were admitted to the neonatal intensive care unit where 
postmenstrual	age	as	well	as	OCT1	genotype	 impacted	the	PK	of	 the	OCT1	substrate	






higher in the fetal livers compared to that term neonatal livers. The protein expressions 
in	infants,	children	and	adults	were	similar.28 OATP1B1 is highly polymorphic. The impact 
of genetic variants on developmental changes in OATP1B1 expression was investigated 
in this cohort but no association was identified for the studied genotypes. When all 
tissue	samples	were	considered,	Prasad	et	al	reported	that	OAPT1B1	did	not	show	age-
dependent changes in the protein expression.29	Yet,	when	the	analysis	was	performed	
on	samples	from	donors	with	the	OATP1B1	reference	allele,	*1A/*1A,	samples	from	>	1	
year old was found to have higher protein expression than the 0 to 12 months group. 
Notably,	 in	 the	>1-year-old	 cohort,	OATP1B1	expression	was	 about	 2.5-fold	higher	 in	
samples	from	donors	with	*14/*1A	than	that	with	*15/*1A.
OATP1B3:	Similar	to	OATP1B1,	mRNA	expression	of	OATP1B3	was	reported	to	be	much	
lower	 in	 fetuses,	neonates	and	 infants	compared	 to	adults.14,23 While proteomics data 
in	one	study	showed	that	OATP1B3	expression	was	not	associated	with	age,	the	other	
illustrated	 that	 the	 expression	 of	 the	 transporter	 was	 subjected	 to	 age-dependent	
increase,	and	by	6	months	of	age,	similar	to	OCT1,	the	protein	expression	would	have	
reached	50%	of	the	adult	level.28,29
OATP2B1: mRNA levels of OAT2B1 was significantly higher in adult livers compared 
to	 that	 in	 livers	 from	 fetus	 at	 gestational	 age	 18-23	weeks.14,30	 However,	 quantitative	
proteomics	 suggested	 that	 OATP2B1	 expression	 in	 liver	 from	 fetus	 of	 median	 23.4	
(range	15.3-41.3)	weeks	was	comparable	to	that	from	preterm	neonates,	term	neonates,	
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children and adults.28 This lack of correlation with age was supported by two other 
analyses.29,31
NTCP:	Various	studies	suggested	that	maturation	of	NTCP	starts	during	perinatal	stage	
and the expression reaches adult levels at birth.14,29,30,32,33	 Protein	 expression	 of	 NTCP	






which then reached a level comparable to adults.22	Despite	the	developmental	changes	
in	gene	expression,	one	study	reported	no	age-related	differences	in	the	relative	protein	
expression in patients from 0.3 to 12 years old.34	Interestingly,	however,	the	results	from	
the	two	recent	proteomic	studies	were	in	agreement	with	the	mRNA	data	–	P-gp	protein	
expression was low in fetal liver tissues but increased with age.28,29	 Further,	TM50 was 
also	estimated	to	be	2.94	years	old,	suggesting	that	the	P-gp	expression	continued	to	
increase postnatally and would achieve adult level later on in children.29
MRP2:	Using	gene	expression	analysis,	previous	studies	have	shown	that	MRP2	mRNA	
levels	were	 substantially	 lower	 in	 fetal,	 neonatal	 and	 infant	 livers	 compared	 to	 older	
children up to 12 years of age.14,23,35 The result reported in one of the recent proteomic 





age,	 and	 was	 significantly	 lower	 than	 that	 found	 in	 adult	 livers.30 Proteomic data 
from recent studies agree with this observation. The fetal MRP3 protein level was 
approximately	 3-folder	 lower	 than	 the	 adult	 level.28 Interestingly it was found in one 
study that the transporter expression appeared to be lower in adolescents compared to 
that in adults. 29
MRP1, MRP4, MRP6:	Developmental	information	on	these	three	MRPs	is	scarce.	In	their	
study,	van	Groen	et	al	showed	that	MRP1	levels	in	livers	from	fetus	and	term	neonates	
were	 about	 two-fold	 lower	 than	 that	 in	 adults.28	 MRP4	 mRNA	 did	 not	 change	 with	









age	 and	 postmenstrual	 age	 within	 the	 fetal	 and	 newborn	 cohort,	 BCRP	 expression	
interestingly	showed	age-dependent	decrease	with	a	spearman	correlation	coefficients	
of	-0.345	and	-0.421,	respectively.28
BSEP:	 Using	 sandwich-cultured	 fetal	 and	 adult	 hepatocytes,	 a	 functional	 study	
was	 conducted,	 which	 showed	 that	 the	 biliary	 excretion	 index	 for	 taurocholate,	 an	
endogenous	BSEP	substrate,	was	lower	in	the	fetal	liver	cells	compared	to	that	in	adults.30 
Results from quantitative proteomics studies coincide with this observation; the fetal 
liver tissues expressed significantly lower BSEP compared to term newborn and adults.28 
Maturation of BSEP appeared to occur mainly during perinatal period as no significant 
age-dependent	changes	were	seen	from	neonates	onwards.28,29
MATE1:	In	contrast	to	the	age-dependent	increase	in	mRNA	reported	previously,	protein	
expression of MATE1 appeared to be independent of age.14,28,29
GLUT1:	 Developmental	 information	 for	 GLUT1	 was	 previously	 lacking	 but	 recent	
proteomic	study	indicated	that	GLUT1	expression	showed	age-dependent	decrease	with	




MCT1:	 Similar	 to	 GLUT1,	 the	 ontogeny	 of	 MCT1	 was	 missing.	 The	 absolute	 protein	
abundance of this transporter was found to be comparable in fetal liver and in other age 
groups after birth.28
Recent knowledge gain on liver transporters
Recent proteomics studies provided valuable ontogeny information for the liver 
transporters. Although gaps in the developmental changes in various liver transporters 





Ontogeny of renal transporters
The kidney is the major site for elimination of many drugs. Three major processes are 
involved	 in	 drug	 disposition:	 glomerular	 filtration,	 active	 secretion	 and	 reabsorption.	
Maturation of glomerular filtration has been studied quite extensively but information 
on	 ontogeny	 of	 renal	 membrane	 transporters,	 which	 are	 key	 players	 in	 the	 active	
secretion was relatively scarce.14,48	Yet,	 information	on	 the	developmental	 changes	 in	
renal	membrane	transporters	has	emerged	recently.	Gene	expression	of	11	transporters	





other age groups but the protein abundance appeared to be comparable across all age 
groups	from	term	neonates	to	adults.	Further	studies	would	be	warranted	to	investigate	
this	 lack	 of	 gene-protein	 correlation	 as	 only	 one	 term	 neonate	was	 included	 for	 the	
proteomic analysis in that study.36
MATE1 and MATE2-K: mRNA and protein levels of MATE1 were independent of age.36 
While	 transcript	 level	 of	MATE2-K	 in	 term	 newborn	was	 significantly	 lower	 than	 that	
in	 adults,	 the	protein	was	 found	 to	be	 comparable	 across	 all	 the	 age	groups	 studied	
from	 term	newborn	 to	adults.	However,	 similar	 to	BCRP,	 the	 cohort	of	 term	neonates	
for proteomic analysis would need to be expanded in order to better characterize the 
correlation between gene and protein expression.
MRP2 and MRP4:	mRNA	 levels	of	MRP2	and	MRP4	appeared	 to	be	 stable	 in	preterm	
newborn,	 term	newborn,	 infants,	 children	 and	 their	 older	 counterparts.	 Interestingly,	
proper	MRP4	localization	was	detected	as	early	as	GA	27	weeks,	postnatal	9	day	old.	This	
result appeared to accompany the stable gene expression during development.36









adolescents and adults. This observation appeared to be translated well to protein 
expressions.	 Sigmoidal	 Emax	 model	 described	 this	 age-dependent	 increase	 and	 the	
TM50 was approximately 1 month.36
GLUT2:	An	efficient	carrier	of	glucose,	GLUT2,	did	not	show	age-dependent	changes	in	
its mRNA expression and protein abundance.36
OAT1 and OAT3:	The	ontogeny	of	these	two	organic	anion	transporters	were	reflected	
in clinical data.48	 For	 instance,	 one	 study	 showed	 that	 the	 secretion	 capacity	 of	
p-aminohippurate	(PAH),	an	OAT1/3	substrate,	appeared	to	be	about	one-fifth	of	adult	
level at birth.49-51	These	observed	age-related	changes	in	pharmacokinetics	of	transporter	
substrates are likely due to a combination of maturation in both transporter expression 
and	glomerular	filtration.	Yet,	 the	changes	 in	 transcript	 levels	and	protein	abundance	
aligned with the clinical observations. mRNA and protein expressions for both OAT1 
and OAT3 increased with age with TM50	 of	 approximately	 5	 months	 and	 8	 months,	
respectively.	Further,	inter-transporter	correlation	analysis	also	demonstrated	that	these	
two transporters were highly correlated in their gene and protein expression.36
OCT2:	Similar	to	OATs	and	P-gp,	the	OCT2	mRNA	levels	and	protein	abundance	are	age-
dependent with the levels in newborns being significantly lower compared to children and 
adults.	Like	P-gp,	OCT2	would	reach	half	of	the	adult	level	about	one	month	after	birth.36
Recent knowledge gain on renal transporters
The	 data	 from	 gene	 expression	 analysis,	 quantitative	 proteomics	 and	
immunohistochemistry have painted a more complete picture for the ontogeny of renal 










APPLICATION OF ONTOGENY OF TRANSPORTERS TO MIDD IN CHILDREN
Overall,	there	has	been	a	recent	surge	in	data	on	the	ontogeny	of	membrane	transporters,	
which will greatly enhance our understanding in not only the disposition of drug 
substrates but the involvement of these transporters in developmental physiology in 
children. While scarce data in the ontogeny of intestinal transporters still limits their 
application	to	modeling	and	simulation	of	oral	drugs,	the	wealth	of	data	in	the	domain	
of hepatic and renal transporter ontogeny present an opportunity to be leveraged for 
pediatric	PBPK	modeling,	especially	 for	 intravenous	administrated	drugs,	 to	assist	 the	
prediction in drug disposition and clearance in children.
The	workflow	of	pediatric	PBPK	model	development	has	been	previously	described	(see	
Figure	2).54-57	In	most	cases,	an	adult	PBPK	model	is	first	established,	verified	and	refined.	
This model is comprised of the drug profile as well as the virtual adult population in 




weights and protein abundance of drug metabolizing enzymes and transporters) using 
algorithms or parameters such as ontogeny scaling factor for transporter abundance or 
Figure 2 Workflow	of	the	pediatric	physiologically-based	pharmacokinetic	model	(PBPK)	establishment	to	
simulate drug exposure in children. 
An adult PBPK model was first established and verified by comparing the output from the simulations to that 
in observed data. After ensuring that adult model was robust, the pediatric model was generated by scaling 
the anatomical and physiological parameters using default age-dependent algorithms, and incorporating 
ontogeny information for the transporters that are pertinent to this study. The pediatric PBPK model was verified, 
once again, by comparing the output from the simulation input with observed data from literature. Predictive 
performance of allometry and PBPK in estimating the clearance in children was also evaluated.
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intrinsic clearance. These are expressed as a function of age and can be derived from 
the developmental changes in the expression data described in previous section. Of 
note,	while	pediatric	PBPK	models	can	also	be	established	based	on	drug	physiological	
properties	and	preclinical	data	alone,	this	approach	could	lead	to	a	lower	confidence	in	
the prediction compared to a model that is verified with adult clinical data.
The	success	and	confidence	of	PBPK	modeling	and	simulation	that	involves	transporter-
mediated	 disposition	 using	 bottom-up	 approach	 are	 critically	 dependent	 on	 factors	
such as the quality and availability of transporter kinetic data and understanding in in 
vitro-in	vivo	correlation.	The	following	case	study	illustrates	that	the	utility	of	leveraging	
transporter	ontogeny	data	in	PBPK	modeling,	with	sufficient	information	gathered,	can	
be useful to simulate drug exposure in pediatric patients.59
PBPK modeling with integrated transporter ontogeny reasonably predicted the 
exposure of an actively renally secreted drug in children
Tazobactam	is	a	beta-lactamase	inhibitor.	Currently,	it	is	formulated	as	an	intravenously-
administered	combination	product	with	either	piperacillin,	a	beta-lactam,	or	ceftolozane,	
a	 cephalosporin,	 as	 a	 broad-spectrum	 antibiotic.60,61 Tazobactam is prescribed for 
infections that could potentially be life threatening when left untreated. Hence 
sufficient exposure is needed to assure therapeutic action without adverse events. As 
much	as	80%	of	 tazobactam	 is	 renally	 cleared	 in	adults.61,62 In addition to glomerular 
filtration,	tazobactam	undergoes	active	tubular	secretion	that	is	mediated	by	OAT1	and	
OAT3.62,63	The	remaining	tazobactam	is	either	converted	to	the	inactive	metabolite,	M1,	
via hydrolysis and then eliminated renally or undergoes biliary excretion (Figure	3).62,64
The	workflow	of	 the	adult	and	pediatric	PBPK	model	establishment	 is	 summarized	 in	
Figure	2.	OAT1/	3	protein	abundance	and	transporter	kinetics	from	 in vitro studies are 
Figure 3 The elimination pathway of tazobactam. 
After intravenous administration, approximately 80% of tazobactam would be cleared renally by glomerular 
filtration and active secretion via OAT1 and OAT3. Majority of the rest of tazobactam would undergo hydrolysis 
to form the inactive metabolite, tazo-M1, which, similar to the parent drug, will be eliminated renally. A small 
amount (<1%) of tazobactam would undergo biliary excretion.
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obtained from literature.36,63	 The	 ontogeny	 scaling	 factors,	 which	 are	 the	 sigmoidal	
Emax	 functions,	of	OAT1/3	were	 incorporated.36 To address the argument on whether 
PBPK	modeling	 is	 preferred	over	 an	 allometric	 scaling	 approach	 in	predicting	 the	PK	
for	 pediatric	 patients	 <	 2	 years	 old,	 the	 clearance	 in	 the	 pediatric	 cohorts	were	 also	
estimated	based	on	allometry	and	compared	to	that	predicted	using	PBPK	models.9
Figure 4 Simulation	of	 tazobactam	exposure	 in	adult	population	 (a)	and	three	pediatric	cohorts	 (b	–	d)	
using	PBPK	(PK-Sim	v7.3).
Following 500mg x 60min infusion in the virtual adult population, the predicted Cmax, AUC and CL were 
between 1.02-1.2-fold of the observed data.65 Three pediatric cohorts were generated: 0-3 months old (b), 3 
months-2 years old (c), and 2-7 years old (d). By taking into account the physiological and anatomical changes 
during development, and the ontogeny of transporters that are pertinent to the disposition of tazobactam, 
the tazobactam exposure was predicted reasonably well with Cmax, AUC and CL were all within 1.5-fold of 
observed data.66 Allometric scaling approach resulted in CL estimation that were comparable to that predicted 
using PBPK. However, for the youngest age group, 0-3 months old (b), PBPK model performed slightly better as 




in	 adults	well	with	 the	predicted	maximal	 concentration	 (Cmax),	 area	 under	 the	 curve	
(AUC)	 and	 clearance	 (CL)	 between	 1.02-	 to-1.2-fold	 of	 the	 observed	 data	 (Fig	 4a).65 
After	 verifying	 and	 ensuring	 that	 the	 adult	model	was	 robust,	 three	 virtual	 pediatric	
populations	 were	 generated	 using	 the	 approach	 as	 outlined	 above:	 0	 to	 3	 months,	
3	months	 to	2	years	old,	2	 to	7	years	old.	Cmax,	AUC	and	CL	were	all	within	1.5-fold	of	
observed	data	when	the	simulation	was	performed	in	these	three	cohorts,	suggesting	
that	 the	 pediatric	 PBPK	model	 predicted	 the	 exposure	 of	 tazobactam	 adequately	 in	




This	 case	 study	 illustrated	 the	utility	of	 a	pediatric	PBPK	model	with	 integrated	 renal	
transporter ontogeny function in simulating exposure of a drug that is actively renally 






The recent emergence of quantitative proteomics data on the expression and 
ontogeny	of	transporters	substantially	improves	the	predictive	power	of	pediatric	PBPK	
models	 for	drug	substrates.	Nonetheless,	 there	are	 important	 factors	 that	need	 to	be	
considered	 when	 incorporating	 protein	 abundance	 into	 PBPK	models.	While	 LC-MS/
MS based quantitative proteomics is a powerful tool by using peptide sequences to 
measure	the	absolute	abundance	of	transporter	proteins,	 it	could	not	acknowledge	 if	
the	 transporters	 are	 successfully	 localized	 to	 the	membrane,	 nor	 could	 it	 distinguish	
truncated	protein	and	splice	variants	from	properly	formed	proteins,	and	glycosylated	
and	 not-glycosylated	 protein.67	 Consequently,	 these	 would	 undermine	 the	 assumed	
correlation	 between	 transporter	 expression	 and	 activity.	 Further,	 scaling	 from	 the	
protein abundance data per crude membrane protein or per gram tissue level to per organ 
level	is	the	first	step	when	integrating	such	data	into	PBPK.	This	should	be	done	carefully	
as	parameters	that	are	used	to	scale,	such	as	membrane	protein	yield	per	gram	of	tissue	
could	also	subject	to	age-related	changes.28	Lastly,	 it	 is	 important	to	reiterate	that	the	
success	of	PBPK	simulation	in	children	using	bottom-up	approach	depends	highly	on	the	
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specific populations such as pediatrics. This understanding is supported by the expansion 
of	knowledge	in	the	ontogeny	of	membrane	transporters,	especially	those	in	the	liver	
and	kidney.	This	increased	knowledge	has	significant	implications	for	PBPK	modeling	for	
drug substrates and therefore is of great importance for pediatric drug development. 
However,	 knowledge	gaps	 in	 the	ontogeny	of	 transporters	 in	 the	 intestine	and	other	
important	barrier	 tissues	 such	as	 the	blood-brain	barrier	 remain,	 and	are	 awaiting	 to	
be	 addressed	 through	 future	 collaborative	work.	 Further	 investigation	would	 also	be	
required to elucidate how gene and protein expression relate to transporter activity. 
Lastly,	as	illustrated	in	the	case	study,	in	addition	to	ontogeny,	a	thorough	understanding	
of	the	disposition	of	drugs	and	their	interplay	are	critical	in	the	application	of	PBPK	to	
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Background: Hepatic membrane transporters are involved in the transport of many 
endogenous	 and	 exogenous	 compounds,	 including	 drugs.	 We	 aimed	 to	 study	 the	
relation	of	 age	with	absolute	 transporter	protein	expression	 in	a	 cohort	of	62	mainly	





and genetic variants with TaqMan assays. We explored relationships between protein 
expression	and	age	(gestational	age	[GA],	postnatal	age	[PNA],	and	postmenstrual	age);	
between protein and mRNA expression; and between protein expression and genotype.
Results: We	analyzed	36	fetal	(median	GA	23.4	weeks	[range	15.3-41.3]),	12	premature	
newborn	(GA	30.2	weeks	[24.9-36.7],	PNA	1.0	weeks	[0.14-11.4]),	10	term	newborn	(GA	
40.0	weeks	 [39.7-41.3],	 PNA	3.9	weeks	 [0.3-18.1]),	 4	pediatric	 (PNA	4.1	 years	 [1.1-7.4])	
and	 8	 adult	 liver	 samples.	 A	 relationship	with	 age	was	 found	 for	 BSEP,	 BCRP,	 GLUT1,	
MDR1,	 MRP1,	 MRP2,	 MRP3,	 NTCP	 and	 OATP1B1,	 with	 the	 strongest	 relationship	 for	
postmenstrual	 age.	 For	 most	 transporters	 mRNA	 and	 protein	 expression	 were	 not	
correlated.	No	genotype-protein	expression	relationship	was	detected.
Discussion and conclusion:	Various	developmental	patterns	of	protein	expression	of	
13 hepatic transporters emerged in fetuses and newborns up to four months of age. 
Postmenstrual age was the most robust factor predicting transporter expression in 
this cohort. Our data fill an important gap in current pediatric transporter ontogeny 
knowledge.
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INTRODUCTION




Children	 admitted	 to	 a	 neonatal	 or	 pediatric	 intensive	 care	 unit	 may	 receive	 many	
drugs. Earlier it was shown that infants with normal weight received on average four 
different	drugs,	and	infants	with	an	extreme	low	birth	weight,	often	prematurely	born,	
up to 17 drugs.2 Many of these drugs are substrates for transporters3,	and	the	expression	
and	activity	of	 certain	 transporters	 are	known	 to	be	 subject	 to	age-related	changes.1 
An	example	of	a	transporter	substrate	is	morphine,	which	is	widely	used	in	newborns	
and	children.	Morphine	is	taken	up	into	the	hepatocyte	by	the	transporter	OCT1,	where	
it	 is	 glucuronidated	 mainly	 by	 UGT2B7.4	 Data	 suggest	 lower	 protein	 expression	 of	
hepatic	OCT1	in	younger	age	groups5,6,	leading	to	elevated	plasma	levels	and	therefore	
posing	a	higher	 risk	of	adverse	events	 like	respiratory	depression.	However,	 the	exact	
developmental	pattern	of	OCT1	in	fetuses	and	premature	newborns	is	not	known,	while	
data for other transporters are also scarce or even lacking.1,3
In	neonates	and	young	infants,	age	can	be	defined	in	various	ways:	gestational	age	(GA)	
-	 reflecting	duration	of	pregnancy	at	birth;	postnatal	 age	 (PNA)	–	 the	age	after	birth;	
and	postmenstrual	age	(PMA)	–	the	combination	of	gestational	age	and	postnatal	age.	
Both	GA	 and	birth	 are	 important	determinants	 of	 postnatal	 gene	 expression	of	 drug	
metabolizing enzymes.7 We hypothesize that this also accounts for drug transporters. 
More insight in the relative importance of these determinants could help personalize 
drug dosing in this young vulnerable population.
Previously,	 we	 explored	 the	 hepatic	 protein	 expressions	 of	 10	 clinically	 relevant	
transporters	 in	 25	 liver	 samples	 from	 fetuses,	 neonates	 and	 young	 infants.8 Protein 
expression	 of	 a	 number	 of	 these	 transporters	 was	 related	 to	 age,	 and	 important	
transporter-specific	 differences	 were	 found.	While	 this	 exploratory	 study	 was	 clearly	
informative,	 the	sample	size	was	too	small	 to	define	transporter-specific	maturational	
patterns. A recent publication from Prasad et al. describes the postnatal ontogeny of 
hepatic	drug	transporters	in	a	wider	cohort,	but	the	younger	ages	(<four	months)	were	
not well represented.6	 Data	 on	 gene	 expression	 of	 transporters	 in	 the	 younger	 ages	




Besides	 ontogeny,	 drug	 transporter	 expression	 and	 activity	 can	 be	 influenced	 by	
genetic	variants,	as	described	in	adults.9	For	SLC22A1/OCT1	a	relationship	with	genotype	
was	suggested	by	variation	in	the	pharmacokinetics	of	tramadol,	an	OCT1	substrate,	in	
preterm	infants,	even	when	 in vitro data suggested developmentally low expression.10 
This is interesting as for some drug metabolizing enzymes the interplay between 
development and genetics obscures an effect of genetic variation. But pediatric clinical 
data for transporters substrates are scarce.
In the current study we aimed to elucidate the developmental expression patterns of 
various hepatic drug transporters in an expanded cohort of mainly fetal and newborn 
samples	up	to	18	weeks	PNA,	also	including	the	samples	from	our	previous	pilot	study.	
The	large	variation	in	GA	and	PNA	in	this	cohort	enabled	us	to	analyze	whether	PNA	or	
PMA correlates strongest with transporter expression. We also investigated correlation 
between	 protein	 expression	 and	 mRNA	 expression	 in	 a	 subset	 of	 this	 cohort,	 and	
analyzed	whether	genotype,	in	addition	to	age,	explains	the	variability	in	expression	of	







or	 stillbirths)	 and	 infants	 were	 provided	 by	 the	 Erasmus	MC	Tissue	 Bank.	 Tissue	was	
procured	at	the	time	of	autopsy	within	24	hours	after	death	and	snap-frozen	at	-800C	
for	 later	 research	 use.	 The	 Erasmus	 MC	 Research	 Ethics	 Board	 waived	 the	 need	 for	
formal	 ethics	 approval	 according	 to	 the	Dutch	 Law	 on	Medical	 Research	 in	Humans.	
Tissue was collected when parental written informed consent for both autopsy and the 
explicit use of the tissue for research was present. The samples were selected when the 
clinical diagnosis of the patient was not related to hepatic problems and the tissue was 
histologically normal (Supplemental Table 1).
Human	adult	liver	tissue	samples	were	a	gift	from	Prof.	G.M.M.	Groothuis	(University	of	
Groningen,	Groningen,	the	Netherlands)	(n=3)	and	Prof.	P.	Artursson	(Uppsala	University,	
Uppsala,	 Sweden)	 (n=5).	 These	 had	 been	 collected	 anonymously	 as	 surgical	 waste	
material	after	partial	hepatectomy	because	of	liver	metastasis.	For	these	samples,	a	no-
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objection	clause	permitted	use	for	research	purposes	in	line	with	the	Dutch	guidelines	
on secondary use of human tissue.
Selection of hepatic transporters
Thirteen clinically relevant hepatic transporters were selected (gene name/protein	
name): breast cancer resistance protein (ABCG2/BCRP),	bile	salt	export	pump	(ABCB11/
BSEP),	glucose	transporter	1	(SLC2A1/GLUT1),	monocarboxylate	transporter	1	(SLC16A1/
MCT1),	multidrug	resistance	protein	1	 (ABCB1/MDR1),	multidrug	resistance	associated	
protein (ABCC/MRP)	 1,	 2	 and	 3,	 sodium-taurocholate	 cotransporting	 polypeptide	
(SLC10A1/NTCP),	 organic	 anion-transporting	 polypeptide	 (SLCO/OATP)	 1B1,	 1B3	 and	
2B1,	 and	 organic	 cation	 transporter	 1	 (SLC22A1/OCT1).	 Analysis	 on	 the	 transporters	
MRP1,	NTCP,	OATP1B3	and	OCT1	was	lacking	in	our	pilot	study8,	but	was	added	in	this	
expanded	study	because	of	their	clinical	relevance.	We	also	selected	ATP1A1,	which	is	
often used as a housekeeping protein.6
Protein expression




include	 nuclei,	 mitochondria	 as	 well	 as	 the	 microsomal	 and	 plasma	 membranes.	
Absolute	 transporter	 expression	was	 also	determined	 in	 cell	 pellets	of	HEK-OATP1B1,	
-OATP1B3,	-OCT1,	MDCKII-MDR1,	-MRP2,	and	–BCRP	cells.
Isolation of crude membrane fractions from tissue samples was conducted as follows. 
Approximately 10 mg liver tissue or approximately 20 x 106 cells was homogenized in a 
hypotonic	buffer	(0.5	mM	sodium	phosphate,	0.1	mM	EDTA,	and	a	cocktail	of	protease	
inhibitors	 containing	 2	 mM	 phenylmethylsulfonylfluoride,	 aprotinin,	 leupeptin,	 and	
pepstatin)	using	a	Potter-Elvehjem	homogenizer.	The	homogenate	was	centrifuged	at	





The	 proteins	 were	 subsequently	 reduced	 with	 0.01	 M	 dithiothreitol	 at	 37°C	 for	 60	
minutes	and	alkylated	with	0.04	M	iodoacetamide	for	20	minutes	at	room	temperature	
in	the	dark.	Digestion	was	performed	after	addition	of	CaCl2 (final concentration 1 nM) 
and	 0.5	mg	 trypsin	 in	 17%	methanol	 by	 diluting	 the	 solution	with	 50	mM	NH4HCO3. 
After	 overnight	 incubation	 the	 samples	were	 incubated	 for	 another	 2	 hours	with	 0.5	
94 Chapter	4
mg trypsin to ensure complete digestion of the protein sample. The efficiency of the 
tryptic	digestion	using	this	protocol	was	previously	checked	using	SDS-PAGE	followed	
by	 silver	 stain,	 confirming	 complete	 digestion.11	 Finally	 the	 protein	 digests	 were	
evaporated	by	vacuum	centrifugation	(Scanvac,	Ballerup,	DK)	and	dissolved	in	100	ml	
15%	 acetonitrile	 containing	 0.1%	 formic	 acid	 and	 5	 ng	ml-1	 internal	 standard	 (AQUA	
peptide	mix,	Supplemental Table 2). Samples were analyzed using an ultraperformance 
liquid	 chromatography	 coupled	 to	 a	 6500	 QTrap	 mass	 spectrometer	 (AB	 Sciex,	
Nieuwerkerk	aan	den	IJssel,	the	Netherlands).	Multiple	reaction	monitoring	transitions	
were	determined	from	tandem	mass	spectra,	obtained	by	direct	infusion	of	0.5	mg	mL-1. 
Per	 peptide,	 three	 transitions	 were	 chosen	 (Q3-1,	 Q3-2,	 and	 Q3-3)	 for	 quantification	
and confirmation. A peptide labeled with 15N and 13C	(AQUA	peptide)	was	synthesized	
(Sigma-Aldrich,	 Steinheim,	 DE)	 and	 used	 as	 an	 internal	 standard	 for	 quantification	
(Supplemental Table 2). Peak identification and quantification were performed using 
Analyst	software	version	1.6.
mRNA expression
mRNA expression of the selected drug transporters was determined in a subset of 31 
samples	using	RNA-Sequencing	(RNA-Seq).	RNA	was	isolated	from	hepatic	tissue	using	
QiaSchredder	column	and	RNeasy	Mini	kit	(both	Qiagen,	Valencia,	CA)	as	described	by	
Mooij et al 12.	 Samples	with	an	RNA	 integrity	number	of	<5	were	excluded.	The	RNA-
Seq	 experiments	 were	 performed	 according	 to	 the	 Illumina	 RNA-Seq	 protocol	 (San	
Diego,	 CA).	 In	 brief,	 a	 population	of	 poly(A)+ mRNA was selected and converted to a 
library	of	cDNA	fragments	(220–450	bp)	with	adaptors	attached	to	both	ends,	using	an	
Illumina	mRNA-Seq	sample	preparation	kit.	The	quality	of	 the	 library	preparation	was	
confirmed	 by	 analysis	 on	 a	 2100	 Bioanalyzer	 (Agilent	Technologies,	 Santa	 Clara,	 CA).	
The	cDNA	fragments	were	then	sequenced	on	an	Illumina	HiSeq	2000	to	obtain	100-bp	
sequences from both ends (paired end). The resulting reads were mapped by Bowtie 
213	to	the	transcriptome	constructed	through	annotated	genes/transcripts	according	to	
the	reference	human	genome	GRCh37.61/hg19.	The	mapped	reads	were	then	assigned	
to transcripts from which the expression of each transcript is estimated by RSEM.14 The 
counts	 of	 RNA-Seq	 fragments	were	 used	 to	 indicate	 the	 amount	 of	 identified	mRNA	
transcripts,	presented	in	transcripts	per	million	(TPM).14
For	each	transporter	we	calculated	the	total	TPM	values	of	all	mRNA	transcripts,	and	the	
TPM values of only the mRNA transcripts coding for a full functioning protein (Ensembl 
genome	database).	Correlation	with	protein	 levels	as	determined	 in	 the	same	sample	
was tested with Spearman’s rank correlation coefficient.




expression	 of	 our	 selection	 of	 transporters	was	 expected	 to	 be	 influenced,	 based	on	
information	in	the	PharmGKB	database.15	Liver	samples	of	children	were	genotyped	for	
these SNPs (Supplemental Table 3).	Next,	within	a	particular	genotype	the	effect	of	age	
was studied. Adult samples were not genotyped for logistic reasons. Because previously 




1000	 Spectrophotometer	 (Thermo	 Fisher	 Scientific®).	 The	 DNA	 isolates	 were	 diluted	
in	 1X	 TE	 Buffer	 to	 a	 10	 ng	 μL-1 solution for SNP analysis. The SNPs were genotyped 
according	to	 the	TaqMan®	allelic	discrimination	assays.	The	PCR	program	consisted	of	
an	 initial	denaturation	and	DNA	polymerase	activation	step	at	92°C	 for	20	s,	 followed	
by	40	cycles	at	95°C	for	3	s	and	60°C	for	30	s.	All	PCR	reactions	and	post‐PCR	detection	




named SLCO1B1) or SLCO1B3	 (NM_019844.3)	were	 generated	 as	 previously	 described	
by our group11,16.	 HEK293	 cells,	 stably	 overexpressing	 SLC22A1	 (NM_003057.2),	 were	
generated	in	a	similar	way,	by	transfection	with	pIRES	puro-OCT1	(internally	designed,	
produced	by	Baseclear,	Leiden,	NL),	applying	puromycin	selection	pressure	and	selecting	
colonies	 for	 further	analysis.	MDCKII	cells	 stably	overexpressing	MDR1,	MRP2	or	BCRP	
were	licensed	from	The	Netherlands	Cancer	Institute	(NKI,	Amsterdam).17-19
Data and statistical analysis
Data	are	expressed	as	median	(range),	unless	otherwise	stated.	The	relationship	of	age	
with	 protein	 expression	 levels	 was	 studied	 as	 follows:	 first,	 differences	 in	 expression	
between	age	groups	were	explored.	We	distinguished	five	age	groups:	fetal,	premature	
newborn	(GA	<37	weeks;	PNA	0	–	18	weeks),	term	newborn	(GA	>37	weeks,	PNA	0	–	18	
weeks),	 pediatric	 (1.5	 –	 18	 year)	 and	 adult	 liver	 samples.	 Next,	 in	 the	 combined	 first	
three	age	groups	(further	referred	to	as	fetal/newborn	cohort)	the	correlation	between	
age	on	a	continuous	scale	(GA,	PNA	and	PMA)	and	protein	levels	was	assessed.	Within	
a particular genotype the effect of age on transporter protein expression was studied 
as above. Relationship between mRNA expression and protein expression were studied 
with correlation.
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Kruskal-Wallis	 tests	 with	 Dunn’s	 post-hoc	 test	 were	 used	 for	 multiple	 comparisons	
between	age	groups,	and	Spearman’s	rank	correlation	coefficient	was	used	for	testing	
correlations.	 Influence	of	gender	on	 transporter	protein	expression	was	 tested	with	a	
Mann-Whitney	U	test.	A	two-sided	significance	level	of	p<0.05	is	used	throughout	the	






In	 total	 71	hepatic	 tissue	 samples	were	 available	 for	 the	 study,	 including	25	 samples	
of our pilot study.8 One sample was detected as an outlier due to inexplicably high 
transporter expression and was excluded. See Table 1	for	the	age	distribution.	Gender	
was	 known	 for	 the	 pediatric	 samples	 only:	 35	male	 and	 27	 female.	 The	 Tissue	 Bank	
provided	only	the	following	clinical	data:	GA,	PNA,	gender,	and	main	clinical	diagnosis.	
The adult tissue was histologically normal tissue and no additional clinical data were 
available,	due	to	the	anonymous	sample	collection.
Table 1 Age distribution of study samples in each age group.

















GA=gestational age, PNA=postnatal age, NA=not available.
Protein expression
The selected hepatic transporter proteins were detected in nearly all samples; in two 
samples MRP2 could not be detected. There was high variability in expression between 
transporters and between individual samples (Supplemental	Table	4). Protein expression 
in males and females was similar (Supplemental	Table	5).	Crude	membrane	protein	yield	
per mg tissue was higher in fetuses than in term newborns (Figure	1A).	Moreover,	it	was	
negatively	correlated	with	PNA	and	PMA	in	the	fetal/newborn	cohort	(Figure	1B	and	1C,	
respectively).
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Figure 1 Crude	membrane	protein	 (CMP)	yield	per	amount	of	hepatic	 tissue,	presented	 for	various	age	
groups	(A),	and,	for	the	fetal/newborn	cohort,	for	postnatal	age	(PNA)	(B)	and	postmenstrual	age	(PMA)	(C).	
ρ=Spearmans	rho.
*Significant after Dunn’s test (*p<0.05)
Age-related transporter protein expression
Overall,	 protein	 expression	 was	 highly	 variable	 within	 age	 groups	 (Figure	 2 and 










partly explain the observed variability (Table 2,	Figure	3 and Figure	4).	BCRP,	BSEP	and	
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Figure 2 Protein	 expression	 of	 hepatic	 transporters	 in	 fetuses	 (n=36),	 preterm	 newborns	 (n=12),	 term	
newborns	(n=10),	pediatrics	(n=4)	and	adults	(n=8).
*Significant after Dunn’s test (*p<0.05, **p<0.01, ***p<0.001)
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NTCP	 expression	 significantly	 increased	 with	 increasing	 GA,	 PNA	 and	 PMA,	 whereas	
GLUT1	 and	OATP1B1	decreased.	 For	 these	 transporters	 the	 strongest	 correlation	was	
shown	 for	with	 PMA.	MRP2	 and	MRP3	were	only	 positively	 correlated	with	 PNA,	 and	
MCT1	 only	with	 PMA.	When	 only	 fetal	 samples	 (postnatal	 age	 =	 0)	 are	 included,	 the	
relationship	between	GA	and	transporter	expression	remains	statistically	significant	for	
GLUT1	and	OATP1B1.	 For	 the	other	 transporters	no	 relationship	between	GA,	PNA	or	
PMA and expression was found.





expression	 levels	 and	 protein	 expression	 of	 ABCB11/BSEP,	 SLC16A1/MCT1,	 ABCC2/
MRP2	and	SLC10A1/NTCP	were	significantly	correlated	when	using	total	TPM	values	of	
all mRNA transcripts (Supplemental	Table	6). When only taking into account the mRNA 






GA (n=58)† GA (fetal) (n=36)‡ PNA (n=58)† PMA (n=58)†
ATP1A1 ρ=0.120,	p=0.371 ρ=0.113,	p=0.513 ρ=0.145,	p=0.278 ρ=0.069,	p=0.605
BCRP ρ=-0.367, p=0.005 ρ=-0.301,	p=0.074 ρ=-0.345, p=0.008 ρ=-0.421, p=0.001
BSEP ρ=0.484, p<0.001 ρ=0.230,	p=0.178 ρ=0.485, p<0.001 ρ=0.513, p<0.001
GLUT1 ρ=-0.536, p<0.001 ρ=-0.365, p=0.028 ρ=-0.512, p<0.001 ρ=-0.585, p<0.001
MCT1 ρ=-0.342, p=0.009 ρ=-0.327,	p=0.052 ρ=-0.096,	p=0.473 ρ=-0.345, p=0.008
MDR1 ρ=-0.047,	p=0.728 ρ=-0.119,	p=0.489 ρ=0.064,	p=0.634 ρ=-0.046,	p=0.733
MRP1 ρ=0.069,	p=0.608 ρ=-0.039,	p=0.822 ρ=0.176,	p=0.187 ρ=0.100,	p=0.453
MRP2 ρ=0.202,	p=0.136 ρ=0.084,	p=0.625 ρ=0.306, p=0.022 ρ=0.214,	p=0.114
MRP3 ρ=0.010,	p=0.942 ρ=-0.218,	p=0.202 ρ=0.273, p=0.038 ρ=0.032,	p=0.812
NTCP ρ=0.502, p<0.001 ρ=0.223,	p=0.190 ρ=0.453, p<0.001 ρ=0.567, p<0.001
OATP1B1 ρ=-0.557, p<0.001 ρ=-0.343, p=0.041 ρ=-0.481, p<0.001 ρ=-0.604, p<0.001
OATP1B3 ρ=0.089,	p=0.508 ρ=-0.043,	p=0.804 ρ=0.090,	p=0.499 ρ=0.072,	p=0.589
OATP2B1 ρ=-0.135,	p=0.312 ρ=-0.102,	p=0.554 ρ=0.005,	p=0.970 ρ=-0.092,	p=0.494
OCT1 ρ=-0.206,	p=0.121 ρ=-0.278,	p=0.101 ρ=0.055,	p=0.684 ρ=-0.175,	p=0.188
ρ= Spearman Correlation Coefficient. Bold=statistically significant (p<0.05). GA: gestational age, PNA: postnatal 
age, PMA: post menstrual age. †fetal/newborn cohort. ‡only fetal samples.
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Figure 3 Transporter-specific	 postnatal	maturation	 of	 hepatic	 protein	 expression	 in	 the	 fetal/newborn	
cohort	(n=58).	
PNA=postnatal age
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Genotype	 results	 are	 presented	 in	 Supplemental Table 3.	 For	 SLC22A1	 1222A>G,	 the	
TaqMan	assay	 failed	 for	 two	patients,	presumably	due	to	poor	quality	of	 the	DNA.	All	
patients were successfully genotyped for other SNPs. Protein expression was neither 








Our study expands and presents data on human hepatic transporter protein expression 
in	 a	 pediatric	 cohort	 with	 a	 focus	 on	 fetal	 and	 newborn	 patients	 up	 to	 18	weeks	 of	
postnatal age. Together with findings on gene expression and genetic variants in the 
same	patient	subcohort,	this	study	is	a	comprehensive	analysis	of	ontogeny	of	human	
hepatic drug transport in the age range where knowledge was still lacking. Below we 
will discuss the main findings.
Age-related	 changes	 in	 protein	 expression	 were	 transporter	 dependent.	 The	 results	
with existing data from literature are summarized in Table 3. Apart from our previous 
exploratory	 study,	 the	 only	 other	 published	 LC-MS/MS	 proteomics	 study	 we	 could	
identify included four neonates.6	At	this	time,	due	to	a	lack	of	biological	data,	drug	dosing	
in preterm and term infants is left with uncertainty regarding the level of exposure. 
Similarly,	in	pregnant	women,	the	level	of	exposure	to	the	fetus	remains	unknown.	Our	
data may aid to optimize dosing of transporter substrates in these patient populations. 
Interestingly,	when	 looking	at	age	groups,	most	differences	 in	 transporter	expression	
were	found	between	the	fetal	and	adult	age	groups,	 indicating	that	major	changes	in	
transporter	protein	expression	occur	 in	early	 life.	 For	example,	previously	was	 shown	
that	OCT1	increased	from	neonatal	to	adult	age.5,6 Our data adds that also in fetal and 
preterm	newborns	 the	OCT1	 levels	 are	 lower	 than	 in	 adults.	While	 the	 expression	 of	
most	 transporters,	 like	 OCT1,	 is	 lower	 in	 the	 perinatal	 period	 than	 at	 adult	 age,	 the	
expression	of	GLUT1	is	significantly	higher	in	the	perinatal	period.	This	likely	reflects	the	
physiological	high	need	of	glucose	early	after	conception.	Moreover,	we	did	not	study	
the	 transporter	GLUT2,	which	 is	highly	 expressed	 in	 the	 adult	 liver.20 This transporter 
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could	be	 subject	 to	 age-related	 changes,	 possibly	 explaining	our	 findings	 on	GLUT1.	
Subsequently,	OATP1B1	is	also	higher	in	the	perinatal	period,	and	is	important	for	the	
hepatic uptake of hormones like estrogens.3	 Importantly,	 the	decrease	 in	GLUT1	 and	
OATP1B1 may also be explained by the observed negative correlation between crude 
membrane	 yield	 and	 age.	 Not	 surprisingly,	 ontogeny	 patterns	 are	 not	 similar	 when	
describing transporter protein expression per membrane yield instead of per amount of 
tissue.	However,	in	literature	these	units	are	used	inconsistent.	As	transporter	proteomic	
data	is	often	used	for	PBPK	modelling,	coming	from	various	sources,	a	correction	factor	
should be applied when describing protein expression results per crude membrane 
protein in young age groups.
Both gestational age and postnatal age may impact transporter activity differently 
and	 independently.	 However,	 the	 combined	 effect,	 i.e.	 postmenstrual	 age,	 needs	 to	
be	considered	as	well.	Our	data	suggest	that	dosing	of	transporter	substrates	for	BCRP,	
BSEP,	 GLUT1	 and	 OATP1B1	 is	 best	 guided	 by	 PMA	 in	 the	 first	 months	 of	 life.	 Using	
linear correlation is problematic in wide age ranges because this implies continuously 
increasing or decreasing expression up to adult age.21 But as we were dealing with a 
limited	age	range	(<18	weeks	PNA),	we	considered	linear	correlation	the	most	suitable	
to describe our data within this subpopulation.
Considerably	more	literature	data	on	pediatric	transporter	mRNA	expression	is	available	
than protein expression data.1	However,	 adults	 studies	have	 shown	 that	mRNA	 levels	
do not always correlate well with transporter protein expression22-24,	 which	was	 also	
shown	in	a	subpopulation	of	our	cohort	(n=31).	Interestingly,	the	earlier	found	ABCB1	
mRNA ontogeny pattern12	 is	similar	to	that	for	the	MDR1	protein	in	the	present	study,	
but	with	a	much	higher	 fold	change,	possibly	explaining	the	 lack	of	correlation.	Also,	
post-translational	 changes	 may	 occur	 introducing	 differences	 between	 protein	
expression	and	protein	activity.	For	example,	a	previous	study	found	that	the	fraction	
of highly glycosylated OATP1B3 increased with age25.	Unfortunately,	because	we	used	
crude	 membrane	 fractions	 to	 measure	 protein	 expression	 with	 LC-MS/MS	 we	 could	
not	distinguish	between	glycosylated	and	un-glycosylated	 transporter	protein.	Other	
techniques,	e.g.	Western	Blot,	could	enable	this,	but	this	is	challenging	in	pediatrics	as	
much more tissue is needed.
We could not identify a relationship between protein expression and the selected 
genetic	variants	in	our	cohort,	although	these	have	been	shown	earlier	to	impact	mRNA	
and/or	protein	expression.	This	finding	may	be	explained	by	our	 low	sample	size,	but	
could	also	partly	 explained	by	 the	 interplay	between	development	 and	genetics.	 For	




expression was stable within SLCO1B1	 diplotypes.	 In	 contrast,	 Prasad	 et	 al.	 showed	
higher	protein	 expression	 in	 neonates	 versus	 older	 children/adults	with	 the	SLCO1B1 
*1A/*1A	haplotype.6	Moreover,	our	group	previously	showed	that	the	SLC22A1 genotype 
is	 related	 to	 tramadol	disposition	 in	preterm	 infants,	 similar	 to	adults.10 This suggests 
that,	 although	 protein	 levels	 are	 low,	 the	 SLC22A1 genotype can result in significant 
differences	in	protein	activity	in	neonates.	Thus,	although	we	did	not	find	a	correlation	
between	 interrogated	 SNPs	 and	 protein	 expression,	 it	 remains	 important	 to	 include	
genotype when analyzing developmental patterns.




not	 require	medications	 like	 ill	newborns	do,	 thus	our	cohort	 represents	 the	 relevant	
population	 for	 our	 intended	 purpose.	 The	 relative	 impact	 of	 these	 factors,	 however,	
deserves	further	study.	Also,	samples	were	snap-frozen	at	-80ºC	for	later	research	use	at	
the	time	of	autopsy	within	24	hours	after	death,	which	might	have	introduced	differences	
in quality of tissue. These limitations warrant careful interpretation of our data.
Nevertheless,	 our	 data	 help	 improve	 our	 understanding	 of	 drugs	 and	 endogenous	
processes	in	human	populations	of	different	ages.	Moreover,	our	data	could	be	integrated	
in	 PBPK	 modeling,	 which	 might	 improve	 prediction	 of	 pediatric	 drug	 clearance.	
Because	 differences	 might	 exist	 between	 protein	 expression	 and	 protein	 activity,	
future perspectives will be to validate these models with clinical data from transporter 
substrates.	 Previously,	we	have	 shown	 the	 value	of	determining	 absolute	 transporter	
protein	expressions	 in	 transfected	cell	 lines	 for	application	 in	PBPK	modelling:	 in vivo 
hepatic disposition of rosuvastatin was predicted by scaling from individually transfected 
cell lines by correcting for absolute transporter protein expression levels.28 In the current 
study we therefore determined the absolute expression levels of the transporter protein 
in	selected	relevant	cell	lines,	frequently	applied	in	in vitro	drug	metabolism	PK	studies.	
Hence,	 the	 obtained	 results	 can	 be	 incorporated	 into	 PBPK	modeling	 to	 extrapolate	
existing	 adult	 PK	data	 to	pediatric	 PK	data29,30,	 or	 used	 as	 appropriate	 scaling	 factors	
to scale between in vitro cell lines and human hepatic expression in adults or pediatric 
patients.




a number of hepatic transporter proteins in children up to four months. This strongly 
suggests that disposition of drugs and endogenous transporter substrates is subject to 
age-related	changes	and	impacts	the	efficacy	and	safety	of	drugs	in	the	first	months	of	
life.	Postmenstrual	age	may	present	the	most	robust	method	to	incorporate	age-related	
variation in transporter protein expression in dosing guidelines. mRNA expression as 
surrogate marker of transporter activity should be carefully interpreted as correlation 
with	 protein	 expression	 is	 mostly	 lacking.	 Moreover,	 adult	 pharmacogenetic	 data	
cannot	be	directly	extrapolated	to	neonates	and	young	infants.	Further	study	is	needed	
to delineate the effect on in vivo drug disposition and effect.
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Supplemental Table 2 Multiple reaction monitoring (MRM) transitions of the used peptides and the 
corresponding	internal	standards	(AQUA)
Name Labelled Peptide sequencea Molecular weight Q1 Q3-1 Q3-2 Q3-3 Q3-4
ATP1A1 unlabeled AAVPDAVGK 827.0 414.2 586.3 685.4 242.1
AQUA AAVPDAVGK 833.0 417.5 592.3
BCRP unlabeled SSLLDVLAAR 1.044.2 522.8 644.3 757.5 529.4
AQUA SSLLDVLAAR 1.060.2 526.3 651.3
BSEP unlabeled STALQLIQR 1.029.2 515.3 657.4 841.6 529.4
AQUA STALQLIQR 1.045.2 518.8 664.3
GLUT1 unlabeled VTILELFR 990.2 495.8 790.5 677.4 201.2
AQUA VTILELFR 1.000.2 500.8 800.5
MCT1 unlabeled SITVFFK 841.0 421.2 173.2 641.3 201.1
AQUA SITVFFK 851.0 426.2 651.3
MDR1 unlabeled NTTGALTTR 934.0 467.7 719.4 216.1 618.4
AQUA NTTGALTTR 950.0 471.2 726.5
MRP2 unlabeled VLGPNGLLK 910.1 455.8 698.5 185.3 213.3
AQUA VLGPNGLLK 926.1 459.2 705.4
MRP3 unlabeled ALVITNSVK 944.1 472.8 760.4 661.4 548.4
AQUA ALVITNSVK 950.1 475.8 766.5
NTCP unlabeled GIYDGDLK 880.44 440.7 710.3 143.2 171.2
AQUA GIYDGDLK 896.44 444.2 717.3
OATP1B1 unlabeled LNTVGIAK 815.0 408.2 399.4 588.3 228.2 702.3
AQUA LNTVGIAK 831.0 411.7 402.9
OATP1B3 unlabeled IYNSVFFGR 1101.3 551.8 826.5 249.1 526.2
AQUA IYNSVFFGR 1111.6 556.8 836.4
OATP2B1 unlabeled SSISTVEK 849.9 425.7 563.3 676.3 175.1
AQUA SSISTVEK 855.9 428.7 569.3
OCT1 unlabeled LPPADLK 752.9 377.2 543.3 183.3 260.3
AQUA LPPADLK 768.9 380.7 550.4
a AQUA: Amino acid presented in italic bold is labelled with 13C and 15N.
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Supplemental Table 3	 Overview	 selection	 of	 SNPs	 known	 to	 influence	mRNA-	 or	 protein	 expression.	
Number	of	livers	from	carriers	of	various	SNPs	present	in	the	studied	cohort.	*Kruskal-Wallis	test


























ABCG2 rs2231142 421C>A Missense 50 10 0 p=0.132
ABCB1 rs1045642 3435C>T Synonymous 15 27 18 p=0.883
ABCC1 rs45511401 16079375G>T Missense 56 4 0 p=0.155
ABCC2 rs2273697 1249G>A Missense 35 19 6 p=0.197
ABCC3 rs4793665 -211C>T 5	Flanking 15 22 23 p=0.792
SLCO1B1 rs4149056 521T>C Missense 44 16 0 p=0.132
rs2306283 388A>G Missense 10 33 17 p=	0.821
rs11045819 463C>A Missense 45 12 3 p=	0.324
SLCO1B3 rs4149117 334T>G Missense 1 19 40 p=0.459
rs7311358 699G>A Missense 1 19 40 p=0.459
SLCO2B1 rs2306168 1457C>T Missense 54 4 1 p=0.132
rs12422149 935G>A Missense 49 10 1 p=0.682
SLC22A1 rs12208357 181C>T Missense 55 5 0 p=0.841
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Transporter Hepatic expression (pmol/g tissue) Distribution over groups*
Male (n=35) Female (n=27)
ATP1A1 292.5	(115.7-604.9) 342.9	(137.6-471.9) p=0.848
BCRP 3.5	(1.6-6.8) 4.0	(0.9-7.7) p=0.122
BSEP 18.0	(0.9-59.7) 20.4	(4.0-47.7) p=0.324
GLUT1 112.0	(21.4-393.0) 144.3	(35.2-546.2) p=0.804
MCT1 12.0	(1.9-39.5) 9.8	(5.7-34.0) p=0.189
MDR1 8.1	(0.7-24.9) 11.2	(0.1-26.7) p=0.456
MRP1 3.8	(0.6-17.7) 3.8	(0.9-13.8) p=0.609
MRP2 8.8	(1.5-23.9) 8.8	(3.1-20.2) p=0.633
MRP3 1.8	(0.5-11.3) 2.5	(1.0-13.7) p=0.138
NTCP 2.6	(0.6-30.1) 3.2	(0.8-15.6) p=0.284
OATP1B1 20.4	(4.9-101.7) 14.7	(5.7-85.8) p=0.624
OATP1B3 18.2	(2.3-59.3) 16.4	(3.9-51.1) p=0.537
OATP2B1 64.6	(13.8-138.7) 72.9	(13.5-123.8) p=0.189
OCT1 67.6	(4.6-139.7) 69.6	(5.2-129.7) p=0.771
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Supplemental Table 6	 Correlation	 of	 mRNA-	 and	 protein	 expression	 of	 hepatic	 transporters.	 mRNA	


















ATP1A1 20.9	(4.4-168.5) ρ=-0.123,	p=0.510 12.1	(0.6-105.7) ρ=0.144,	p=0.441
ABCG2/BCRP 1.8	(0.0-7.7) ρ=-0.080,	p=0.670 1.8	(0.0-7.7) ρ=-0.080,	p=0.670
ABCB11/BSEP 8.3	(0.0-41.8) ρ=0.533, p=0.002 7.5	(0.0-27.3) ρ=0.525, p=0.002
SLC2A1/GLUT1 9.0	(0.0-125.7) ρ=0.293,	p=0.110 6.2	(0.0-92.9) ρ=0.313,	p=0.087
SLC16A1/MCT1 9.1	(0.0-77.0) ρ=0.517, p=0.003 4.3	(0.0-19.7) ρ=0.342,	p=0.060
ABCB1/MDR1 1.9	(0.0-8.6) ρ=0.150,	p=0.419 0.9	(0.0-5.0) ρ=0.394, p=0.028
ABCC1/MRP1 2.6	(0.0-17.5) ρ=0.118,	p=0.527 0.6	(0.0-6.2) ρ=0.104,	p=0.577
ABCC2/MRP2 15.9	(0.4-70.6) ρ=0.467, p=0.011 14.7	(0.4-61.8) ρ=0.512, p=0.005
ABCC3/MRP3 11.1	(0.0-128.7) ρ=0.096,	p=0.606 1.4	(0.0-5.6) ρ=0.260,	p=0.158
SLC10A1/NTCP 1.4	(0.0-26.0) ρ=0.584, p=0.001 1.4	(0.0-26.0) ρ=0.584, p=0.001
SLCO1B1/OATP1B1 26.1	(0.0-69.4) ρ=0.182,	p=0.328 26.1	(0.0-69.4) ρ=0.182,	p=0.328
SLCO1B3/OATP1B3 10.6	(0.0-56.8) ρ=-0.093,	p=0.620 9.2	(0.0-49.6) ρ=-0.114,	p=0.541
SLCO2B1/OATP2B1 24.7	(0.4-84.0) ρ=0.296,	p=0.106 17.6	(0.3-72.6) ρ=0.313,	p=0.087
SLC22A1/OCT1 2.4	(0.0-122.1) ρ=-0.032,	p=0.865 1.4	(0.0-57.6) ρ=-0.090,	p=0.629
Supplemental Table 7	Absolute	transporter	expression	in	selected	cell-lines
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ABSTRACT
Human renal membrane transporters play key roles in the disposition of renally cleared 
drugs	 and	 endogenous	 substrates	but	 their	 ontogeny	 is	 largely	 unknown.	Using	 184	
human	 postmortem	 frozen	 renal	 cortical	 tissues	 (preterm	 newborns	 –	 adults)	 and	 a	
subset	of	62	tissue	samples,	we	measured	the	mRNA	levels	of	11	renal	transporters	and	






Collectively,	 our	 study	 revealed	 that	 renal	 drug	 transporters	 exhibited	 different	 rates	
and	patterns	of	maturation,	suggesting	that	renal	handling	of	substrates	may	change	
with age.
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INTRODUCTION
Renal	membrane	 transporters,	which	 are	 located	 on	 the	 apical	 and	 basolateral	 sides	
of	 the	 tubular	 epithelium,	 are	 key	 players	 in	 tubular	 secretion	 and	 reabsorption	 of	 a	
plethora of endogenous and exogenous compounds in the kidney.1,2 Because of their 
role	 in	 renal	 elimination,	 many	 transporters	 in	 the	 kidney	 play	 critical	 roles	 in	 the	
disposition,	efficacy	and	toxicity	of	drugs.	Notably,	renal	drug	transporters	have	received	
increasing	 regulatory	attention	 in	 recent	years,	highlighting	 their	 significance	 in	drug	
disposition.3-6
Interindividual variation in expression levels and functional activities of membrane 
transporters	 can	 affect	 the	 homeostasis	 of	 endogenous	 substrates,	 as	 well	 as	 the	
pharmacokinetics and pharmacodynamics of drugs.1 As a result of developmental 
changes	 in	 key	 transporters	 and	 enzymes,	 levels	 of	 endogenous	 substrates,	 such	
as	 metabolites,	 nutrients,	 antioxidants	 and	 hormones,	 change	 as	 children	 grow.7 
Reduced hepatic clearance of the opioid morphine in newborns and young infants 
was reported.8 This was suggested due to significantly lower hepatic levels of both the 
drug	metabolizing	enzyme	uridine	5-diphosphoglucuronic	acid	glucuronyl	transferase	
(UGT)	2B7	and	the	organic	cation	 transporter	 (OCT)	1	 in	young	pediatric	populations	
compared to adults.9,10	In	contrast	to	the	liver,	less	is	known	about	the	maturation	and	
ontogeny pattern of renal membrane transporters. This knowledge gap limits the ability 
to	predict	the	pharmacokinetics	of	renally	eliminated	drugs	in	children,	which	may	be	
critical	for	rational	dosing	and	drug	efficacy	and	safety.	Thus,	there	is	an	urgent	need	to	
understand the ontogeny of human drug transporters in the kidney.
The	 current	 study	 aimed	 to	 identify	 age-related	 differences	 in	 gene	 expression	 and	
protein abundance of renal transporters. We chose to focus on renal transporters with 
demonstrated	 clinical	 relevance	 in	 drug	 disposition,	 and	 those	 that	 handle	 various	
endogenous	 and	 exogenous	 substances	 important	 for	 developing	 children,11,12	 i.e.,	
breast	 cancer	 resistance	 protein	 (gene	 name/protein	 name	 ABCG2/BCRP),	 multidrug	
and toxin extrusion protein (SLC47A/MATE)	 1	 and	 2-K,	multidrug	 resistance	protein	 1	
(ABCB1/MDR1/P-gp),	 multidrug	 resistance-associated	 protein	 (ABCC/MRP)	 2	 and	 4,	
and urate transporter 1 (SLC22A12	 /URAT1)	 on	 the	 apical	 site	 of	 the	membrane	 and	
glucose transporter 2 (SLC2A2/GLUT2),	 organic	 anion	 transporter	 1	 (SLC22A6/OAT1)	
and 3 (SLC22A8/OAT3),	and	SLC22A2/OCT2	 located	on	the	basolateral	site.	 In	an	effort	
to	explore	 a	 regulatory	mechanism	 for	maturation	of	 transporter	 expression,	we	also	
studied	renal	gene	expression	of	the	nuclear	pregnane	X	receptor	(PXR) in relation to the 
transporter expression levels.13
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In	 addition,	 altered	 localization	 of	 a	 transporter	 may	 introduce	 variation	 in	
pharmacokinetics	 of	 transporter	 substrates.	 However,	 little	 is	 known	 about	 the	
localization	of	transporters	during	development	of	the	kidney.	MRP4	is	an	apical	efflux	





Tissue procurement and sample characteristics
Two sample sets were analyzed and the demographic information of donors is 
reported in Table 1.	Age	groups	were	predefined	based	on	the International	Council	for	
Harmonisation	guidelines:	preterm	newborns	(0-28	days	PNA,	<37	weeks	GA),	newborns	
(0-28	days	PNA),	infants	(1-24	months	old),	children	(2-12	years	old),	adolescents	(12-16	





















slight modifications (Material S1).15
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Quantitative proteomics using LC-MS/MS with Selective Reaction Monitoring 
(SRM)
Quantitative proteomics was only performed in sample set 2 (Figure	1).	Unless	otherwise	
stated,	 reagents	 from	MyOmicsDx,	 Inc	 (Towson,	MD)	were	used.	Details	of	 the	LC	and	
MS method and parameters are described in the supplemental documents (Material 
S2).	 Briefl	y,	 membrane	 proteins	 were	 extracted	 from	 the	 renal	 cortical	 tissues	 using	
Figure 1 Sample analysis scheme.
The subset of 62 samples from sample set 2 for quantitative proteomics consisted of the 57 African American 
samples and 5 adult Caucasian samples (See Table 1).


























Total Gestational age Postnatal age
Preterm newborns 9 - - 9 34.00	(24.00-36.71)	wks 1.29	(0.14-4.00)	wks
Term newborns 8 10 1 19 NA 1.29	(0.14-3.86)	wks
Infants 21 30 30 81 NA 17.86	(4.14-103.00)	wks
Children 7 15 16 38 NA 4.74	(2.00-11.56)	yr
Adolescents - 5 5 10 NA 13.38	(12.48-15.26)	yr






MyPro-MembraneEx	buffer.	The	 total	 extracted	membrane	protein	 concentration	was	
determined	 using	 BCA	 protein	 assay	 kit.	 The	 membrane	 protein	 samples	 were	 then	
processed	 by	 MyOmicsDx,	 Inc	 (Towson,	 MD)	 using	 Filter-aided	 Sample	 Preparation	
method.16
Five	peptides	were	chosen	for	each	transporter	as	SRM	quantifying	targets	and	six	best	
transitions per peptide precursors were selected for SRM quantification (Table S7). 
Peptide	samples	that	were	previously	reconstituted	in	MyPro-Buffer	3	were	spiked	with	
MyPro-SRM	 Internal	Control	Mixture	and	were	 subjected	 to	SRM	analysis.	The	peptide	
samples	were	eluted	through	an	online	Agilent	1290	HPLC	system	into	the	Jet	Stream	ESI	
source	of	an	Agilent	6495	Triple	Quadrupole	Mass	Spectrometer	(Agilent,	Santa	Clara,	CA).
Quantitative data were imported into Skyline 3.1.17 The abundance of a target peptide 
was	represented	by	the	area	under	the	curve	(AUC)	of	all	 its	transitions	normalized	to	
the	total	AUC	of	all	transitions	from	the	most	nearby	(sharing	a	similar	hydrophobicity)	
heavy	 isotope-labeled	 peptide	 from	 MyPro-SRM	 Internal	 Control	 Mixture	 spiked	 in	




Immunohistochemistry was performed using an immunoperoxidase staining method 
for	amplified	antigen	detection.	Sections	of	4	µm	thick	cortex	were	gained	from	formalin	
fixed,	paraffin-embedded	post-mortem	kidney	tissue	blocks,	and	were	mounted	on	glass	
slides.	They	were	heated	at	60°C	 for	30	min,	deparaffinized	 in	xylene,	and	 rehydrated	












performed for every age group.
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age	 groups,	 the	 ontogeny	 would	 be	 referred	 to	 as	 “stable”.	 Sigmoidal	 Emax	 models	
are used often for maturational processes as it allows gradual maturation of clearance 
in	 early	 life	 and	a	“mature”	 clearance	 to	be	 achieved	at	 a	 later	 age.18	Therefore,	 Emax	
models were used to fit the protein abundance data on a continuous scale of age for 
those	 transporters	 that	 showed	 between-group	 differences.	The	 data	 point	 from	 the	
term	newborn	in	this	set	of	data	was	excluded	prior	to	fitting	to	eliminate	bias,	as	it	was	
the only sample quantified for that age group. We first set the median of adult data to be 
100%,	and	then	normalized	the	data	points	from	pediatric	samples	towards	the	median	
of adult data. Potential outliers were assessed and excluded using the Robust Regression 
followed	by	Outlier	 Identification	method	 (ROUT)	during	 the	model	fit	process.19 The 
age	at	which	50%	maturation	was	reached	(TM50) was determined from the Emax model. 
Visual	inspection	and	95%	CI	of	the	Emax	parameter	estimates	were	used	to	assess	the	
goodness of fit of the Sigmoidal model. Spearman’s correlation analysis was used to 
evaluate the relationship between mRNA and protein abundances within the same and 
among other transporters.
For	 the	analysis	of	staining	 intensity	after	 immunohistochemistry,	a	semi-quantitative	
scoring	 system	 was	 used,	 graded	 by	 two	 observers	 (BG,	 MB)	 who	 independently	
confirmed	cell	staining	intensity	as	negative	(0),	low	staining	(+1)	or	high	staining	(+2).	
Simultaneously,	the	localization	of	MRP4	in	the	kidney	tissue	was	determined	for	each	
sample by the same observers.





analyzed in this study (Figure	1 and Table 1).	Sample	set	1	represented	62	samples	from	
individuals	of	different	 ages	 ranging	 from	preterm	newborns	 (gestational	 age	 (GA)	>	
24	weeks,	postnatal	age	(PNA)	1	day)	to	adult	donors	(oldest	75	years).	The	122	tissues	
in	 sample	 set	2	were	 from	African	American	and	Caucasian	 term	newborns	 to	adults.	
No statistical difference was observed in gene or protein abundance levels for any of 
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the	 transporters	 between	 males	 and	 females,	 and	 between	 African	 Americans	 and	
Caucasians	(Table	S1,	Table	S2	and	Table	S3);	hence	subsequent	analyses	were	performed	
by combining both sexes and all ethnic groups.
Relative mRNA quantitation
All	 184	 tissues	were	processed	 for	mRNA	quantitation	 (Figure	2	and	Table	S4).	mRNA	










Transporters are grouped according to their primary localization in the kidney (basolateral or apical). The bar 
represents the median for each age group. *p<0.05, **p<0.01, ***p<0.001
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Proteomics
62	 samples	were	 assessed	 for	 transporter	 protein	 levels	 (Figure	 3	 and	Table	 S5).	The	
median	 total	membrane	protein	yield	 for	all	 samples	was	49.5	mg/g	 (range	41.7-62.1	




in term newborn and infants than in the older age groups (Figure	3). Sigmoidal Emax 
models	were	used	 to	 fit	 the	protein	 abundance	 levels	 of	 these	 five	 transporters,	 and	
all	 but	 URAT1	 expression	 data	 conformed	 to	 the	 model	 (Figure	 4a).	 OCT2	 and	 P-gp	
expression increased at a faster rate than OAT1 and OAT3 as evidenced by the younger 
age at which half of the adult expression was reached (TM50).	Moreover,	the	transporters	
OCT2	and	P-gp,	shared	a	similar	maturation	pattern,	as	well	as	 the	 transporters	OAT1	
and OAT3 (Figure	4b). No difference in protein abundance levels was found between age 
groups	for	BCRP,	MATE1,	MATE2-K	and	GLUT2.
Figure 3 Protein abundance levels of nine renal membrane transporters in different age groups.
The bar represents the median for each age group. Term newborn and infants were combined here for analysis 
since there was only one term newborn included for this part of the study. *p<0.05, **p<0.01, ***p<0.001
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Correlation between mRNA expression and protein abundance levels
Potential correlation between mRNA expression and protein abundance levels of the 
transporters	was	investigated	(Figure	S1).	Significant	correlation	was	found	for	MATE1,	
P-gp,	URAT1,	OAT3	and	OCT2.











BCRP - 0.69 0.44 NA NA 0.59 0.43
MATE1 - 0.63 0.36 0.57 0.74 0.50 0.57 0.44 0.53 0.61 0.54 0.54 0.62 0.57
MATE2-K - 0.39 0.57 0.51 0.47 0.59 0.56 0.49
MDR1 - 0.47 0.32 0.56 0.37 0.52 0.72 0.49 0.60 0.57 0.67
MRP2 - NA NA 0.79 0.83 0.67
MRP4 - NA NA






l GLUT2 - 0.64 0.64 0.49
OAT1 - 0.85 0.83 0.74 0.70
OAT3 - 0.73 0.72
OCT2 -
Italic: mRNA expression; Bold:	 protein	 expression;	 NA=not	 available.	 All	 reached	 p	 <	 0.0001.	 Data	 not	
presented	if	p	>	0.001
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Inter-transporter correlation
To	 assess	 the	 potential	 shared	 expression	 regulation,	 we	 studied	 the	 correlation	 of	
mRNA expression and protein abundance levels between transporters (Table 2).	Levels	
of OAT1 and OAT3 were the most significantly correlated.












year	 c)	 represents	 the	negative	 control,	 and	d)	 the	 semi	quantification	of	MRP4	 staining	 in	 various	age	
groups:	negative	(0),	low	staining	(+1)	or	high	staining	(+2).
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Figure	5b). See Figure	5c for the negative control. Although the examples showed lower 
staining at 3.3 weeks (Figure	5a) than 3.1 years old (Figure	5b),	no	statistically	significant	
age-related	 changes	 were	 detected	 in	 the	 semi-quantification	 of	 the	 staining	 in	 the	
whole sample set (Figure	5d).
DISCUSSION
This	study,	to	our	best	knowledge,	is	the	first	to	comprehensively	describe	the	ontogeny	
of human renal membrane transporters via mRNA expression analysis and quantitative 
proteomics in tissues representing a large span of ages. Albeit data on developmental 
changes	in	transporter	mRNA	expression	in	animals	were	reported	previously,20-24 cross 
species	differences	limit	extrapolation,	especially	concerning	the	rates	of	maturation.25
Our study revealed two major findings with respect to the developmental maturation 
of renal transporters: (i) the expression of most of the transporters characterized in this 
study increased with age during the earliest developmental periods (< 2 years old); and 
(ii)	maturation	pattern	was	transporter-dependent.	Additionally,	we	observed	that:	 (a)	
there were maturational differences between mRNA expression and protein abundance; 
(b) there were correlations between the expression levels of various transporters; (c) 
PXR	 seems	 to	 play	 a	 minimal	 role	 in	 regulating	mRNA	 expression	 of	 transporters	 in	
the	kidney;	and	(d)	stable	MRP4	mRNA	expression	was	accompanied	by	proper	apical	
localization during development.
Transporter-dependent maturation patterns during the earliest developmental 
periods
The	 findings	 that	most	 of	 the	 studied	 transporters	 showed	 a	 transporter-dependent	
age-related	 increase	 in	 their	 expression	 levels,	 especially	 during	 the	 earliest	 years	 of	
life were expected. Renal membrane transporters play critical roles in elimination and 
detoxification	pathways	in	the	body.	They	work	in	concert	with	enzymes	in	the	kidney,	
as well as enzymes and transporters in other organs such as the intestine and liver to 
mediate the removal of ingested potential harmful compounds such as toxins derived 
from	food,	environmental	toxins,	drugs	and	their	metabolites.7	During	infancy,	dietary	
exposure to potential toxins is limited and begins to increase as infants are switched from 
an	exclusively	milk	diet,	to	foods	that	may	contain	more	toxins.26,27	Thus,	detoxification	
pathways are increasingly needed as the diet of infants expands and diversifies into 
childhood.
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Further,	 besides	 changes	 in	 dietary	 intake	 and	 nutritional	 requirement,	 ontogeny	 of	
renal	 transporters	 can	 alter	 the	 disposition	 of	 endogenous	 compounds,	 suggesting	
important	developmental	roles	for	these	renal	transporters.	Both	BCRP	and	URAT1	are	
thought	to	play	a	clear	role	in	uric	acid	(UA)	homeostasis.28,29 It was previously reported 
that	 the	 fractional	excretion	of	UA	 (FEUA:	 the	%	of	filtered	UA	not	 reabsorbed	by	 the	
tubules),	was	30-40%	in	term	newborns	<5	days	old,	which	then	decreased	to	8-10%	in	











In vivo pharmacokinetic data of drugs that are transporter substrates may be used to 
support	our	expression	data.	However,	renal	elimination	of	these	drugs	is	accomplished	
not	 only	 by	 active	 tubular	 secretion	 facilitated	 by	 various	 transporters,	 but	 also	 by	
glomerular	 filtration,	which	 is	 also	 subjected	 to	 age-dependent	 changes.	 As	 children	
grow	and	develop,	the	glomerular	filtration	rate	(GFR)	matures	and	is	predicted	to	reach	
50%	of	adult	values	by	2	months	PNA	and	90%	of	adult	values	by	1	year	of	age.34 Though 
the	 full	 complement	 of	 nephrons	 in	 each	 kidney	 is	 complete	 around	GA	 36	weeks,35 
GFR	continues	to	develop	as	a	result	of	 increases	in	kidney	blood	flow,	improvements	
in	 filtration	 coefficients,	 and	 maturation	 of	 the	 tubules.	 Our	 findings	 that	 there	 are	
age-related	changes	in	transporter	expression	early	in	life	(<2	years)	support	the	notion	
that	active	 tubular	 secretion	matures	 in	parallel	with	GFR	maturation.	Thus,	observed	
age-related	changes	 in	pharmacokinetics	of	 transporter	 substrates	are	 likely	due	 to	a	
combination	of	both	maturation	in	transporter	expression	and	GFR.	For	instance,	after	
hepatic	 metabolism,	 the	 antiviral	 drug	 valacyclovir	 undergoes	 renal	 elimination	 via	
glomerular	filtration	and	active	tubular	secretion	likely	by	OAT1/3.36 Apparent clearance 
of	valacyclovir	in	infants	<	3	months	old	is	50%	lower	than	that	in	young	children.36 The 
GFR	in	infants	<3	months	old	is	expected	to	be	>50%34,	and	therefore	this	discrepancy	
may be explained by our findings that the TM50 of OAT1 and OAT3 were approximately 




our	 data	 could	 be	 integrated	 into	 physiologically-based	 pharmacokinetic	 models	 to	
improve	prediction	of	pediatric	drug	clearance.	When	doing	so,	scaling	factors	should	
be used to correct for membrane protein yield and total organ weight.
Other observations from data analysis
The	abundance	pattern	of	the	transporters	in	our	adult	samples	were	assessed.	P-gp	has	




of	 the	 transporters,	or	 to	differences	 in	 the	 inclusion	criteria	and	quality	of	 the	 tissue	
samples	used	in	the	studies.	In	addition,	our	study	also	showed	much	higher	absolute	
abundance for most proteins in our adult samples compared to other studies 39.	As	Li	et	
al suggested40,	such	inter-laboratory	difference	may,	 in	part,	be	explained	by	different	
instrumental performance and varying tissue handling techniques.
Differences	 in	the	patterns	and	rates	of	change	among	mRNA	expression	and	protein	
abundance	 levels	 of	 various	 transporters	 were	 noticed.	 For	 example,	 age-related	
changes	 were	 found	 in	 BCRP,	 GLUT2	 and	 MATE2-K	 mRNA	 levels	 but	 not	 in	 protein	
abundance levels. This may suggest maturational differences in the regulation of gene 
transcription	 and	 post-translational	 processing.	 For	 gene	 transcription,	 alternative	
splicing is suggested to occur due to developmental signals.41 Some of the alternatively 
spliced mRNA transcripts may not be translated into the protein of interest but will be 
quantified	by	qRT-PCR	as	the	total	mRNA	expression	could	be	derived	from	a	mixture	
of different transcripts of the targeted gene. 42 Quantitative proteomics overcomes this 
challenge by measuring the actual expression of the protein of interest. This process 
could explain the lack of correlation between mRNA and protein expression.
Our data showed that transporter expression is correlated among various transporters. 
The strong correlation between expression of OAT1 and OAT3 is not surprising as they 
are located in adjacent regions on chromosome 11.43	Moreover,	they	are	both	regulated	
by	the	transcription	factors	hepatocyte	nuclear	factor	(HNF)	1α	and	1β,	which	increase	
their transcription.44	 Our	 study	 of	 transcription	 factors	 was	 confined	 to	 PXR,	 and	 in	
agreement	with	previously	 reported	findings;	PXR	mRNA	 levels	 in	kidney	were	 low	 in	
all age groups compared to the mRNA levels of the studied transporters.33,45,46	Thus,	PXR	
seems to have a minor role in regulating transporter gene expression in the kidney than 
in	 other	 organs.	This	 is	 supported	by	 findings	 in	mice,	where	 the	 potent	 rodent	 PXR	
activator	 pregnenolone-16α-carbonitrile	 induced	 transporter	 expression	 in	 liver	 and	
intestine,	but	not	 in	kidney.45 More research is needed to identify the developmental 
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triggers	 by	which	 transcription	 of	 transporters	 increase	 and	 decrease.	Moreover,	 the	
relationship	between	transcription	factors	maintaining	basal	expression	 level,	 like	the	
HNF	family,	and	renal	transporter	expression,	should	be	studied.
Detoxification	 involves	 the	 interplay	 between	 enzymes	 and	 transporters	 that	 are	
ubiquitously	expressed	in	tissues	throughout	the	human	body.	P-gp	expression	levels	
in	the	liver	only	reached	50%	of	adult	expression	levels	at	2.9	years	of	age9 whereas our 
results	suggested	that	full	adult	levels	were	achieved	in	the	kidney	by	that	age.	For	BCRP,	
our	results	for	mRNA	expression	in	the	kidney	were	consistent	with	that	in	the	liver,	which	
showed a decline from newborns to adults.47 As more transporter ontogenetic data in 




factors,	 such	 as	 the	 use	 of	 co-medications	 and	 inflammation	 that	 can	 influence	
transporter expression and thereby contribute to the expression variability.48 The impact 
of	acute	and	chronic	inflammation	on	transporter	expression	and	activity	is	related	to	
the	 activity	 of	multiple	 proinflammatory	 cytokines.	 49 The exact mechanism remains 
unknown,	 and	may	be	 related	 to	 various	 nuclear	 receptors	 and	 transcription	 factors.	




significant	changes	 in	 the	expression	 levels	by	age	were	still	observed.	However,	due	




levels	and	 increased	variability	 in	expression	 level	measurements.	Moreover,	with	 the	
exception	 of	 PXR,	 we	 did	 not	 study	 the	 ontogeny	 of	 other	 transcription	 factors	 and	
proteins	involved	in	gene	and	protein	regulation;	therefore,	the	mechanisms	underlying	
the	 ontogeny	 of	 transporters	 observed	 in	 this	 study	 are	 not	 known.	 Finally,	 mRNA	
expression,	protein	abundance	and	transporter	activity	ex-vivo and in-vivo studies are 
needed to confirm the implications of our results to drug disposition in the kidney.
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CONCLUSIONS





strategies may improve predictability of pediatric drug disposition and exposure 
models.	Importantly,	our	findings	set	the	stage	for	future	research	in	understanding	the	
mechanisms of developmental changes in renal drug transporters.
Ontogeny of renal transporters 135
5
REFERENCES
 1. Morrissey	 KM,	 Stocker	 SL,	 Wittwer	 MB,	 Xu	 L,	 Giacomini	 KM.	 Renal	 transporters	 in	 drug	
development.	Annu	Rev	Pharmacol	Toxicol	2013;53:503-529.
 2. Motohashi	H,	Nakao	Y,	Masuda	S,	et	al.	Precise	comparison	of	protein	 localization	among	OCT,	
OAT,	and	MATE	in	human	kidney.	J	Pharm	Sci	2013;102(9):3302-3308.
 3. Food	 and	 Drug	 Administration.	 In	 vitro	 metabolism-	 and	 transporter-mediated	 drug-drug	
interaction	 Studies.	 https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm064982.htm.	Accessed	September	24,	2018.
	 4.	 International	 Council	 for	 Harmonisation.	 Guidance	 for	 Industry.	 E11	 Clinical	 investigation	 of	
medicinal products in the pediatric population. 2000.
	 5.	 European	Medicines	 Agency.	 Guideline	 on	 the	 investigation	 of	 drug	 interactions.	 Committee	
for	 Human	 Medicinal	 Products.	 http://www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2012/07/WC500129606.pdf.	Accessed	April	3,	2018.











 12. Brouwer	 KL,	 Aleksunes	 LM,	 Brandys	 B,	 et	 al.	 Human	 ontogeny	 of	 drug	 transporters:	 review	
and	 recommendations	 of	 the	 pediatric	 transporter	 working	 group.	 Clin	 Pharmacol	 Ther	
2015;98(3):266-287.






















 22. Maher	 JM,	Slitt	AL,	Cherrington	NJ,	Cheng	X,	Klaassen	CD.	Tissue	distribution	and	hepatic	and	
renal	 ontogeny	 of	 the	 multidrug	 resistance-associated	 protein	 (MRP)	 family	 in	 mice.	 Drug	
Metabolism	and	Disposition	2005;33(7):947-955.
 23. Nakajima	 N,	 Sekine	 T,	 Cha	 SH,	 et	 al.	 Developmental	 changes	 in	 multispecific	 organic	 anion	
transporter	1	expression	in	the	rat	kidney.	Kidney	Int	2000;57(4):1608-1616.
	 24.	 Slitt	 AL,	 Cherrington	 NJ,	 Hartley	 DP,	 Leazer	 TM,	 Klaassen	 CD.	 Tissue	 distribution	 and	 renal	




	 26.	 Nicklaus S. The role of dietary experience in the development of eating behavior during the first 
years	of	life.	Ann	Nutr	Metab	2017;70(3):241-245.
 27. Bearer	 CF.	 Environmental	 health	 hazards:	 how	 children	 are	 different	 from	 adults.	 Future	Child	
1995;5(2):11-26.
	 28.	 Brackman	DJ,	Giacomini	KM.	Reverse	translational	research	of	ABCG2	(BCRP)	 in	human	disease	
and	drug	response.	Clin	Pharmacol	Ther	2018;103(2):233-242.










	 34.	 Rhodin	 MM,	 Anderson	 BJ,	 Peters	 AM,	 et	 al.	 Human	 renal	 function	maturation:	 a	 quantitative	
description	using	weight	and	postmenstrual	age.	Pediatr	Nephrol	2009;24(1):67-76.
	 35.	 Faa	G,	Gerosa	C,	Fanni	D,	et	al.	Morphogenesis	and	molecular	mechanisms	 involved	 in	human	
kidney	development.	J	Cell	Physiol	2012;227(3):1257-1268.
	 36.	 Mooij	 MG,	 Nies	 AT,	 Knibbe	 CA,	 et	 al.	 Development	 of	 human	 membrane	 transporters:	 drug	
disposition	and	pharmacogenetics.	Clin	Pharmacokinet	2016;55(5):507-524.
 37. Motohashi	 H,	 Uwai	 Y,	 Hiramoto	 K,	 Okuda	 M,	 Inui	 K.	 Different	 transport	 properties	 between	
famotidine	and	cimetidine	by	human	renal	organic	 ion	transporters	(SLC22A).	Eur	J	Pharmacol	
2004;503(1-3):25-30.






Ontogeny of renal transporters 137
5




	 42.	 Zhang	M,	Liu	YH,	Chang	CS,	et	al.	Quantification	of	gene	expression	while	taking	 into	account	
RNA	alternative	splicing.	Genomics	2018:DOI:	10.1016/j.ygeno.2018.1010.1009.






	 46.	 Miki	 Y,	 Suzuki	 T,	 Tazawa	 C,	 Blumberg	 B,	 Sasano	 H.	 Steroid	 and	 xenobiotic	 receptor	 (SXR),	
cytochrome	P450	3A4	and	multidrug	resistance	gene	1	in	human	adult	and	fetal	tissues.	Mol	Cell	
Endocrinol	2005;231(1-2):75-85.













mRNA isolation and cDNA synthesis
Total RNA was isolated from the tissue using a Nucleospin®	RNA	II	kit	 (Machery-Nagel,	
Düren,	Germany)	for	sample	set	1	and	RNeasy	Mini	Kit	(Qiagen,	Valencia,	CA)	for	sample	set	
2,	according	to	the	manufacturer’s	instructions.	Approximately	5-30	mg	of	frozen	tissue	
was manually homogenized on ice in an Eppendorf tube using pellet pestles to yield 
22	–	570	ng/Ul	(range)	RNA.	Quality	Control	standards	were	applied	to	all	RNA	samples	
in	 this	 study.	 Purity	 was	 assessed	 both	 with	 A260nm/A280nm	 1.9-2.1.	 Absorbance	
measurements	at	260	nm	in	water	were	used	to	adjust	the	stock	concentrations	of	all	
RNA	samples	to	1	Ug/Ul.
For	 reverse	 transcription,	 samples	were	 treated	with	 DNAse	 to	 digest	 contaminating	
DNA.	For	sample	set	1	cDNA	was	obtained	following	local	protocol,	and	for	sample	set	
2	 using	 SuperScript	 VILO	 cDNA	 Synthesis	 Kit	 (Life	 Technologies)	 per	 manufacturer’s	
protocol.
Quantitative RT-PCR
For	 sample	 set	 1,	 expression	was	measured	 by	 a	 SYBR	 green	 (SensiMix	 SYBR	Hi-ROX	
kit;	Bioline)	quantitative	RT-PCR	using	a	7900	Sequence	detector	(Applied	Biosystems)	
on	 a	 96	 well	 optical	 reaction	 plate	 (Applied	 Biosystems).	 In	 house	 designed	 primer	
sequences,	with	confirmed	specificity	in	appropriate	melting	curves	for	each	PCR,	can	
be	 found	 in	 Table	 S1	 and	 were	 derived	 from	 Eurogentec	 (Eurogentec	 Netherlands,	
Maastricht,	 Netherlands).	 PCR	 efficiency	 of	 each	 primer	 pair	 was	 determined	 using	
serial	dilutions	of	cDNA	from	the	Caco-2	(colon	carcinoma)	cell	line	and	from	peripheral	








expression	 levels	 (ratio	 transporter/GAPDH)	 and	 relative	 expression	 was	 compared	
across the age range. Quality was assessed by measuring the RNA integrity number (RIN) 






Quantitative proteomics was only performed in sample set 2 (Figure	1).	Unless	otherwise	

















lyophilized	 overnight	 and	 reconstituted	 in	 37	 µL	 MyPro-Buffer	 3	 (MyOmicsDx,	 Inc.,	
Towson,	MD).
Five	 peptides	 were	 chosen	 for	 each	 transporter	 as	 SRM	 quantifying	 targets	 from	
MyOmicsDx’s	 SRM	 target	 peptide	 database,	 MyPro-SRM	 Map,	 based	 on	 their	
performance in documented experiments. Transition parameters and retention times of 
the	45	peptides	were	established	individually	using	an	Agilent	6495	Triple	Quadrapole	
Mass	Spectrometer	for	1+,	2+,	3+	and	4+	charged	precursor	ions.	Six	best	transitions	per	
peptide precursor were selected for SRM quantification (Table S2).
Peptide	 samples	previously	 reconstituted	 in	MyPro-Buffer	 3	were	 spiked	with	MyPro-
SRM	Internal	Control	Mixture	which	composed	of	a	pool	of	1	femto	mole	heavy	isotope	





The	 Agilent	 6495	 Triple	 Quadrupole	 Mass	 Spectrometer	 was	 tuned	 using	 the	
manufacturer’s	 tuning	mixture	 by	MyPro-SRM	Tuning	 Booster	 after	 every	 preventive	




Figure S1 Correlations	 between	 mRNA	 expressions	 and	 protein	 expressions	 (Spearman’s	 correlation	
coefficient,	rs)

































Female Male Female Male
BCRP 0.00304	(0.00012-0.12) 0.0031	(0.00014-0.026) 0.71 0.41	(0.18-0.62) 0.37	(0.15-0.63) 0.52
MATE1 0.028	(0.0012-0.56) 0.032	(0-0.51) 0.44 17.24	(6.211-29.13) 16.12	(5.72-31.72) 0.4
MATE2-K 0.032	(0.0032-0.39) 0.034	(0.0022-0.51) 0.89 0.25	(0.14-0.81) 0.24	(0.00-0.31) 0.27
MRP2 0.013	(6.32E-5	-	0.083) 0.018	(0.00089	-	0.18) 0.32 NA NA NA
MRP4 0.019	(0.0042-0.031) 0.017	(0.0014-0.041) 0.91 NA NA NA
MDR1 0.031	(0.00032-0.37) 0.034	(0.0016-0.23) 0.52 66.12	(11.68-102) 54.6	(7.84-112.4) 0.2
URAT1 0.14	(0.0082-0.7204) 0.1582	(5.65E-5	-	1.35) 0.89 39.1	(2.17-76.05) 35.26	(2.79-74.50) 0.54
GLUT2 0.017	(0.0012-0.50) 0.024	(0.0012-0.099) 0.35 32.01	(7.21-73.94) 26.12	(6.41-68.55) 0.39
OAT1 0.076	(2.3E-5	-	0.36) 0.11	(0.00037-0.67) 0.18 3.14	(0.93	-	4.49) 2.35	(0.96	-	5.45) 0.87
OAT3 0.052	(0-0.40) 0.071	(0.00039-0.44) 0.21 13.91	(4.54-27.23) 15.17	(3.43-37.92) 0.6
OCT2 0.087	(3.37E-5	-	0.57) 0.094	(0.00061-0.50) 0.54 27.82	(8.48-45.94) 26.62	(6.66-45.44) 0.78




statistical differences in the mRNA expression between these two ethnic groups in all age groups.
  Preterm to term newborn* Infant* Children* Adolescent* Adults*
BCRP -6.7 5.68 11.32 26.00 -29.40
MATE1 16.07 35.92 11.98 1.00 23.20
MATE2-K -76.09 20.14 3.00 -36.70 20.40
MDR1 5.08 17.25 -30.64 -38.4 62.60
URAT1 20.4 -0.87 27.52 9.30 22.80
GLUT2 51.17 11.15 -20.51 14.00 2.60
OAT1 61.50 -1.39 23.31 22.58 23.00
OAT3 -34.70 19.54 -6.32 16.60 18.00
OCT2 -27.98 14.69 1.44 -16.28 24.60
* mean rank differences
Table S3 Mann-Whitney	U	test	 to	examine	the	differences	 in	protein	expression	 levels	between	African	
American	adults	and	Caucasian	adults
Median (range)
Mann-Whitney U test p-value
African American Caucasian
BCRP 0.49	(0.33-0.63) 0.46	(0.38-0.5) 0.60
MATE1 16.8	(13.47-20.08) 23.01	(17.83-44.01) 0.095
MATE2-K 0.28	(0.14-0.49) 0.23	(0.19-0.27) 0.14
MDR1 64.57	(49.76-86.57) 70.98	(61.82-117.00) 0.55
URAT1 31.72	(24.79-45.64) 44.2	(12.95-71.51) 0.55
GLUT2 36.47	(22.02-42.34) 48.5	(22.37=66.12) 0.31
OAT1 4.49	(1.5-5.45) 3.95	(2.46-5.9) 0.84
OAT3 19.84	(5.39-27.23) 27.75	(14.43-31.51) 0.22
OCT2 28.6	(13.76) 33.52	(15.47-69.08) 0.69
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Table S5 Absolute abundance of nine selected renal membrane transporters+
Apical Basolateral
BCRP MATE1 MATE2-K MDR1 URAT1 GLUT2 OAT1 OAT3 OCT2
All samples



















Term newborn and infants















































































+Term newborn and infants were combined for analysis because there was only one term newborn included in 
this part of the study. Levels of significance are shown in Figure 3.
^pmol/mg total membrane protein *African American and Caucasian adults
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Table S7 Surrogate peptides for each of the renal membrane transporters studied and their corresponding 
MS/MS	parameters










OCT2 VSLQLLR.light 414.7687 729.4618 380 6 5 Positive
OCT2 VSLQLLR.light 414.7687 642.4297 380 10 5 Positive
OCT2 VSLQLLR.light 414.7687 529.3457 380 10 5 Positive
OCT2 VSLQLLR.light 414.7687 401.2871 380 10 5 Positive
OCT2 VSLQLLR.light 414.7687 321.7185 380 8 5 Positive
OCT2 LNPSFLDLVR.light 587.335 946.5356 380 12 5 Positive
OCT2 LNPSFLDLVR.light 587.335 849.4829 380 24 5 Positive
OCT2 LNPSFLDLVR.light 587.335 762.4509 380 24 5 Positive
OCT2 LNPSFLDLVR.light 587.335 530.7929 380 12 5 Positive
OCT2 LNPSFLDLVR.light 587.335 473.7715 380 8 5 Positive
OCT2 LNPSFLDLVR.light 587.335 228.1343 380 8 5 Positive
OCT2 LNPSFLDLVR.light 391.8924 559.2875 380 1 5 Positive
OCT2 LNPSFLDLVR.light 391.8924 502.2984 380 1 5 Positive
OCT2 LNPSFLDLVR.light 391.8924 473.7715 380 1 5 Positive
OCT2 LNPSFLDLVR.light 391.8924 387.2714 380 5 5 Positive
OCT2 LNPSFLDLVR.light 391.8924 336.6894 380 1 5 Positive
OCT2 SPGVAELSLR.light 514.7904 844.4887 380 18 5 Positive
OCT2 SPGVAELSLR.light 514.7904 688.3988 380 14 5 Positive
OCT2 SPGVAELSLR.light 514.7904 471.2744 380 18 5 Positive
OCT2 SPGVAELSLR.light 514.7904 341.1819 380 14 5 Positive
OCT2 SPGVAELSLR.light 514.7904 242.1135 380 18 5 Positive
OCT2 SPGVAELSLR.light 343.5293 541.2617 380 4 5 Positive
OCT2 SPGVAELSLR.light 343.5293 488.3191 380 4 5 Positive
OCT2 SPGVAELSLR.light 343.5293 412.2191 380 8 5 Positive
OCT2 SPGVAELSLR.light 343.5293 375.235 380 8 5 Positive
OCT2 SPGVAELSLR.light 343.5293 309.1845 380 8 5 Positive
OCT2 KLNPSFLDLVR.light 434.5907 687.3824 380 3 5 Positive
OCT2 KLNPSFLDLVR.light 434.5907 615.3824 380 3 5 Positive
OCT2 KLNPSFLDLVR.light 434.5907 502.2984 380 3 5 Positive
OCT2 KLNPSFLDLVR.light 434.5907 400.7369 380 3 5 Positive
OCT2 KLNPSFLDLVR.light 434.5907 308.1949 380 3 5 Positive
OCT2 VVAGVADAL.light 407.7371 683.3723 380 2 5 Positive
OCT2 VVAGVADAL.light 407.7371 612.3352 380 2 5 Positive
OCT2 VVAGVADAL.light 407.7371 426.2711 380 2 5 Positive
OCT2 VVAGVADAL.light 407.7371 389.2031 380 2 5 Positive
OCT2 VVAGVADAL.light 407.7371 342.1898 380 2 5 Positive
OCT2 VVAGVADAL.light 407.7371 203.139 380 2 5 Positive
OAT1 IYLTLLR.light 446.2867 778.4822 380 11 5 Positive
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Table S7 Surrogate peptides for each of the renal membrane transporters studied and their corresponding 
MS/MS	parameters	(continued)










OAT1 IYLTLLR.light 446.2867 615.4188 380 11 5 Positive
OAT1 IYLTLLR.light 446.2867 502.3348 380 7 5 Positive
OAT1 IYLTLLR.light 446.2867 390.2387 380 7 5 Positive
OAT1 IYLTLLR.light 446.2867 277.1547 380 7 5 Positive
OAT1 LVGFLVINSLGR.light 644.3928 1075.626 380 18 5 Positive
OAT1 LVGFLVINSLGR.light 644.3928 871.536 380 22 5 Positive
OAT1 LVGFLVINSLGR.light 644.3928 758.4519 380 14 5 Positive
OAT1 LVGFLVINSLGR.light 644.3928 659.3835 380 18 5 Positive
OAT1 LVGFLVINSLGR.light 644.3928 417.2496 380 10 5 Positive
OAT1 LVGFLVINSLGR.light 644.3928 213.1598 380 22 5 Positive
OAT1 NGGLEVWLPR.light 570.8116 799.4461 380 20 5 Positive
OAT1 NGGLEVWLPR.light 570.8116 670.4035 380 8 5 Positive
OAT1 NGGLEVWLPR.light 570.8116 385.2558 380 12 5 Positive
OAT1 NGGLEVWLPR.light 570.8116 342.1772 380 8 5 Positive
OAT1 NGGLEVWLPR.light 570.8116 272.1717 380 12 5 Positive
OAT1 NGGLEVWLPR.light 570.8116 229.0931 380 24 5 Positive
OAT1 GQASAMELLR.light 538.2819 890.4764 380 11 5 Positive
OAT1 GQASAMELLR.light 538.2819 819.4393 380 15 5 Positive
OAT1 GQASAMELLR.light 538.2819 732.4073 380 11 5 Positive
OAT1 GQASAMELLR.light 538.2819 661.3702 380 11 5 Positive
OAT1 GQASAMELLR.light 538.2819 257.1244 380 11 5 Positive
OAT1 TSLAVLGK.light 394.7475 600.4079 380 9 5 Positive
OAT1 TSLAVLGK.light 394.7475 487.3239 380 9 5 Positive
OAT1 TSLAVLGK.light 394.7475 416.2867 380 13 5 Positive
OAT1 TSLAVLGK.light 394.7475 317.2183 380 13 5 Positive
OAT1 TSLAVLGK.light 394.7475 204.1343 380 17 5 Positive
OAT3 TFSEILNR.light 490.264 731.4046 380 13 5 Positive
OAT3 TFSEILNR.light 490.264 644.3726 380 13 5 Positive
OAT3 TFSEILNR.light 490.264 515.33 380 13 5 Positive
OAT3 TFSEILNR.light 490.264 402.2459 380 13 5 Positive
OAT3 TFSEILNR.light 490.264 289.1619 380 13 5 Positive
OAT3 TFSEILNR.light 490.264 249.1234 380 9 5 Positive
OAT3 INLQKEI.light 429.2582 744.425 380 7 5 Positive
OAT3 INLQKEI.light 429.2582 726.4145 380 11 5 Positive
OAT3 INLQKEI.light 429.2582 630.3821 380 11 5 Positive
OAT3 INLQKEI.light 429.2582 517.298 380 7 5 Positive
OAT3 INLQKEI.light 429.2582 228.1343 380 7 5 Positive
OAT3 VAVLDGK.light 351.2132 602.3508 380 8 5 Positive
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Table S7 Surrogate peptides for each of the renal membrane transporters studied and their corresponding 
MS/MS	parameters	(continued)










OAT3 VAVLDGK.light 351.2132 531.3137 380 8 5 Positive
OAT3 VAVLDGK.light 351.2132 432.2453 380 8 5 Positive
OAT3 VAVLDGK.light 351.2132 319.1612 380 16 5 Positive
OAT3 VAVLDGK.light 351.2132 204.1343 380 16 5 Positive
OAT3 YTASDLFR.light 486.7429 809.4152 380 13 5 Positive
OAT3 YTASDLFR.light 486.7429 708.3675 380 9 5 Positive
OAT3 YTASDLFR.light 486.7429 637.3304 380 13 5 Positive
OAT3 YTASDLFR.light 486.7429 435.2714 380 21 5 Positive
OAT3 YTASDLFR.light 486.7429 265.1183 380 5 5 Positive
OAT3 TVLAVFGK.light 417.7578 634.3923 380 6 5 Positive
OAT3 TVLAVFGK.light 417.7578 521.3082 380 10 5 Positive
OAT3 TVLAVFGK.light 417.7578 450.2711 380 14 5 Positive
OAT3 TVLAVFGK.light 417.7578 351.2027 380 18 5 Positive
OAT3 TVLAVFGK.light 417.7578 201.1234 380 6 5 Positive
MATE1 QEEPLPEHPQDGAK.light 525.5864 659.3253 380 10 5 Positive
MATE1 QEEPLPEHPQDGAK.light 525.5864 594.804 380 10 5 Positive
MATE1 QEEPLPEHPQDGAK.light 525.5864 546.2776 380 10 5 Positive
MATE1 QEEPLPEHPQDGAK.light 525.5864 489.7356 380 6 5 Positive
MATE1 QEEPLPEHPQDGAK.light 525.5864 439.886 380 6 5 Positive
MATE1 QEEPLPEHPQDGAK.light 525.5864 396.8718 380 10 5 Positive
MATE1 TGEPQSDQQMR.light 638.783 989.4469 380 18 5 Positive
MATE1 TGEPQSDQQMR.light 638.783 559.7484 380 10 5 Positive
MATE1 TGEPQSDQQMR.light 638.783 495.2271 380 18 5 Positive
MATE1 TGEPQSDQQMR.light 638.783 486.2069 380 22 5 Positive
MATE1 TGEPQSDQQMR.light 638.783 288.119 380 18 5 Positive
MATE1 VGNALGAGDMEQAR.light 694.833 1047.489 380 20 5 Positive
MATE1 VGNALGAGDMEQAR.light 694.833 934.4047 380 20 5 Positive
MATE1 VGNALGAGDMEQAR.light 694.833 806.3461 380 20 5 Positive
MATE1 VGNALGAGDMEQAR.light 694.833 455.2613 380 16 5 Positive
MATE1 VGNALGAGDMEQAR.light 694.833 342.1772 380 24 5 Positive
MATE1 VGNALGAGDMEQAR.light 463.5577 467.706 380 4 5 Positive
MATE1 VGNALGAGDMEQAR.light 463.5577 455.2613 380 4 5 Positive
MATE1 VGNALGAGDMEQAR.light 463.5577 439.1953 380 4 5 Positive
MATE1 VGNALGAGDMEQAR.light 463.5577 411.5278 380 4 5 Positive
MATE1 VGNALGAGDMEQAR.light 463.5577 374.2146 380 4 5 Positive
MATE1 VGNALGAGDMEQAR.light 463.5577 246.1561 380 4 5 Positive
MATE1 GGPEATLEVR.light 514.7722 688.3988 380 14 5 Positive
MATE1 GGPEATLEVR.light 514.7722 617.3617 380 18 5 Positive
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Table S7 Surrogate peptides for each of the renal membrane transporters studied and their corresponding 
MS/MS	parameters	(continued)










MATE1 GGPEATLEVR.light 514.7722 516.314 380 14 5 Positive
MATE1 GGPEATLEVR.light 514.7722 457.7507 380 10 5 Positive
MATE1 GGPEATLEVR.light 514.7722 412.1827 380 14 5 Positive
MATE1 MEAPEEPAPVR.light 613.2977 894.468 380 21 5 Positive
MATE1 MEAPEEPAPVR.light 613.2977 539.33 380 25 5 Positive
MATE1 MEAPEEPAPVR.light 613.2977 483.2562 380 13 5 Positive
MATE1 MEAPEEPAPVR.light 613.2977 447.7376 380 17 5 Positive
MATE1 MEAPEEPAPVR.light 613.2977 332.1275 380 9 5 Positive
MATE1 MEAPEEPAPVR.light 613.2977 261.0904 380 17 5 Positive
MATE2-K SFGSPNR.light 382.6879 530.2681 380 5 5 Positive
MATE2-K SFGSPNR.light 382.6879 473.2467 380 9 5 Positive
MATE2-K SFGSPNR.light 382.6879 386.2146 380 9 5 Positive
MATE2-K SFGSPNR.light 382.6879 379.1612 380 5 5 Positive
MATE2-K SFGSPNR.light 382.6879 339.1719 380 9 5 Positive
MATE2-K SFGSPNR.light 382.6879 235.1077 380 5 5 Positive
MATE2-K AAEEAKK.light 373.7058 675.3672 380 13 5 Positive
MATE2-K AAEEAKK.light 373.7058 604.3301 380 9 5 Positive
MATE2-K AAEEAKK.light 373.7058 475.2875 380 9 5 Positive
MATE2-K AAEEAKK.light 373.7058 338.1872 380 9 5 Positive
MATE2-K AAEEAKK.light 249.4729 475.2875 380 4 5 Positive
MATE2-K AAEEAKK.light 249.4729 346.2449 380 4 5 Positive
MATE2-K AAEEAKK.light 249.4729 338.1872 380 4 5 Positive
MATE2-K AAEEAKK.light 249.4729 302.6687 380 0 5 Positive
MATE2-K AAEEAKK.light 249.4729 201.087 380 4 5 Positive
MATE2-K AAEEAKK.light 249.4729 200.7711 380 4 5 Positive
MATE2-K FSIAVSR.light 390.2241 632.3726 380 13 5 Positive
MATE2-K FSIAVSR.light 390.2241 545.3406 380 9 5 Positive
MATE2-K FSIAVSR.light 390.2241 432.2565 380 9 5 Positive
MATE2-K FSIAVSR.light 390.2241 361.2194 380 9 5 Positive
MATE2-K FSIAVSR.light 390.2241 235.1077 380 9 5 Positive
MATE2-K TPEEAHALSAPTSR.light 489.5793 683.3415 380 13 5 Positive
MATE2-K TPEEAHALSAPTSR.light 489.5793 634.8151 380 9 5 Positive
MATE2-K TPEEAHALSAPTSR.light 489.5793 618.3206 380 17 5 Positive
MATE2-K TPEEAHALSAPTSR.light 489.5793 460.2514 380 13 5 Positive
MATE2-K TPEEAHALSAPTSR.light 489.5793 455.8968 380 13 5 Positive
MATE2-K VGMALGAADTVQAK.light 666.353 973.5313 380 19 5 Positive
MATE2-K VGMALGAADTVQAK.light 666.353 860.4472 380 23 5 Positive
MATE2-K VGMALGAADTVQAK.light 666.353 803.4258 380 15 5 Positive
Ontogeny of renal transporters 151
5
Table S7 Surrogate peptides for each of the renal membrane transporters studied and their corresponding 
MS/MS	parameters	(continued)










MATE2-K VGMALGAADTVQAK.light 666.353 732.3886 380 15 5 Positive
MATE2-K VGMALGAADTVQAK.light 666.353 472.2588 380 15 5 Positive
MATE2-K VGMALGAADTVQAK.light 444.5711 616.8188 380 7 5 Positive
MATE2-K VGMALGAADTVQAK.light 444.5711 588.3081 380 7 5 Positive
MATE2-K VGMALGAADTVQAK.light 444.5711 546.3246 380 11 5 Positive
MATE2-K VGMALGAADTVQAK.light 444.5711 392.5411 380 3 5 Positive
MATE2-K VGMALGAADTVQAK.light 444.5711 218.1499 380 11 5 Positive
MDR1 EIIGVVSQEPVLFATTIAENIR.light 800.4442 917.5051 380 16 5 Positive
MDR1 EIIGVVSQEPVLFATTIAENIR.light 800.4442 816.4574 380 16 5 Positive
MDR1 EIIGVVSQEPVLFATTIAENIR.light 800.4442 715.4097 380 24 5 Positive
MDR1 EIIGVVSQEPVLFATTIAENIR.light 800.4442 531.2885 380 16 5 Positive
MDR1 EIIGVVSQEPVLFATTIAENIR.light 800.4442 512.3079 380 16 5 Positive
MDR1 EIIGVVSQEPVLFATTIAENIR.light 800.4442 955.5095 380 16 5 Positive
MDR1 AGAVAEEVLAAIR.light 635.3617 971.552 380 18 5 Positive
MDR1 AGAVAEEVLAAIR.light 635.3617 900.5149 380 18 5 Positive
MDR1 AGAVAEEVLAAIR.light 635.3617 430.2772 380 10 5 Positive
MDR1 AGAVAEEVLAAIR.light 635.3617 359.2401 380 10 5 Positive
MDR1 AGAVAEEVLAAIR.light 635.3617 299.1714 380 18 5 Positive
MDR1 AGAVAEEVLAAIR.light 423.9102 543.3613 380 6 5 Positive
MDR1 AGAVAEEVLAAIR.light 423.9102 430.2772 380 2 5 Positive
MDR1 AGAVAEEVLAAIR.light 423.9102 420.7267 380 2 5 Positive
MDR1 AGAVAEEVLAAIR.light 423.9102 359.2401 380 2 5 Positive
MDR1 AGAVAEEVLAAIR.light 423.9102 272.1843 380 2 5 Positive
MDR1 IATEAIENFR.light 582.3064 979.4843 380 16 5 Positive
MDR1 IATEAIENFR.light 582.3064 749.3941 380 16 5 Positive
MDR1 IATEAIENFR.light 582.3064 678.357 380 24 5 Positive
MDR1 IATEAIENFR.light 582.3064 565.2729 380 24 5 Positive
MDR1 IATEAIENFR.light 582.3064 490.2458 380 12 5 Positive
MDR1 IATEAIENFR.light 388.54 565.2729 380 1 5 Positive
MDR1 IATEAIENFR.light 388.54 486.2558 380 5 5 Positive
MDR1 IATEAIENFR.light 388.54 436.2303 380 5 5 Positive
MDR1 IATEAIENFR.light 388.54 283.1401 380 1 5 Positive
MDR1 STVVQLLER.light 522.806 856.5251 380 10 5 Positive
MDR1 STVVQLLER.light 522.806 757.4567 380 18 5 Positive
MDR1 STVVQLLER.light 522.806 658.3883 380 14 5 Positive
MDR1 STVVQLLER.light 522.806 530.3297 380 18 5 Positive
MDR1 STVVQLLER.light 522.806 428.7662 380 10 5 Positive
MDR1 TTIVIAHR.light 455.7771 708.4515 380 12 5 Positive
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MDR1 TTIVIAHR.light 455.7771 595.3675 380 12 5 Positive
MDR1 TTIVIAHR.light 455.7771 496.299 380 16 5 Positive
MDR1 TTIVIAHR.light 455.7771 354.7294 380 12 5 Positive
MDR1 TTIVIAHR.light 455.7771 298.1874 380 12 5 Positive
MDR1 TTIVIAHR.light 304.1871 496.299 380 8 5 Positive
MDR1 TTIVIAHR.light 304.1871 405.2532 380 4 5 Positive
MDR1 TTIVIAHR.light 304.1871 354.7294 380 0 5 Positive
MDR1 TTIVIAHR.light 304.1871 298.1874 380 0 5 Positive
MDR1 TTIVIAHR.light 304.1871 203.1026 380 0 5 Positive
BCRP SSLLDVLAAR.light 522.806 757.4567 380 18 5 Positive
BCRP SSLLDVLAAR.light 522.806 644.3726 380 10 5 Positive
BCRP SSLLDVLAAR.light 522.806 435.774 380 14 5 Positive
BCRP SSLLDVLAAR.light 522.806 430.2772 380 14 5 Positive
BCRP SSLLDVLAAR.light 522.806 317.1932 380 6 5 Positive
BCRP LAEIYVNSSFYK.light 717.3692 1007.483 380 21 5 Positive
BCRP LAEIYVNSSFYK.light 717.3692 844.4199 380 17 5 Positive
BCRP LAEIYVNSSFYK.light 717.3692 745.3515 380 13 5 Positive
BCRP LAEIYVNSSFYK.light 717.3692 427.2551 380 17 5 Positive
BCRP LAEIYVNSSFYK.light 717.3692 314.171 380 21 5 Positive
BCRP LFDSLTLLASGR.light 646.8641 1032.568 380 18 5 Positive
BCRP LFDSLTLLASGR.light 646.8641 717.4254 380 14 5 Positive
BCRP LFDSLTLLASGR.light 646.8641 503.2936 380 14 5 Positive
BCRP LFDSLTLLASGR.light 646.8641 390.2096 380 18 5 Positive
BCRP LFDSLTLLASGR.light 646.8641 319.1724 380 10 5 Positive
BCRP TIIFSIHQPR.light 404.568 737.4053 380 10 5 Positive
BCRP TIIFSIHQPR.light 404.568 499.2825 380 2 5 Positive
BCRP TIIFSIHQPR.light 404.568 442.7405 380 10 5 Positive
BCRP TIIFSIHQPR.light 404.568 369.2063 380 10 5 Positive
BCRP TIIFSIHQPR.light 404.568 215.139 380 2 5 Positive
BCRP VIQELGLDK.light 507.7951 802.4305 380 9 5 Positive
BCRP VIQELGLDK.light 507.7951 674.3719 380 9 5 Positive
BCRP VIQELGLDK.light 507.7951 432.2453 380 17 5 Positive
BCRP VIQELGLDK.light 507.7951 401.7189 380 9 5 Positive
BCRP VIQELGLDK.light 507.7951 213.1598 380 9 5 Positive
URAT1 AFSELLDLVGGLGR.light 723.9012 899.5309 380 25 5 Positive
URAT1 AFSELLDLVGGLGR.light 723.9012 786.4468 380 25 5 Positive
URAT1 AFSELLDLVGGLGR.light 723.9012 459.2674 380 21 5 Positive
URAT1 AFSELLDLVGGLGR.light 723.9012 402.2459 380 13 5 Positive
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URAT1 AFSELLDLVGGLGR.light 723.9012 232.1404 380 13 5 Positive
URAT1 AFSELLDLVGGLGR.light 482.9366 889.4666 380 5 5 Positive
URAT1 AFSELLDLVGGLGR.light 482.9366 558.3358 380 5 5 Positive
URAT1 AFSELLDLVGGLGR.light 482.9366 459.2674 380 5 5 Positive
URAT1 AFSELLDLVGGLGR.light 482.9366 459.2575 380 5 5 Positive
URAT1 AFSELLDLVGGLGR.light 482.9366 402.2459 380 5 5 Positive
URAT1 AFSELLDLVGGLGR.light 482.9366 279.6715 380 5 5 Positive
URAT1 GAVQDTLTPEVLLSAMR.light 600.989 836.9506 380 9 5 Positive
URAT1 GAVQDTLTPEVLLSAMR.light 600.989 787.4163 380 13 5 Positive
URAT1 GAVQDTLTPEVLLSAMR.light 600.989 786.3992 380 9 5 Positive
URAT1 GAVQDTLTPEVLLSAMR.light 600.989 723.3871 380 9 5 Positive
URAT1 GAVQDTLTPEVLLSAMR.light 600.989 558.3028 380 9 5 Positive
URAT1 MGALLLLSHLGR.light 640.879 908.5676 380 26 5 Positive
URAT1 MGALLLLSHLGR.light 640.879 795.4835 380 22 5 Positive
URAT1 MGALLLLSHLGR.light 640.879 682.3995 380 22 5 Positive
URAT1 MGALLLLSHLGR.light 640.879 569.3154 380 18 5 Positive
URAT1 MGALLLLSHLGR.light 640.879 260.1063 380 26 5 Positive
URAT1 GGAILGPLVR.light 476.8006 654.4297 380 16 5 Positive
URAT1 GGAILGPLVR.light 476.8006 541.3457 380 8 5 Positive
URAT1 GGAILGPLVR.light 476.8006 484.3242 380 12 5 Positive
URAT1 GGAILGPLVR.light 476.8006 412.2554 380 4 5 Positive
URAT1 GGAILGPLVR.light 476.8006 299.1714 380 12 5 Positive
URAT1 GGAILGPLVR.light 476.8006 271.1765 380 20 5 Positive
URAT1 GGAILGPLVR.light 318.2028 484.3242 380 4 5 Positive
URAT1 GGAILGPLVR.light 318.2028 387.2714 380 8 5 Positive
URAT1 GGAILGPLVR.light 318.2028 274.1874 380 4 5 Positive
URAT1 GGAILGPLVR.light 318.2028 271.1765 380 0 5 Positive
URAT1 GGAILGPLVR.light 318.2028 242.6657 380 4 5 Positive
GLUT2 SFEEIAAEFQK.light 649.8168 1064.526 380 15 5 Positive
GLUT2 SFEEIAAEFQK.light 649.8168 693.3566 380 15 5 Positive
GLUT2 SFEEIAAEFQK.light 649.8168 622.3195 380 11 5 Positive
GLUT2 SFEEIAAEFQK.light 649.8168 235.1077 380 27 5 Positive
GLUT2 SFEEIAAEFQK.light 433.547 1211.594 380 15 5 Positive
GLUT2 SFEEIAAEFQK.light 433.547 1064.526 380 15 5 Positive
GLUT2 SFEEIAAEFQK.light 433.547 622.3195 380 11 5 Positive
GLUT2 SFEEIAAEFQK.light 433.547 606.277 380 3 5 Positive
GLUT2 SFEEIAAEFQK.light 433.547 551.2824 380 7 5 Positive
GLUT2 SFEEIAAEFQK.light 433.547 339.1607 380 3 5 Positive
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Table S7 Surrogate peptides for each of the renal membrane transporters studied and their corresponding 
MS/MS	parameters	(continued)










GLUT2 VSIIQLFTNSSYR.light 764.4119 1115.548 380 19 5 Positive
GLUT2 VSIIQLFTNSSYR.light 764.4119 987.4894 380 23 5 Positive
GLUT2 VSIIQLFTNSSYR.light 764.4119 874.4054 380 19 5 Positive
GLUT2 VSIIQLFTNSSYR.light 764.4119 727.3369 380 15 5 Positive
GLUT2 VSIIQLFTNSSYR.light 764.4119 413.2758 380 15 5 Positive
GLUT2 VSIIQLFTNSSYR.light 509.9437 727.3369 380 10 5 Positive
GLUT2 VSIIQLFTNSSYR.light 509.9437 654.4185 380 6 5 Positive
GLUT2 VSIIQLFTNSSYR.light 509.9437 626.2893 380 10 5 Positive
GLUT2 VSIIQLFTNSSYR.light 509.9437 512.2463 380 14 5 Positive
GLUT2 VSIIQLFTNSSYR.light 509.9437 437.7063 380 6 5 Positive
GLUT2 VSIIQLFTNSSYR.light 509.9437 364.1721 380 6 5 Positive
GLUT2 HVLGVPLDDR.light 374.2085 615.3097 380 5 5 Positive
GLUT2 HVLGVPLDDR.light 374.2085 506.3085 380 1 5 Positive
GLUT2 HVLGVPLDDR.light 374.2085 407.2401 380 9 5 Positive
GLUT2 HVLGVPLDDR.light 374.2085 405.1728 380 9 5 Positive
GLUT2 HVLGVPLDDR.light 374.2085 308.1585 380 1 5 Positive
GLUT2 HVLGVPLDDRK.light 416.9068 533.2678 380 10 5 Positive
GLUT2 HVLGVPLDDRK.light 416.9068 506.3085 380 10 5 Positive
GLUT2 HVLGVPLDDRK.light 416.9068 416.2398 380 2 5 Positive
GLUT2 HVLGVPLDDRK.light 416.9068 407.2401 380 10 5 Positive
GLUT2 HVLGVPLDDRK.light 416.9068 372.206 380 10 5 Positive
GLUT2 HVLGVPLDDRK.light 416.9068 237.1346 380 14 5 Positive
GLUT2 LGPSHILIIAGR.light 416.2592 567.3431 380 10 5 Positive
GLUT2 LGPSHILIIAGR.light 416.2592 538.8324 380 6 5 Positive
GLUT2 LGPSHILIIAGR.light 416.2592 359.716 380 6 5 Positive
GLUT2 LGPSHILIIAGR.light 416.2592 359.5573 380 6 5 Positive
GLUT2 LGPSHILIIAGR.light 416.2592 303.1775 380 10 5 Positive
GLUT2 LGPSHILIIAGR.light 416.2592 303.1739 380 10 5 Positive
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ABSTRACT
The	 hepatic	 influx	 transporter	 OATP1B1	 (SLCO1B1)	 plays	 an	 important	 role	 in	 the	
disposition of endogenous substrates and drugs prescribed to children. Alternative 
splicing	 increases	 the	 diversity	 of	 protein	 products	 from	>90%	 of	 human	 genes	 and	
may be triggered by developmental signals. As concentrations of several endogenous 






for truncated proteins. The expression of eight isoforms was associated with age. We 
conclude	that	alternative	splicing	of	SLCO1B1	occurs	frequently	in	children;	although	the	
functional	consequences	remain	unknown,	the	data	raise	the	possibility	of	a	regulatory	





membranes	 of	 organs,	 such	 as	 the	 liver.1 Their biological role is the trafficking of 
substrates	across	membranes,	making	them	critical	determinants	of	tissue	and	cellular	






dietary	 constituents,	 recruiting	 pathways	 not	 or	 differentially	 expressed	 during	 fetal	
life.	Hence	ontogeny	of	DMEs	 and	 transporters	 occurs,	 influencing	 the	disposition	of	
their	endogenous	and	exogenous	substrates	over	age.	Moreover,	ontogeny	may	well	be	
driven by developmental homeostatic changes in endogenous substrates.3
A	classic	example	of	age-related	changes	in	a	DME	that	plays	an	important	physiological	
role	is	hepatic	cytochrome	P450	(CYP)	3A7.	CYP3A7	is	highly	expressed	in	fetal	liver	but	
steadily declines throughout the last trimester of pregnancy and first year of postnatal 
life to low levels characteristic of adult liver.4,5	From	a	 functional	perspective,	CYP3A7	
catalyzes	 the	16α-hydroxylation	of	dehydroepiandosteron	3-sulfate	 (DHEA-S),	 to	 form	
16α-DHEA-S,	a	precursor	for	estriol	synthesis	by	placental	syncytiotrophoblasts.6	DHEA-S	
concentrations are high during the fetal and neonatal periods and decline postnatally.7,8 
DHEA-S	has	been	reported	to	activate	CYP3A7	activity,	which	explains	the	high	expression	
of	 CYP3A7	 in	 fetal	 liver.9	 DHEA-S	 also	 provides	 an	 example	 of	 the	 interplay	 between	
DMEs	 and	 transporters	 in	 a	 developmental	 context	 as	 prior	 to	 biotransformation	 by	
CYP3A7	in	fetal	liver,	DHEA-S	needs	to	cross	the	hepatocyte	membrane,	using	the	solute	
carrier organic anion transporter (gene name SLCO1B1,	protein	name	OATP1B1)	located	
on the basolateral membrane.10	Consistent	with	CYP3A7,	the	OATP1B1	expression	also	
has been demonstrated to decline directly after birth11,	 followed	 by	 age-dependent	
increases in mRNA expression throughout childhood.12	Data	are	conflicting	 regarding	
developmental	patterns	of	OATP1B1	protein,	with	expression	increased	around	age	eight	
years,	compared	to	younger	children	in	one	study,	using	immunoblotting	techniques13,	
and	 no	 apparent	 statistically	 significant	 relationship	 with	 age,	 using	 a	 quantitative	
proteomic approach.14
Whereas	the	contribution	of	CYP3A7	to	drug	clearance	postnatally	 is	 relatively	minor,	
OATP1B1 plays an important role in the clearance of potentially toxic endogenous 
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molecules. One example illustrating the importance of transporter function early after 
birth involves bilirubin; an association has been demonstrated between the SLCO1B1 




Malfunctioning of the OATP1B1 transporter may put children at risk of toxic or sub 
therapeutic	 effects	 of	 these	 drugs.	 Thus,	 understanding	 the	 regulatory	 mechanisms	
of the gene SLCO1B1 in response to developmental signals is critical to understand 
physiological changes in endogenous substrates and to provide safe and effective drug 
therapy in children.
To	 date,	 ontogeny	 studies	 have	 generally	 focused	 on	 mRNA	 expression	 and,	 more	
recently,	have	expanded	to	protein	abundance	targeting	specific	regions	of	the	reference	




of	exons,	different	 length	of	exons,	and	varying	lengths	of	untranslated	regions.17 Not 
all products of alternative splicing necessarily result in the production of functional 
proteins. Alternative splicing may be the result of developmental signals expressed 
during the course of growth and development.17-19	 For	 example,	 developmentally	
regulated alternative splicing has been demonstrated for neuronal sodium channels 
genes SCN1A, SCN2A, SCN3A, SCN8A and SCN9A	in	brain	tissue;	the	alternative	exon	5N	
predominates	in	the	neonatal	period	whereas	5A	predominates	in	the	adult.20-25 In the 
case of SCN1A, a gene implicated in the pathogenesis of febrile seizures in newborns26,	
an allelic variant SCN1A	 IVS5–91	G>A	disrupts	 the	5’	 splice	donor	site	of	exon	5N	and	
potentially	influences	the	relative	expression	of	exons	5N	and	5A.	Although	the	SCN1A 
IVS5–91	 G>A	 variant	 does	 not	 appear	 to	 be	 associated	with	 febrile	 seizures	 per se27, 
studies suggest that presence of the variant allele may affect dose requirements for 
phenytoin and carbamazepine.25,28	 Thus,	 alternative	 splicing	 and	 genetic	 variants	
affecting	alternative	splicing,	may	have	therapeutic	consequences.
The SLCO1B1	gene,	consisting	of	14	coding	and	one	non-coding	exons,	codes	 for	 the	
protein	OATP1B1	that	is	composed	of	691	amino	acids,	and	consists	of	12	transmembrane	
(TM) regions.10 It is part of the SLCO1B	 family,	 for	 which	 splice	 variants	 have	 been	





from SLCO1B3 and SLCO1B7,	and	has	functional	transporter	properties.30	In	contrast,	for	
SLCO1B1	 there	 is	 only	 one	 reported	mRNA	 transcript,	 ENST00000256958.2,	 encoding	
the	functional	691	amino	acid	OATP1B1	protein;	referred	to	hereafter	as	the	“reference	
isoform”.10
Given	 these	 considerations,	 the	 purpose	 of	 this	 exploratory	 study	was	 to	 investigate	
alternative splicing of SLCO1B1	 in	post-mortem	pediatric	 liver	 tissue	over	 a	wide	 age	
range	from	fetal	to	adolescent	ages.	Using	RNA	sequencing	(RNA-seq)	data,	we	created	a	
process involving computational software integrating our bioinformatics pipelines and 
an	in-house	developed	RNA-seq	database	query	system	to	perform	a	structured	analysis	
of	the	RNA-seq	data	 in silico.	Using	this	data	analysis	pipeline,	we	aimed	(1)	to	predict	
splice variants for SLCO1B1,	 (2)	to	 identify	potential	hybrid	splice	variants	overlapping	
SLCO1B1 and SCLO1B7 (another member of the SLCO1B	 family),	 and	 (3)	 to	 study	age-








at	 the	 time	of	 autopsy	within	24	hours	 after	death	and	 snap-frozen	at	 -800C	 for	 later	
research	use.	For	the	tissues	provided	by	the	Erasmus	MC	tissue	bank,	the	Erasmus	MC	
Research Ethics Board waived the need for formal ethics approval according to the 
Dutch	Law	on	Medical	Research	in	Humans.	Tissue	was	collected	when	parental	written	
informed consent for both autopsy and the explicit use of the tissue for research was 
present. The samples were selected when the clinical diagnosis of the patient was not 
related to hepatic problems and the tissue was histologically normal (as estimated by a 




















sample preparation kit. The quality of the library preparation was confirmed by analysis on 
a	2100	Bioanalyzer	(Agilent	Technologies,	Santa	Clara,	CA).	The	cDNA	fragments	were	then	
sequenced	on	an	Illumina	HiSeq	2000	to	obtain	100-bp	sequences	from	both	ends	(paired	
end). The resulting reads were mapped by Bowtie2 and StringTie31-33 to the transcriptome 
constructed	through	reference	genes/transcripts	according	to	the	reference	human	genome	
GRCh37.61/hg19.34 The mapped reads were then assigned to transcripts from which the 





(Ensembl	 transcript	 ID	ENST00000256958.3).	Moreover,	 to	 further	validate	 the	 results,	
the	presence	of	the	alternatively	spliced	transcript	LST-3TM1230 was detected using the 
algorithm	RSEM	combined	with	Bowtie2	and	the	assembly	GRCh37.
Protein prediction
Sequence alignment and overlap of splice variants with consensus coding sequences 
(CCDS)37 for SLCO1B1 and the adjacent gene SLCO1B7	was	performed	using	Basic	Local	
Alignment	Search	Tool	(BLAST).38 Splice variants were prioritized for further investigation 
when one of the following criteria was met and when the presence of the splice variant 
was	verified	with	RT-PCR:
-	 the	 expression	 of	 the	 splice	 variant	 was	 >5%	 of	 the	 expression	 of	 the	 reference	
isoform,
-	 the	splice	variant	was	a	SLCO1B7 and SLCO1B1	hybrid	transcript,	or
-	 the	expression	of	the	splice	variant	was	associated	with	age	(see	‘Data	and	Statistical	
analysis’)
Next,	 the	 open	 reading	 frame	 (ORF)	 of	 >600	 nt	 of	 the	 relevant	 splice	 variants	 was	
predicted	with	ORF-Finder	 by	NCBI.39 Prediction of transmembrane (TM) regions and 
orientation was done with TMpred based on the TMbase database.40 Two dimensional 
protein structures were generated with TOPO2.41
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To provide additional bioinformatic confirmation that candidate novel alternatively 
spliced	 products	 represent	 coding	 transcripts,	 sequencing	 data	 were	 analyzed	 using	
two	additional	tools:	the	Coding	Potential	Calculator	Algorithm	(CPC2)	and	the	Coding-
Potential	Assessment	Tool	 (CPAT).42,43 These algorithms both use logistic regression to 
distinguish	between	coding	and	non-coding	transcripts	based	on	four	intrinsic	features:	
the	 Fickett	 testcode	 score	 (both),	ORF	 length	 (both),	ORF	 integrity	 (CPC2),	 isoelectric	
point	(CPC2),	ORF	coverage	defined	as	the	ratio	of	ORF	to	transcript	lengths	(CPAT)	and	
hexamer	usage	bias	(CPAT).







Valencia,	 CA).	 One	 µg	 of	 total	 RNA	 was	 DNase	 treated	 and	 reverse	 transcribed	 with	
the	 Maxima	 H	 Minus	 First	 Strand	 cDNA	 Synthesis	 Kit,	 following	 the	 manufacturer’s	







DNA	 Analyzer	 (Thermo	 Fisher).	 The	 results	 were	 analyzed	with	 Sequencher	 software	
(Gene	Codes,	Ann	Arbor,	MI).
Data and Statistical analysis
Because	 of	 non-normal	 distribution,	 the	 data	 are	 presented	 as	median	 (range).	 First,	
the relative abundance of the expression of each transcript compared to the reference 
isoform	was	calculated.	Also,	the	relationship	of	age	with	expression	levels	 (TPM)	was	
studied by comparing expression levels between age groups. Samples were assigned to 
one	of	five	age	groups:	fetal,	0-1.5	years,	1.5-6	years,	6-12	years	and	12-18	years.	Kruskal-
Wallis	test	with	Dunn’s	post-hoc	test	were	used	for	multiple	comparisons	of	expression	
levels	 between	 age	 groups.	 For	 Dunn’s	 post-hoc	 test	 for	 multiple	 comparisons	 the	




and expression levels of splice variants were examined. To control for the number of 
correlations	 tested	 (54),	 p-values	were	 considered	 statistically	 significant	 only	 if	 their	
corresponding	 q-value	 was	 less	 than	 .05	 after	 Benjamini-Hochberg	 adjustment	 to	
control the false discovery rate. Statistical analyses were performed using IBM SPSS 
Statistics	 software	 (SPSS	 Statistics	 for	Windows,	 version	 21.0;	 IBM,	 Armonk,	 NY)	 and	
graphical	exploration	was	done	with	GraphPad	Prism.	We	explored	negative	binomial	
and	zero-inflated	negative	binomial	models	in	SAS	9.4,	but	the	former	did	not	fit	well,	





can be found in Table 1.	The	reference	isoform	of	SLCO1B1	was	detected	in	all	but	one	
sample	with	a	median	expression	of	33.4	(range	0-134.2)	TPM.	The	transcript	consisted	of	
2791	nucleotides	(nt)	of	which	95	nt	comprise	the	5’-UTR	and	621	nt	the	‘3-UTR,	resulting	
in	a	protein	of	691	amino	acids.	This	is	in	accordance	with	Niemi	et al.10 In Figure	2A the 




a	 total	 expression	of	 18.8	 (0.2-105.0)	TPM	 (Figure	 2B). These are numbered randomly 
between	21	and	55.	The	 ratio	of	 the	 total	expression	of	 the	splice	variants	versus	 the	




Age groups Number of samples Gestational age (weeks) Postnatal age (years)
Fetus 22 16.4	(14.7-41.3) -
0	–	1.5	yr 35 - 0.1	(0-1.2)
1.5	–	6	yr 16 - 3	(1.8-6)
6	–	12	yr 15 - 9	(7-12)
12	–	18	yr 9 - 15	(13-17)
Total 97
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The	 splice	 junctions	 of	 variant	 46	were	 not	 sufficiently	 unique	 to	design	primers	 that	
would amplify only this variant or to generate a product with a size that could resolved 











Splice variants meeting the abundance criterion





Splice variants overlapping with SLCO1B7 and SLCO1B1
Four	splice	variants	were	identified	with	exons	overlapping	the	SLCO1B1 as well as the 
SLCO1B7 gene region (Table 2).	They	all	had	an	ORF	overlapping	>40%	of	the	amino	acid	
sequence	of	OATP1B1.	However,	the	ORF	of	none	of	them	was	overlapping	the	SLCO1B7 
region. Two of these isoforms are predicted to translate into similar protein versions of 
OATP1B1,	as	they	have	100%	overlap	with	the	reference	isoform.	All	four	splice	variants	
have longer untranslated regions than the reference isoform.
One	isoform,	sv28,	overlapped	with	SLCO1A2.	This	hybrid	isoform	contains	an	intron-less	
complete	coding	sequence,	which	is	officially	located	in	intron	13	of	SLCO1A2.


















































































































































46‡* 26.55 16.48 63 10 4638 284 274	(40%) 10 - - - 6
50‡ 14.26 8.85 93 17 34388 453 444	(65%) 9 - - - 10
34‡ 9.24 5.73 46 18 4156 625 622	(90%) - - 3 - 11
24◊* 0.32 0.20 77 25 3151 659 622	(90%) - 0 - 37 11
26◊* 1.80 1.12 81 24 13158 691 691	(100%) - 0 - - 12
28◊* 1.21 0.75 96 20 14577 691 691	(100%) - 0 - - 12
210 - - - - 210 0
881 - - - - 881 1
30◊* 0.34 0.21 54 20 5684 484 453	(66%) - 0 - 31 8
38* 0.52 0.33 95 15 22310 453 444	(65%) 9 - - - 10
44* 7.86 4.88 65 3 7364 98 98	(14%) - - - - 2
51* 0.73 0.46 76 17 15407 522 522	(75%) - - - - 8
AA=amino acid nt=nucleotides TM=transmembrane, †SLCO1A2 is on the reverse strand ‡Abundant splice 
variant ◊ Hybrid SLCO1B1 and -1B7 *Age related changes in expression
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Figure 3 Expression (A) and expression in relation to the reference isoform (B) of developmentally regulated 




Splice variants with age-related expression
Age groups
The	splice	variants	26	and	46	showed	age-related	changes	in	their	expression	with	lower	
expression in fetal tissue than in tissue from older children (see Figure	3A for specific 
changes and Table 2 for splice variant information). When analyzed as a ratio to the 
expression	of	the	reference	isoform,	for	one	splice	variant	(26)	the	ratio	variant/reference	
isoform	increased	with	age,	while	three	splice	variants	decreased	with	age:	isoforms	24,	
28	and	44	(see	Figure	3B for specific changes and Table 2 for splice variant information). 
This	latter	observation	reflects	that	for	the	individual	samples	either	the	expression	of	
the	splice	variant	was	lower,	or	the	expression	of	reference	isoform	was	higher.	As	the	
expression of the reference isoform was shown to be similar when binned in age groups 
(Figure	3A),	it	is	therefore	likely	that	the	expression	of	the	splice	variants	that	decreased	
with age was lower.
Age on continuous scale
The	expression	of	four	of	the	five	hybrid	SLCO1B7	and	SLCO1B1	splice	variants	(24,	26,	








In	Table	 S3	 the	 coding-potential	prediction	 results	using	 the	CPAT	and	CPC2	 tool	 are	




on	a	 log-likelihood	 ratio	 to	measure	differential	 hexamer	usage	between	 coding	and	
noncoding sequences.44 All other splice variants have a very high probability to be 
translated into a protein product. In Figure	4A	the	2D	structure	of	OATP1B1	is	presented,	




and	 (B)	 the	predicted	2D	 structure	of	 splice	 variants	of	OATP1B1,	 centered	on	 the	4th intracellular loop 
(dashed line) of the reference structure for OATP1B1.
The number of the splice variant is presented in the upper left corner of each structure. Red and blue: overlapping 
amino acid sequence with OATP1B1. Blue: overlapping structure OATP1B1.
Alternative	splicing	of	the	SLCO1B1	gene	in	pediatric	liver 171
6
Table 3 Spearman correlations expression splice variant vs. postnatal age
Splice variant Expression splice variant (TPM) vs. 
postnatal age (weeks)
Ratio expression splice variant/reference 
isoform vs. postnatal age (weeks)
rs p value rs p value
21 0.231 0.023 0.194 0.057
24 -0.330 0.001* -0.392 0.000*
26 0.489 0.000* 0.518 0.000*
28 -0.263 0.009* -0.433 0.000*
30 0.290 0.004* 0.296 0.003*
33 0.142 0.166 0.143 0.163
34 0.133 0.193 0.110 0.285
35 -0.035 0.734 -0.222 0.029
36 0.063 0.539 0.058 0.575
37 0.069 0.501 0.006 0.955
38 -0.070 0.496 -0.271 0.007*
39 -0.141 0.167 -0.188 0.065
40 -0.017 0.869 -0.092 0.371
41 0.003 0.977 -0.001 0.990
42 0.055 0.591 -0.059 0.566
43 0.065 0.528 0.063 0.542
44 -0.121 0.240 -0.259 0.010*
45 -0.017 0.867 -0.020 0.843
46 0.386 0.000* 0.343 0.001*
47 -0.023 0.825 -0.106 0.299
48† -0.243 0.016 -0.463 0.000*
49 -0.117 0.253 -0.146 0.152
50 0.204 0.045 -0.202 0.047
51 -0.177 0.083 -0.308 0.002*
53 -0.029 0.779 -0.043 0.678
54 -0.155 0.129 -0.169 0.097
55 -0.173 0.091 -0.203 0.046
* Significant after adjustment to control false discovery rate at .05 †excluded from further analysis because the 
presence was not confirmed by RT-PCR
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DISCUSSION
In the current study we have developed a data analysis pipeline that allowed a 
structured	analysis	of	 a	 large	amount	of	RNA-seq	data	generated	 from	pediatric	 liver	
samples and used this to investigate alternative splicing of the SLCO1B1 gene that could 
potentially	translate	into	functional	OATP1B1	proteins.	More	specifically,	we	report	three	
major findings from the ten relevant splice variants that we identified: (1) two splice 
variants are predicted to translate into the same amino acid sequence as the reference 
isoform for OATP1B1; (2) eight splice variants may translate into truncated versions of 
the	OATP1B1	protein	because	of	an	altered	length	of	amino	acid	sequence,	and	(3)	the	
expression of eight splice variants was associated with age. None of the splice variants 
had	an	ORF	that	covered	the	SLCO1B7 region.
Our results show that the SLCO1B1	 gene	 locus	 is	 subject	 to	 alternative	 splicing,	 as	
supported	 by	 the	 major	 findings	 presented	 above.	 More	 specifically,	 the	 fact	 that	
eight	 splice	 variants	 of	 SLCO1B1	 showed	 a	 developmental	 pattern	 is	 consistent	with	
developmentally	 regulated	 alternative	 splicing	 as	 a	mechanism	 for	 altered	 SLCO1B1/
OATP1B1 expression during growth and maturation. This finding may have implications 
for	the	functionality	of	the	transporter	 in	children,	and	with	that	the	disposition	of	 its	
endogenous	and	exogenous	substrates,	as	most	of	these	splice	variants	were	predicted	
to result in truncated OATP1B1 isoforms with fewer TM regions compared to the reference 
OATP1B1 protein. Available evidence suggests that SLCO1B7 is a pseudogene resulting 
in	a	non-functional	protein	product	with	only	11	TM	regions,	whereas	the	SLCO1B1	gene,	
the SLCO1B3	gene	and	the	hybrid	transcript	LST-3TM12	give	rise	to	at	least	one	mRNA	
transcript that translates into functional transporters with 12 TM regions.30	Moreover,	the	






Some of the alternative proteins of OATP1B1 reported in this study therefore are likely to 
result	in	non-functional	protein	products	incapable	of	cellular	transport,	but	could	possibly	
possess	alternative	functional	properties,	such	as	regulating	the	activity	of	the	functional	







was decreased in the presence of i2 proteins despite the same amount of i1 enzyme.47 
This	 phenomenon	 is	 explained	 by	 oligomerization	 of	 UGT1A	 enzyme;	 i2	 proteins	 can	
form	dimers	with	i1	enzymes,	inhibiting	the	activity	of	i1	enzymes.48	Interestingly,	OATP1B	
transporters	not	only	 form	homo-oligomers,	but	can	also	 form	hetero-oligomers,	even	
with	 transporters	 from	 another	 family,	 e.g.	 with	 Na+/taurocholate	 co-transporting	
polypeptide	(NTCP).49,50	It	has	been	demonstrated	that	a	non-functional	unit	of	OATP1B3,	
containing	a	 lysine	at	position	41	 in	place	of	 the	wild-type	cysteine	 in	 the	homodimer	
did	not	affect	normal	substrate	transport	by	the	functional,	cysteine-containing	OATP1B3	
component	of	the	homodimer,	suggesting	that	each	unit	within	the	dimer	works	as	an	
independent functional unit.49	However,	each	splice	variant	may	have	 its	own	 function	
and	 so	 we	 hypothesize	 that	 those	 resulting	 in	 truncated	 proteins	 may	 influence	 the	
transporter activity of the reference protein OATP1B1 and other transporters.
The specific SLCO1B1 region is part of the wider SLCO1B-family	 region,	 which	 gives	
rise	 to	 the	SLCO1B3/SLCO1B7	hybrid	 transcript	LST-3TM12	 that	 results	 in	a	 functional	
transporter.30	The	four	SLCO1B1	splice	variants	found	in	this	study	that	contained	exons	
covering the region of SLCO1B7 did not contain the start codon from the SLCO1B7	locus,	
thus we conclude that the SLCO1B1 gene is not subject to hybridization with adjacent 
genes.	However,	the	length	of	the	untranslated	region	(UTR)	of	these	and	other	transcripts	
could	well	 be	 influencing	 the	 function	of	 the	 transporter,	 even	when	 the	ORF	of	 the	
splice	variant	is	the	same	as	the	reference	sequence.	We	note	that	a	transcript	of	CYP3A4	
with	a	shorter	3’-UTR	than	the	canonical	transcript	due	to	an	additional	polyadenylation	
site was more stable and generated more protein51 than an alternative transcript with 
a	longer	3’-UTR.	Interestingly,	this	shorter	transcript	showed	developmental	regulation	
as	it	was	higher	expressed	in	adult	livers	than	in	pediatric	livers.	Nevertheless,	it	remains	
to be seen whether this is also the case for the splice variants presented in this study.
Another consequence of these truncated versions of OATP1B1 is that they may interfere 
with	 the	 estimation	of	OATP1B1	 content	 using	 LC-MS/MS-based	proteomic	methods.	
This quantitative proteomic approach utilizes short peptides to target the protein of 
interest. All truncated versions of OATP1B1 presented in this manuscript contained the 
amino	acid	sequences	NVTGFFQSFK14	and	of	LNTVGIAK11 that have been used in studies 
presenting results on expression of OATP1B1 protein in pediatric liver tissue. The latter 
refers	 to	our	previous	 study,	where	a	poor	correlation	was	 seen	between	 total	mRNA	
expression	of	SLCO1B1	as	measured	with	RNA-seq	and	protein	abundance	of	OATP1B1	




detected	 by	 the	 peptide	 sequences	 used	 to	 quantitate	OATP1B1	 content,	 could	 also	
result	in	poor	correlations	between	abundance	and	activity.	Thus,	care	may	be	needed	
when	 extrapolating	 mRNA	 expression	 to	 protein	 abundance,	 protein	 abundance	 to	
actual	activity,	and	ultimately	the	prediction	of	disposition	of	transporter	substrates.
We recognize that a limitation of our study is that our results are based on in silico 
predictions,	 and	 the	 presence	 of	 the	 corresponding	 truncated	 proteins	 must	 be	
confirmed by protein abundance studies before any of the implications we propose 
above	can	be	assessed,	including	investigations	of	a	dominant-negative	regulatory	role	
analogous	to	the	UGT1A	situation.	Developmental	regulation	of	alternative	splicing	is	a	
commonly recognized phenomenon during tissue development and cell differentiation. 
In	 fact,	 level	 of	 expression,	 localization	 within	 the	 cell,	 mRNA	 stability,	 translation	
efficiency and splicing of specific RNA binding proteins (RBPs) is finely regulated. RBPs 
bind	to	cis-elements	and	promote	or	inhibit	splice	site	recognition,	and	therefore	RBP	
expression coordinates alternative splicing networks during development.18	 Further	
work is necessary to characterize the specific developmental signals responsible for the 
observed	changes	in	expression	of	the	SLCO1B1	splice	variants.
These exploratory data imply that the complexity of processes involved with growth 
and	development	throughout	childhood	may	have	influences	on	transporter	expression	
and	subsequent	substrate	disposition,	as	yet	unrecognized.	The	observed	age-related	
changes	 in	 expression	 of	 splice	 variants	 in	 the	 context	 of	 age-related	 changes	 in	
concentrations	 of	 endogenous	 OATP1B1	 substrates,	 such	 as	 DHEA-S	 and	 16alpha-
hydroxylated	metabolites,	makes	 it	 tempting	 to	 speculate	 that	 additional	 regulatory	
mechanisms	may	be	in	play,	with	implications	for	the	disposition	of	exogenous	substrates	
used	 in	 pediatrics.	 Most	 importantly,	 the	 data	 analysis	 pipeline	 we	 have	 developed	
allows	the	analyses	described	in	this	manuscript	for	SLCO1B1	to	be	applied	to	any	other	
gene of interest and will be repeated for other transporters and genes involved in drug 
disposition or growth of children in the future.
In	 conclusion,	 we	 have	 shown	 that	 SLCO1B1	 splice	 variants	 with	 an	 ORF	 could	
potentially translate into proteins with unknown function; they are unlikely to code for 
functional,	transporters,	but	may	have	other	roles,	such	as	regulatory	activity.	Moreover,	
as	 the	 expression	 of	 particular	 SLCO1B1	 splice	 variants	 showed	 age-related	 changes,	
the data raise the possibility of a regulatory role for alternative splicing in mediating 
developmental	 changes	 of	 SLCO1B1/OATP1B1	 in	 drug	 disposition.	 These	 data	 can	
contribute	to	improved	understanding	of	age-related	changes	in	expression	of	SLCO1B1,	
and possibly other enzymes and transporters involved in the disposition of endogenous 
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The arrow indicates the band which was excised from the gel; the amplicon was extracted and sequenced. Black 
indicates correct amplicon size which was confirmed by sequencing. Gray indicated band sizes which were either 
too large (sv21), too short (sv37) or did not amplify at all. The universal SLCO1B1 primer pair (sv-all) was used for 







Primer Name Sequences (5’-3’) Sv

































SLCO1B1	sv-all	F CTGGGAAATTGACAGAAAGTACTCTG all sv
SLCO1B1	sv-all	F	nest GGGAAGATAATGGTGCAAATAAAG all sv


















































































































































































































































































































































































































































































































































































24 0.701 -0.145 0.999 Coding 0.390 8.704 1 1.000 Coding
26 0.659 -0.152 0.999 Coding 0.294 8.852 1 1.000 Coding
28 0.845 0.029 1.000 Coding 0.334 9.696 1 1.000 Coding
30 0.648 -0.146 0.999 Coding 0.324 8.682 1 0.999 Coding
34 0.661 -0.152 0.999 Coding 0.304 8.905 1 1.000 Coding
38 0.841 -0.146 0.999 Coding 0.275 9.185 1 0.999 Coding
44 0.621 -0.284 0.005 Noncoding 0.294 8.864 1 0.089 Noncoding
46 0.845 -0.154 0.924 Coding 0.285 9.026 1 0.972 Coding
50 0.841 -0.146 0.998 Coding 0.271 9.185 1 0.999 Coding
51 0.663 -0.159 0.999 Coding 0.266 8.633 1 0.999 Coding
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drug metabolism. Microdose studies present an innovation to study pharmacokinetics 
(PK)	 in	 paediatrics,	 however,	 it	 should	 be	 used	 only	 when	 the	 PK	 is	 dose	 linear.	We	
aimed	to	assess	dose-linearity	of	a	[14C]midazolam	microdose,	by	comparing	the	PK	of	




to	 36	 hours.	 Plasma-concentrations	 of	 [14C]midazolam	 and	 [14C]1-hydroxy-midazolam	
were	 determined	 by	 accelerator	mass	 spectrometry.	 Non-compartmental	 PK	 analysis	
(NCA)	was	performed	and	a	population	PK	model	was	developed.
Results:	Of	15	infants	(median	gestational	age	39.4	[range	23.9-41.4]	weeks,	postnatal	
age	 11.4	 [0.6-49.1]	 weeks),	 six	 received	 a	 microtracer	 and	 nine	 a	 microdose	 [14C]
midazolam (111 Bq kg-1;	 37.6	 ng	 kg-1).	 In	 a	 two-compartment	 PK	model,	 bodyweight	
was the most significant covariate for volume of distribution. There was no statistically 
significant	difference	in	any	PK	parameter	between	the	microdose	and	microtracer,	nor	
in	the	AUC	ratio	[14C]1-OH-midazolam/[14C]midazolam,	showing	the	PK	of	midazolam	to	
be linear within the range of the therapeutic and microdoses.
Conclusion:	 Our	 data	 supports	 the	 dose-linearity	 of	 the	 PK	 of	 an	 IV	 [14C]midazolam	
microdose	in	children.	Hence,	a	[14C]midazolam	microdosing	approach	may	be	used	as	






Drug	disposition	 in	children	may	vary	 from	adults	due	 to	age-related	variation	 in	 the	
processes	governing	absorption,	distribution,	metabolism	and	excretion.1,2 This variation 
is largest in the first years of life and is not directly proportionate to size.3,4	However,	in	
daily clinical practice drug dosing in paediatrics is often based on bodyweight based 
corrections,	which	 because	 of	 variation	 arising	 from	development,	 can	 result	 in	 sub-
therapeutic or toxic drug exposure in certain subgroups.2	Hence,	doses	used	for	children	
cannot	simply	be	extrapolated	from	adults	using	a	simple	bodyweight-based	correction.
Phenotyping	 studies,	 in	which	model	 drugs	 representative	 for	 a	 certain	 pathway	 are	
studied	 across	 the	 paediatric	 age	 range,	 can	 be	 used	 to	 elucidate	 the	 age-related	
variation in drug disposition pathways in vivo.5	However,	 these	studies	are	faced	with	
ethical,	 practical	 and	 scientific	 challenges.	 Children	 are	 vulnerable,	 and	 so	 exposing	
them	 to	 (almost)	 therapeutic	 doses	 of	 drugs	 for	 a	 non-therapeutic	 reason,	 as	 in	 a	
phenotyping	 study,	 may	 not	 be	 ethically	 acceptable.	 Moreover,	 blood	 sampling	 for	
pharmacokinetic	(PK)	analyses	in	children	is	challenging	because	of	the	burden	for	the	
individual	child,	 the	smaller	blood	volume	 that	can	be	 taken,	as	well	as	 the	 technical	
difficulties associated with sampling.
Microdosing studies present an attractive alternative to overcome the ethical and 
analytical challenges of phenotyping studies.6	 A	 microdose	 is	 a	 very	 small,	 sub-
therapeutic	dose	of	a	drug	(<1/100th	of	the	therapeutic	dose	or	<100	µg),	that	is	unlikely	
to result in pharmacological effects or adverse events.7,8	A	radioactive	label	[14C]	allows	
ultra-sensitive	 quantification	 of	 extremely	 low	 plasma-concentrations	 by	 accelerator	






as shown successfully before.6,11-13	Importantly,	a	prerequisite	is	that	the	PK	of	a	microdose	









of clinically relevant drugs.1,2,16-21	 As	midazolam	 is	 a	well-established	model	 substrate	
for	CYP3A	activity,	this	drug	may	be	used	for	phenotyping	studies	using	a	microdosing	
approach	 to	 elucidate	 developmental	 changes	 in	 CYP3A.5,22-25 To the best of our 
knowledge,	dose-linearity	of	 the	PK	of	a	microdose	 to	 those	of	a	 therapeutic	dose	of	
midazolam has been established in adults14,26,27,	 but	 not	 in	 children.	 Yet,	 the	 results	








This	 study	 was	 part	 of	 the	 ERA-NET	 PRIOMEDCHILD	 project	 ‘Paediatric	 Accelerator	
Mass Spectrometry Evaluation Research Study (PAMPER)’. The two units participating 
in	 this	 study	were	 the	Alder	Hey	 Children’s	 NHS	 Foundation	Trust,	 Liverpool,	 UK	 and	
the	 Liverpool	Women’s	NHS	 Foundation	Trust,	 Liverpool,	 UK.	 Children	were	 recruited	
on	 the	 paediatric	 intensive	 care	 units	 (PICUs)	 of	 these	 units.	 Ethical	 approval	 was	
obtained	 from	the	Research	Ethics	Committees	 for	 the	hospitals	where	patients	were	
enrolled. All parents or an adult who carried parental responsibility provided written 
informed	consent	for	their	child	to	be	included	prior	to	any	study-specific	procedures.	





they	 had	 intravenous	 lines	 in	 place	 for	 intravenous	 administration,	 and	 had	 suitable	









microtracer during therapeutic midazolam infusion or as an isolated microdose (Figure	












specific time points for each patient were decided based on discussion between the 
research	team,	clinical	team	and	parents	to	ensure	cares	were	coordinated	at	this	time	
and with minimal disruption to the patients’ routine. The maximum amount of blood 
could	not	exceed	the	guidelines	by	European	Medicines	Agency	(up	to	1%	of	calculated	





[14C]midazolam	 was	 synthesized	 by	 Selcia	 Ltd,	 United	 Kingdom	 at	 a	 specific	 activity	





to	 the	 required	 concentration.	The	final	 solution	was	filter	 sterilised	 (pore	 size	0.2	µm)	
and	batched	for	intravenous	injection.	The	final	[14C]midazolam	concentration	was	500Bq	
mL-1.
[14C]midazolam and [14C]1-hydroxy-midazolam plasma concentration analysis
Plasma sample extraction and Ultra Performance Liquid Chromatography (UPLC) 
Separation
Methanol	 (10	 µL)	was	 added	 to	 plasma	 samples	 in	 order	 precipitate	 proteins	 and	 to	
extract the test substance using protein precipitation plates. Each run consisted of 
samples	measured	once	and	eight	calibrator	levels	in	duplicate	plus	three	different	QC	
levels	 in	duplicate.	The	extract	was	evaporated	 to	dryness,	 re-dissolved	and	analysed	
using	 UPLC.	 The	 fraction	 where	 midazolam	 and	 1-hydroxy-midazolam	 eluted	 from	
the	 column	was	 collected	 for	 each	 sample,	 evaporated	 to	 dryness	 and	 subsequently	
analysed	using	Combustion-CO2-AMS.	Fractions	were	 transferred	 to	a	 tin	 foil	 cup	and	
evaporated to dryness prior to Accelerator Mass Spectrometry (AMS) analysis.
Accelerator Mass Spectrometry analysis
[14C]levels	 were	 quantified	 as	 described	 before.13,30	 The	 UPLC	 and	 AMS	 qualification	
was performed in accordance with the recommendation of the European Bioanalytical 
Forum.31	The	tin	 foil	cups	 (see	5.5.1)	were	combusted	on	an	elemental	analyser	 (Vario	
Micro;	Elementar,	Langenselbold,	Germany).	Generated	CO2	was	transferred	to	a	home-
built	gas	interface,	composed	of	a	zeolite	trap	and	syringe.30	CO2 was adsorbed to the 
trap	on	the	interface;	and	after	heating	of	the	trap,	the	CO2 was transferred to a vacuum 
syringe	using	helium.	A	final	CO2/helium	mixture	of	 6%	was	directed	 to	 the	AMS	 ion	
source,	at	a	pressure	of	1	bar	and	a	flow	of	60	µL	min-1.	A	1-MV	Tandetron	AMS	(High	
Voltage	Engineering	Europe	B.V.,	Amersfoort,	The	Netherlands)32 was used. The lower 
limit	of	quantification	(LLOQ)	was	0.31	mBq	mL-1.
Patient characteristics






as data were not distributed normally.
Pharmacokinetic Analysis
Exploration of the data
The	 data	 was	 first	 explored	 by	 visualization	 of	 time-concentration	 profiles	 of	 [14C]
midazolam	and	[14C]1-hydroxy-midazolam	(GraphPad	Prism	5).	Next,	their	area	under	the	
curve	(AUC)	and	the	ratio	AUC	[14C]1-hydroxy-midazolam/[14C]midazolam	was	estimated	
using	 a	 log-linear	 non-compartmental	 model	 (Excel	 PKSolver	 add-in	 software33) and 
compared	between	microdose	and	microtracer	administration	using	Mann-Whitney	U	
test.
Nonlinear mixed effects modelling
[14C]midazolam	 concentration–time	 data	 were	 analysed	 using	 the	 nonlinear	 mixed	
effects	modelling	 software	 NONMEM	 version	 7.4	 (ICON;	 Globomax	 LLC,	 Ellicott,	MD).	
Model	development	was	in	four	steps:	(1)	selection	of	a	structural	model,	(2)	selection	
of	 an	error	model,	 (3)	 covariate	 analysis,	 and	 (4)	 internal	 validation	of	 the	model.	 For	






variability	 (IIV)	 was	 tested	 on	 all	 model	 parameters.	 For	 the	 residual	 unexplained	
variability	 additive,	 proportional	 and	 a	 combination	 of	 additive	 and	 proportional	
error	 model	 were	 tested.	 The	 continuous	 covariates	 evaluated	 were	 postnatal	 age,	
postmenstrual	age,	bodyweight,	creatinine,	ALAT,	ASAT,	and	total	bilirubin.	Categorical	
covariates included treatment arm (i.e. microdosing or microtracer administration) only. 
All covariates were tested on all model parameters. Potential covariates were evaluated 









Fifteen	 infants	 (gestational	 age	 39.4	 [23.9-41.4]	 weeks,	 postnatal	 age	 11.4	 [0.6-49.1	
weeks])	 were	 included	 in	 the	 study	 of	 which	 nine	 received	 a	 microdose	 and	 six	 a	
microtracer	 [14C]midazolam.	See	Table 1 for the patient characteristics. There were no 
Table 1 Characteristics	of	patients	that	participated	in	the	study	and	received	a	microdose	or	microtracer	
[14C]midazolam.	Data	is	presented	as	median	(range).	*microdose	vs	microtracer	group
Total Microdose Microtracer Mann Whitney U
(p-value)*
Number of patients 15 9 6 -
Number of samples 67 37 30 -
Samples per patient (n) 5	(2-5) 5	(2-5) 5	(5-5) -
Gestational	age	(weeks) 39.4	(23.9-41.4) 39.4	(23.9-41.4) 38.4	(26.7-41.0) 0.15
Postnatal age (weeks) 11.4	(0.6-49.1) 11.4	(0.6-49.1) 13.4	(2.6-42.3) 0.39
Weight (kg) 3.6	(2.6-8.9) 3.5	(2.7-8.9) 3.8	(2.6-6.0) 1.00
Plasma	creatinine	(µmol	L-1) 35	(20-51) 41	(29-51) 33	(20-36) 0.07
Total	bilirubin	(µmol	L-1) 9	(2-274) 9	(5-274) 9	(2-146) 0.46
ASAT	(U	L-1) 42	(12-93) 41	(12-93) 57	(25-85) 0.39
ALAT	(U	L-1) 17	(7-68) 15	(7-43) 23	(16-68) 0.09





significant differences found between characteristics of the microdose and microtracer 
group.	The	complete	dataset	included	data	on	67	blood	samples.	Eight	measurements	
had	 [14C]midazolam	 concentrations	 under	 the	 AMS	 detection	 limit	 and	 were	 not	
included in the analysis.38
Exploration of the data
The	time-concentration	profiles	of	[14C]midazolam	and	[14C]1-hydroxy-midazolam	of	the	
individual subjects are depicted in Figure	2	and	3. In Table 2	the	individual	AUCs	and	ratio	
AUC0-t	[14C]1-hydroxy-midazolam/[14C]midazolam	of	the	microdose	and	microtracer	are	
presented. There were no significant differences found between the two groups.
Nonlinear mixed effects modelling
A	two-compartment	model	described	the	PK	of	[14C]midazolam	best.	Inclusion	of	IIV	for	
clearance improved the model statistically significantly. A combined error model was 
superior over a proportional error model or an additive error model. Bodyweight was a 
significant predictor for the central volume of distribution and was therefore included 
in	the	model.	After	inclusion	of	bodyweight,	age	and	other	tested	covariates	were	not	
found to be statistically significant. There was a trend for a relation between bodyweight 
and	 clearance,	 but	 this	 did	 not	 reach	 statistical	 significance	 (OFV	 -4.38).	 Inclusion	 of	





that the estimates are precise. Mean bootstrap values are close to model estimates and 
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Proportional error 0.09	(24) 0.08	(0.05-0.14)
Additional error 0.08	(50) 0.07	(0.01-0.20)
Definition of abbreviations: CL= population predicted clearance; Q= intercompartmental clearance; V1i = 
individual predicted volume of distribution in the central compartment for individual i; V14kg = population value 
for volume of distribution in the central compartment at 4 kg; WT= body weight; k1 = exponent to relate body 
weight to volume of distribution; V2 = volume of distribution in the peripheral compartment; ω2 = variance for 
the inter-individual variability of the parameter mentioned. The bootstrap was based on 50 resampled datasets.
Table 2 Area	under	the	curve	(AUC)	of	[14C]midazolam	and	[14C]1-hydroxy-midazolam	after	administration	
of	a	microdose	or	microtracer	[14C]midazolam	presented	as	median	(range).	afor one subject this parameter 
could not be established as there were only 2 plasma samples available. bAUC0-t	 ratio=[14C]1-hydroxy-
midazolam	AUC0-t/[14C]midazolam	AUC0-t	*microdose	vs	microtracer	group
Total (n=15) Microdose (n=9) Microtracer (n=6) Mann Whitney
U (p-value)*
[14C]midazolam
AUC0-t	(ng	L-1	*h) 46.77	(32.42	–	196.77) 46.77	(32.42	–	196.77) 48.28	(39.17	–	81.40) 0.86
AUC0-inf	(ng	L-1	*h) 48.90	(34.15	–	218.80)(n=14a) 48.90	(34.15	–	218.80)(n=8a) 49.11	(39.75	–	82.45) 0.66
[14C]1-hydroxy-midazolam
AUC0-t	(ng	L-1	*h) 10.89	(5.28	–	24.21) 10.19	(5.28	–	24.21) 11.20	(5.84	–	19.93) 0.86
AUC0-inf	(ng	L-1	*h) 12.39	(5.99	–	26.41)(n=14a) 13.14	(7.40	–	26.41)(n=8†) 12.39	(5.99	–	26.27) 0.95
[14C]1-hydroxy-midazolam / [14C]midazolam




0	is	not	in	the	95%	bootstrap	interval,	meaning	the	model	is	robust.	Figure	4 shows the 
diagnostic plots for the final model and illustrates the predictive value of the model for 
both	the	microtracer	and	microdose	group.	The	figure	shows	no	bias,	suggesting	that	











dose	 in	 children,	 by	 the	 finding	 that	 none	 of	 the	 PK	 parameters	 of	midazolam	were	
influenced	by	the	treatment	group,	i.e.	microdose	or	microtracer	[14C]midazolam.	A	lack	
of	difference	 in	AUC	values	 for	 [14C]midazolam	and	 [14C]1-hydroxy-midazolam	 further	
supports	that	there	is	no	difference	between	the	PK	of	a	microtracer	and	microdose.
These	results	are	in	line	with	the	findings	in	adults	(n=6),	where	dose-linearity	of	a	100	
µg	 [14C]midazolam	microdose	 was	 assessed	 in	 a	 cross-over	 design	 with	 3	 treatment	
regimens.14	The	subjects	were	administered	(1)	an	oral	microdose,	(2)	an	IV	microdose	
and	 (3)	 a	 simultaneous	dose	of	 an	 IV	microtracer	with	a	 therapeutic	nonradiolabeled	
oral	dose.	Like	our	results,	no	difference	in	IV	disposition	of	midazolam	was	found	when	
given as a microdose alone or in presence of a therapeutic dose in children.
Previously,	 studies	 have	 reported	 the	 midazolam	 PK	 in	 paediatrics	 after	 a	 single	 IV	
administration.39-41	 Clearance	 in	 our	 study	was	 found	 to	be	 2.06	 L	 h-1 for an infant of 
4	kg	 (equal	 to	8.6	ml	kg-1 min-1). In preterm infants the clearance was reported to be 
lower	 (median	1.8	 [range	0.7-6.7]	ml	kg-1 min-1)39	 reflecting	 that	CYP3A	activity	 is	 less	
mature	 in	preterm	 infants	 than	 in	an	 infant	of	4	kg.	A	 study	with	critically	 ill	 children	
reported	a	clearance	of	1.11	L	h-1	for	an	infant	of	5	kg	(equal	to	3.7	ml	kg-1 min-1)42,	which	
is	 lower	 than	 in	our	population.	This	paper	concludes	that	 inflammation	 (reflected	by	
high	 C-reactive	 protein	 concentrations)	 and/or	 number	 of	 failing	 organs	 influenced	
midazolam	 clearance,	 possibly	 as	 a	 result	 of	 reduced	 CYP3A	 activity.42 The lower 




was	found	to	be	similar	(3-10	year	old,	clearance	mean±SD	9.11±1.21	ml	kg-1 min-1 41) as 
or	slightly	higher	(0.5-2	year,	clearance	11.3±6.3	ml	kg-1 min-1	40) than in our population.
Regulatory authorities have indicated that microdose studies with radioactive labelled 
compounds are an acceptable component of drug development.7,43	Yet,	to	the	best	of	
our	knowledge	this	approach	has	not	been	used	during	paediatric	drug	development,	
despite this study and previous other studies illustrating feasibility and ethical 
acceptance in that population.11-13	 For	 paracetamol	 the	 dose-linearity	 of	 an	 oral	 and	
IV	microdose	was	 successfully	 assessed	 in	 paediatrics.12 A slightly different approach 





with	a	therapeutic	dose	of	IV	paracetamol.11,13 The known developmental change from 
mainly	sulfation	to	glucuronidation	was	confirmed,	and	data	were	added	on	intestinal	
and hepatic metabolism of paracetamol in a large paediatric age range. Together with 
our	 study,	 these	 studies	 pave	 the	way	 for	microdose	 studies	 to	 be	 incorporated	 into	
paediatric	drug	development	plans	to	explore	PK	in	this	vulnerable	population.
This	study	is	limited	by	the	lack	of	information	on	the	severity	of	disease	and	inflammation	
in these patients and by the wide age range in which extensive development in drug 
metabolism	 and	 transport	 occurs.	 The	 effect	 of	 age	 and	 disease	 on	 CYP3A	 activity	
increased	the	variability	 in	PK	of	midazolam,	possibly	obscuring	a	difference	between	
the	 PK	 of	 a	 microtracer	 and	 a	 microdose.	 However,	 we	 showed	 the	 age	 range	 was	
comparable	 in	 both	 treatment	 groups,	 and	 we	 assumed	 the	 disease	 severity	 was	







can	be	made	 in	extrapolating	 the	 results	 to	other	CYP3A-substrates	and	predict	 their	
disposition	 using	 a	 physiology	 based	 pharmacokinetic	 (PBPK)	 modelling	 approach.	
Importantly,	whether	this	may	be	possible	will	depend	on	the	characteristics	of	these	
substrates,	as	described	by	Calvier	et	al.44 As a substantial number of clinically relevant 
drugs	used	in	children	are	metabolized	by	CYP3A16,	this	has	the	potential	to	impact	the	
efficacy and safety of drug dosing in paediatrics through more informed adaptations of 
dosing regimens to this population.
We	conclude	 that	 the	PK	parameters	 of	 [14C]midazolam	administered	 as	 a	microdose	
did not differ significantly in infants from that of a microtracer. This supports the 
dose-linearity	 of	 an	 IV	 [14C]midazolam	microdose	 in	 children,	 thus	 a	 [14C]midazolam	
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unknown for the entire pediatric age span. We aimed to fill these knowledge gaps with 
a	 pediatric	 [14C]midazolam	 microtracer	 population	 pharmacokinetic	 study.	 Forty-six	
stable,	critically	ill	children	(median	age	9.8	[range	0.3	–	276.4]	weeks)	received	a	single	
oral	 [14C]midazolam	microtracer	 (58	 [40-67]	 Bq/kg)	when	 they	 received	 a	 therapeutic	
continuous intravenous midazolam infusion and had an arterial line in place enabling 
blood	 sampling.	 For	 midazolam,	 in	 a	 one-compartment	 model,	 bodyweight	 was	 a	
significant	predictor	 for	 clearance	 (0.98	L/h)	 and	volume	of	distribution	 (8.7L)	 (values	
for	 a	 typical	 individual	 of	 5	 kg).	The	 typical	 oral	bioavailability	 in	 the	population	was	
66%	(range	25%-85%).	The	exposures	of	OHM	and	OHMG	were	highest	for	the	youngest	
age groups and significantly decreased with postnatal age. The oral bioavailability of 
midazolam,	 largely	reflective	of	 intestinal	and	hepatic	CYP3A	activity,	was	on	average	
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INTRODUCTION
Midazolam	 is	 a	 short-acting	 benzodiazepine	 that	 is	widely	 used	 in	 pediatric	 hospital	
practice	 for	 various	 indications,	 including	 the	 induction	 of	 anesthesia	 by	 oral	
administration.1,	 2	 When	 an	 orally	 administered	 drug	 is	 subject	 to	 intestinal	 and/or	
hepatic	drug	metabolism,	 variation	 in	 its	metabolism	 is	 an	 important	determinant	of	
bioavailability and systemic clearance of that drug.
Oral bioavailability is defined as the fraction of the administered oral dose reaching 
the systemic circulation unchanged and importantly depends on the absorption and 
first-pass	 metabolism	 by	 both	 intestinal	 and	 hepatic	 drug	 metabolizing	 enzymes.	
Cytochrome	 P450	 (CYP)	 3A	 is	 a	 drug	metabolizing	 enzyme	 family,	 abundant	 in	 both	
the	 liver	 and	 the	 gut,	 which	 contributes	 to	 the	 first-pass	metabolism	 of	many	 orally	
administered drugs.3	CYP3A	consists	of	the	three	main	isoforms	CYP3A4,	-3A5	and	-3A7,	
for which the substrate specificity differs.3,	4 In vitro studies	have	shown	that	the	CYP3A7	
abundance	in	the	 liver	declines	rapidly	after	birth	and	that	the	abundance	CYP3A4	in	




with	substrate	specificity	for	CYP3A4/5	and	almost	none	for	CYP3A7.8,	9 In preterm infants 
(gestational	age	26-31	weeks	and	postnatal	age	3-13	days),	oral	midazolam	clearance	
was	markedly	lower	(0.16	L/h/kg	vs	3.0	L/h/kg)	and	oral	bioavailability	higher	(49-92%	vs	
21%)	than	in	children	beyond	1	year	of	age.10-12 These findings suggest developmentally 
lower	 intestinal	and/or	hepatic	CYP3A	activity	 in	preterm	neonates.	Midazolam	is	one	




The oral bioavailability of midazolam has been previously studied across the pediatric 
age span.10-14	However,	there	is	a	distinct	knowledge	gap	for	the	age	group	from	birth	
(term	born)	 throughout	 infancy,	 i.e.	 <1-year-old.	The	 classical	 study	 design	 to	 obtain	
data	on	oral	bioavailability	entails	a	cross-over	study	in	which	an	oral	and	IV	dose	of	a	
drug	 are	 administered	 alternately,	with	 a	wash-out	period	 in	between.	This	 design	 is	
ethically and practically challenging as children are exposed twice to therapeutic drug 
doses with extensive blood sampling.
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An	 interesting	 approach	 to	 study	 oral	 bioavailability	 is	 by	 a	 [14C]labelled	microtracer,	
which has been shown practically and ethically feasible to study developmental changes 
in	PK	in	children.15-17	A	microtracer	is	defined	as	‘<1/100th	of	the	dose	needed	to	reach	
the	no	observed	adverse	 effect	 level	 (NOAEL)	or	<100	µg’,	 concurrently	 administered	






Besides	 the	 oral	 bioavailability	 of	 midazolam,	 the	 systemic	 exposure	 to	 the	 major	
metabolites	 1-OH-midazolam	 (OHM)	 and	 1-OH-midazolam-glucuronide	 (OHMG)	 after	
oral	 dosing	 is	 also	 of	 interest,	 since	 both	 metabolites	 are	 pharmacologically	 active,	
although to a lesser extent than midazolam.22	 Also,	 a	 better	 understanding	 of	 age-
related variation in metabolite disposition provides further insight in developmental 
pharmacology.	 OHM	 is	 the	 primary	 metabolite	 formed	 by	 CYP3A,	 which	 is	 further	
glucuronidated	 to	 OHMG	 by	 UDP-glucuronosyltransferase	 (UGT)	 2B4,	 -2B7	 and,	 to	 a	
lesser	 extent,	 -1A4.23,	 24	A	high	 systemic	exposure	 to	OHMG	may	 result	 in	 therapeutic	
effects of this metabolite despite its lower potency.25 A report of five critically ill adults 
with	severe	renal	failure	showed	accumulation	of	OHMG	after	continuous	IV	infusion	of	
midazolam.25 This accumulation led to prolonged sedation (assessed by Ramsey score 
and	 electroencephalographic	 [EEG]	 evaluation)	 that	 could	 be	 reversed	 by	 the	 use	 of	
flumazenil,	which	 is	 a	 competitive	benzodiazepine	antagonist.	This	finding	highlights	
the importance of knowledge on disposition of the metabolites of midazolam. The 
metabolism and disposition of midazolam and the primary metabolite OHM after oral 






the aim to answer two questions: (1) what is the oral bioavailability of midazolam; and 
(2) what is the systemic exposure to midazolam and its major metabolites OHM and 
OHMG	after	oral	dosing	in	this	population.





of	 the	 Erasmus	MC–Sophia	 Children’s	 Hospital,	 Rotterdam,	 the	 Netherlands	 (October	
2015-March	 2018)	 and	 the	 Radboudumc-Amalia	 Children’s	 Hospital,	 Nijmegen,	 the	
Netherlands	 (May	 2017-March	 2018).	 The	 study	 was	 approved	 by	 the	 Dutch	 Central	
Committee	on	Research	Involving	Human	Subjects	(EudraCT	2014-003269-46).	Parental	
written informed consent was obtained. The radiation exposure of a single microtracer 




Radiological	Protection,	where	a	maximum	exposure	of	 100	µSv	 is	 allowed.	Category	
1 risk studies are considered minimal risk and ethically justified in humans when they 








vasopressor	 drug,	 or	 increase	 of	 the	 dose	 of	 a	 vasopressor	 drug	 in	 the	 last	 6	 hours),	
kidney	 failure	 (according	 to	 the	 pediatric	 Risk,	 Injury,	 Failure,	 Loss,	 End	 stage	 renal	
disease	 (pRIFLE)	 criteria	‘failure’,	 i.e.	 estimated	 creatinine	 clearance	decreased	by	75%	
or	an	urine	output	of	<0.3	ml/kg/h	for	24h	or	anuria	for	12	hours),	liver	failure	(defined	
by	 aspartate-aminotransferase	 [ASAT]	 or	 alanine-aminotransferase	 [ALAT]	 >2	 times	
the	 upper	 limit	 for	 age),	 gastrointestinal	 disorders,	 or	 concomitant	 administration	 of	
co-medication	known	to	interact	with	midazolam	(according	to	the	Flockhart	Table™30).
Study design
A	 single	 [14C]midazolam	 (20.3	 [14.1-23.6]	 ng/kg;	 58	 [40-67]	 Bq/kg;	 0.25	 ml/kg)	 dose	
was administered as an oral microtracer via the enteral feeding tube to ensure delivery 
in	 the	 gastrointestinal	 tract,	 followed	 by	 either	 1-2	 mL	 of	 saline	 or	 food	 to	 ensure	
rinsing	of	the	tube.	The	IV	therapeutic	midazolam	dose	was	prescribed	by	the	treating	
physician for clinical purposes and was adjusted on the guidance of validated sedation 
scores and according to a standardized sedation titration protocol. According to this 
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protocol,	midazolam	bolus	doses	varied	between	0.05-0.2	mg/kg	and	 the	continuous	
infusion	 rate	 between	 0.05-0.3	 mg/kg/h.	 Blood	 samples	 were	 taken	 pre-microtracer	
administration	 and	 around	 0.5h,	 1h,	 2h,	 4h,	 6h,	 12h,	 and	 24h	 after	 administration	 of	
the	[14C]midazolam	microtracer	to	ensure	that	the	PK	of	the	oral	absorption	phase	was	
captured.	The	maximum	number	of	blood	samples	 for	 the	study	was	 limited	 to	8	per	
subject and the maximum amount of blood could not exceed the guidelines by EMA (up 
to	1%	of	 calculated	circulating	blood	volume).31 The blood samples were centrifuged 
and	plasma	was	stored	at	-80ºC	until	analysis.
Midazolam
Midazolam for therapeutic infusion was manufactured and compounded by the 
Pharmacy	A15	(Gorinchem,	NL)	under	Good	Manufacturing	Practice	(GMP)	conditions.	
[14C]midazolam	 was	 synthesized	 by	 Selcia	 Ltd,	 United	 Kingdom	 at	 a	 specific	 activity	








[14C]midazolam, [14C]OHM and [14C]OHMG plasma concentration quantification
Plasma sample extraction and Ultra Performance Liquid Chromatography Separation




to precipitate proteins and to extract the test substance using protein precipitation 
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Accelerator Mass Spectrometry analysis
[14C]levels	were	quantified	as	described	before.16,	33	The	 tin	 foil	cups	 (see	5.5.1.1)	were	
combusted	on	an	elemental	analyser	(Vario	Micro;	Elementar,	Langenselbold,	Germany).	
Generated	CO2	was	transferred	to	an	in-house	developed	gas	interface,	composed	of	a	






Therapeutic midazolam plasma concentration quantification by liquid 
chromatography–tandem mass spectroscopy
Midazolam and the major metabolites were quantified by means of a liquid 
chromatography–tandem	mass	spectroscopy	 (LC-MS/MS)	with	electrospray	 ionization	
in	 the	 positive	 ionization	 mode	 (Waters)	 validated	 according	 to	 Food	 and	 Drug	
Administration	(FDA)	guidance.35	The	LLOQ	for	midazolam	was	2	µg/L,	for	OHM	3	µg/L	
and	for	OHMG	10	µg/L.	The	upper	limit	of	quantification	for	midazolam	was	2400	µg/L,	







respective timings of administration and blood sampling. Patient characteristics and 
relevant clinical and laboratory measurements were prospectively recorded.
Pharmacokinetic analysis
Population pharmacokinetics to assess the oral bioavailability
The	oral	bioavailability	of	a	drug	was	quantified	by	means	of	a	population	PK	analysis.	All	
[14C]midazolam	and	midazolam	concentration–time	data	were	analyzed	simultaneously	
using	 nonlinear	mixed	 effects	modeling	with	NONMEM	version	 7.4	 (ICON;	Globomax	
LLC,	 Ellicott,	 MD)	 after	 log	 transformation	 of	 the	 concentration	 data.	 [14C]midazolam	
concentrations	under	 the	AMS	detection	 limit	 (<LLOQ)	were	discarded.36	Pirana	2.9.7,	
R	(version	3.4.1),	and	R-studio	(version	1.0.153)	were	used	to	visualize	the	data.	Model	
development was in four steps (see Methods S1 for detailed information): (1) selection 
of	 a	 structural	 model,	 (2)	 selection	 of	 an	 error	 model,	 (3)	 covariate	 analysis,	 and	 (4)	
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internal validation of the model. The absorption rate constant (ka) for midazolam was 
fixed	at	4.16	h−1,	which	yields	peak	concentrations	to	be	reached	round	30	min,	which	is	
in agreement with the observed tmax in our data and with values reported for children 
in previous literature.13
Non-compartmental analysis to assess the systemic exposure to midazolam and its 
major metabolites after oral dosing
To	 calculate	 the	 systemic	 exposure	 of	 midazolam	 and	 its	 major	 metabolites,	 the	
concentration-time	 areas	 under	 the	 curve	 after	 oral	 dosing	 were	 determined	 with	
non-compartmental	analyses.	The	[14C]midazolam	and	metabolite	concentrations	were	




method;	the	AUC	from	time	zero	to	infinite	time	(AUC0-inf) was calculated by extrapolation 
beyond the last observation.37	 If	AUCtlast–inf	was	 larger	than	20%	of	the	actual	AUC0–tlast,	
then	the	AUC0–inf	was	excluded	from	the	analysis,	as	 it	would	 limit	 the	accuracy	of	the	





















could be detected in the plasma samples. The undetectable concentrations can be 
explained	 by	 clinical	 practice,	 because	 immediately	 before	 extubation	 the	 child’s	
















Number of patients (n) 46
Location	(n	Erasmus	MC/n	Radboudumc) 39/7
Postnatal age (weeks) 9.8	(0.3	–	276.4)

















Number of organs failing on study day 1	(0	–	2)
PRISM 16	(3	–	32)
PIM -2.5	(-4.8	–	-0.4)








PELOD=Pediatric Logistic Organ Dysfunction; PRISM=Pediatric Risk of Mortality; PIM=Pediatric Index of 
Mortality; ASAT= aspartate-aminotransferase; ALAT=alanine-aminotransferase; CRP=C-reactive protein; *As 
determined by TNO growth curves
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8statistically significantly. Bodyweight was the most significant predictor for clearance 
(∆OFV	 -11.11)	 and	 volume	 of	 distribution	 (∆OFV	 -15.95)	 in	 exponential	 relationships	
(see Table 2).	After	this	inclusion,	both	the	variance	of	the	IIV	for	clearance	and	volume	
of distribution decreased. Age and other tested covariates were found not statistically 
significant after inclusion of bodyweight.
All	 relative	 standard	 error	 (RSE)	 values	 of	 the	 parameter	 estimates	 were	 below	 50%,	
indicating that the estimates could be obtained from the data with good precision. 
The	diagnostic	plots	 for	 the	final	model	 are	presented	 in	Figure	S1	 (oral	data)	 and	 in	
Figure	S2	 (IV	data).	 Both	figures	 indicate	 that	 the	model	describes	 the	obtained	data	
accurately,	upon	both	oral	and	 IV	administration,	even	though	for	 the	oral	data	more	
random variability is observed. The robustness of the estimated model parameters was 
evaluated in a bootstrap analysis. The bootstrap analysis confirmed the precision of 
parameter	estimates	of	the	final	model,	as	the	parameter	estimates	were	very	similar	to	
the	bootstrap	medians	and	within	the	95%	confidence	interval	(Table 2). The distribution 
of	the	NPDEs	indicates	that	the	model	can	adequately	predict	both	the	median	trend	and	
the variability in the observed concentrations. This is further supported by the absence 
of	visible	trends	in	NPDE	versus	time	and	NPDE	versus	predictions	(see	Figure	S3	and	S4).
Systemic exposure to midazolam and its major metabolites after oral dosing
The	systemic	exposures,	as	reflected	by	the	AUCs	of	midazolam	and	its	major	metabolites	
after	 administration	 of	 the	 oral	 [14C]midazolam	microtracer	 are	 presented	 in	Table 3. 
The	complete	dataset	 included	data	on	335	plasma	samples	 from	43	patients.	A	total	
of	21	 (6%),	41	 (12%),	and	14	 (4%)	samples	were	set	on	0.5*LLOQ	for	 respectively	 [14C]
midazolam,	[14C]OHM	and	[14C]OHMG.	A	total	of	9	(3%),	93	(28%),	and	2	(0.6%)	samples	
were	discarded	for	respectively	[14C]midazolam,	[14C]OHM	and	[14C]OHMG.	Eight	(19%),	
Figure 2 Oral bioavailability of midazolam 
and its variability versus bodyweight. 
Bodyweight did not explain the variability in 
oral bioavailability.
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Bq/L/h 162.6	(10.4-898.4)	(n=43) 12.0	(1.1-77.0)	(n=38) 254.4	(62.6-821.6)	(n=43)
ng/L/h 50.4	(3.2-278.5)	(n=43) 4.0	(0.4-25.4)	(n=38) 127.2	(31.3-410.8)	(n=43)
AUC0-inf
Bq/L/h 160.9	(10.6-753.3)	(n=32) 17.9	(3.0-81.7)	(n=29) 272.2	(71.6-921.8)	(n=22)
ng/L/h 49.9	(3.3-233.5)	(n=32) 5.9	(1.0-27.0)	(n=29) 136.1	(35.8-460.9)	(n=22)
AUC0-tlast	ratio	OHM/M 0.1	(<0.1-1.5)	(n=38)
AUC0-tlast	ratio	OHM/OHMG 0.05	(<0.01	–	0.20)	(n=38)
Data is presented as median (range). n= number of patients. M=midazolam, OHM=1-OH-midazolam, OHMG=1-
OH-midazolam-glucuronide, AUC=Area Under the Curve. See 4.3 for explanation on the patient numbers.
Table 2 Parameter	estimates	of	a	one-compartmental	model.
Parameter Model parameters 
estimates (RSE%)






















ω2 = variance for the inter-individual variability of the indicated parameter; CL = clearance; CLi = predicted 
clearance of individual i; CL5kg = population-predicted clearance for a subject with a median weight of 5 kg; 
CV= coefficient of variation; F = absolute oral bioavailability; Fi = predicted absolute oral bioavailability of 
individual i; k1 = exponent to relate body weight to clearance; k2 = exponent to relate body weight to volume 
of distribution; RSE = relative standard error; TVF = population parameter in the logit equation for oral 
bioavailability; V = volume of distribution; Vi = individual predicted volume of distribution for individual i; V5kg = 
population-predicted volume for a subject with a median weight of 5 kg; WT= body weight
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9	 (21%),	 and	 21	 (49%)	 patients	 were	 excluded	 from	 AUC0-inf	 analyses of respectively 
[14C]midazolam,	 [14C]OHM	 and	 [14C]OHMG	 as	 the	 AUCtlast–inf	 was	 larger	 than	 20%	 of	




was	found.	For	5	patients	(12%)	the	AUC0-tlast	and	AUC0-inf of OHM could not be calculated 
as	most	plasma	concentrations	were	<LLOQ.





AUC0-tlast	and	 AUC0-inf with postnatal age (see Figure	 3B	 and	 C	 for	 AUC0-tlast,	 results	 for	
AUC0-inf not shown). No significant relationship was identified between postnatal age 
and	[14C]midazolam	AUC0-tlast	(see Figure	3),	[14C]midazolam	AUC0–inf,	OHM/M	AUC	ratio,	
and	OHM/OHMG	ratio	(data	not	shown).
Figure 3 Area under the curve from time zero 
to	 the	 last	 sampling	 time	 point	 (AUC0–tlast) 
after	 administration	 of	 an	 oral	 [14C]midazolam	
microtracer	 (20.3	 [14.1-23.6]	 ng/kg;	 58	 [40-67]	
Bq/kg)	 of	 midazolam	 (A),	 1-OH-midazolam	
(B),	 and	 1-OH-midazolam-glucuronide	 (C)	
versus	 postnatal	 age	 (log	 scale).	 OHM=1-
OH-midazolam	 (n=38),	 OHMG=1-OH-
midazolam-glucuronide	 (n=43)	 ρ=Spearman’s	




To study the oral bioavailability of midazolam and the systemic exposure to midazolam 
and	 its	major	metabolites	 in	children,	we	designed	a	prospective	oral	 [14C]midazolam	
microtracer	population	PK	study	in	children	receiving	midazolam	for	clinical	purposes.	
Our main observations were that (1) the median oral bioavailability of midazolam was 
66%	and	varied	greatly	with	a	range	of	25-85%	and	(2)	the	systemic	exposure	(AUC)	of	
the	major	metabolites	 1-OHM	 formed	by	 CYP3A	 and	 1-OHMG	 formed	 out	 of	 1-OHM	
by	UGT2B4,	 -2B7	and	 -1A4	were	highest	 for	 the	youngest	age	 ranges,	despite	weight	
normalized midazolam doses.
Our study design has previously been applied to investigate the oral bioavailability 
of paracetamol and the systemic exposure to its metabolites in children15,	 17 and has 
now	shown	to	be	successful	 for	midazolam.	The	 informed	consent	rate	of	50%	was	 in	
agreement	with	the	consent	rate	of	other	non-therapeutic	studies	in	pediatric	intensive	
care.	 Moreover,	 our	 population	 PK	 model	 results	 were	 in	 agreement	 with	 reported	









of	 1-18	 years.12	 Also	 the	 reported	mean	±SD	of	 28±7%	 in	 adults	 is	 lower	 than	 in	 our	
population.40	These	latter	findings	can	be	explained	by	the	expected	CYP3A	ontogeny,	
as	older	children	and	adults	are	thought	to	have	a	higher	CYP3A	activity	in	both	the	gut	
wall	and	liver,	 resulting	 in	a	 lower	oral	bioavailability3	 than	found	in	our	patients,	and	
vice versa for preterm neonates. Statistically significant covariate relationships that could 





healthier patients. A previous study from Vet et al. found a significant impact of organ 
failure on midazolam clearance 38,	with	 the	 greatest	 impact	 on	midazolam	 clearance	
in	 the	presence	of	≥3	 failing	organs	and	 inflammation	as	 reflected	by	CRP.38 We were 
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not	 able	 to	 identify	 these	 covariates	 in	 our	 data,	 likely	 because	 children	with	 severe	
circulatory,	kidney	or	liver	failure	were	excluded,	and	the	number	of	failing	organs	in	our	
study	ranged	from	0	to	3	per	child.	CRP	values	in	our	study	were	comparable	to	those	
in the previous study from Vet et al.; i.e.,	 (median	 [range]	43	 [2	–	298]	vs	32	 [0.3–385]	
mg/L,	resp.).	However,	we	only	included	6	patients	with	a	CRP	>	100	mg/L,	whereas	the	
previously	reported	cohort	consisted	of	more	patients	with	CRP	>	100	mg/L.
The variability in oral bioavailability as observed in our study leads to unpredictable 
systemic	exposure	to	midazolam,	and	potentially	also	other	CYP3A-substrates,	after	oral	
dosing in (critically ill) children. These children may be at risk of subtherapeutic or toxic 
exposure	after	oral	dosing	of	other	CYP3A-substrates.
In	 addition,	 the	 systemic	 exposures	 of	 the	 main	 metabolites	 OHM	 and	 OHMG	 were	
highest in the youngest age ranges at similar exposure of midazolam across age. This 
observation	can	most	 likely	not	be	attributed	solely	 to	CYP3A	ontogeny,	but	to	other	
developmental	changes	as	well,	 as	 the	exposure	of	each	metabolite	 is	dependent	on	




increases over age42-44 This explanation is supported by a reported postconceptional 
age-related	increase	in	urinary	excretion	of	OHMG	in	preterm	neonates.45 A metabolic 
shift,	as	seen	for	paracetamol	where	a	switch	from	mainly	sulphation	to	glucuronidation	
is seen in the first of years life is less likely. As in the case of midazolam this would mean 





reports	 on	 the	 association	 between	 OHMG	 accumulation	 and	 prolonged	 sedation25,	





can speculate that the variability in oral availability of midazolam and the higher systemic 
exposure	 to	OHMG	may	 lead	 to	 subtherapeutic	or	 toxic	 exposure.	The	 real	 impact	of	
this variability on pharmacodynamics parameters should be assessed in future studies. 
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Second,	 data	 of	 21	 patients	 were	 excluded	 from	 AUC0-inf	 analyses	 of	 OHMG	 because	
the	 elimination	 of	 this	metabolite	 was	 not	 complete	 after	 24h.	 In	 retrospect,	 longer	
sampling	time	would	have	benefited	this	analysis.	Third,	the	absorption	of	midazolam	
may	 be	 influenced	 by	 food	 intake	 as	 food	 in	 the	 gastrointestinal	 tract	may	 alter	 the	
gastrointestinal	physiology,	including	the	motility	patterns,	intestinal	transit	time,	and	
the	 local	blood	flow.49	However,	 information	on	food	was	not	collected	and	the	study	
was not powered to detect an effect of food on midazolam absorption but may have 
contributed	to	the	variability	in	our	data.	Also,	dose	linearity	of	the	PK	of	an	oral	microdose	
to those of a therapeutic dose of midazolam has been established in adults.50-52 We made 
the	assumption	that	this	also	accounts	for	children,	further	supported	by	dose-linearity	
of	IV	midazolam	in	children53,	but	not	been	formally	established.
This	 study	presents	 some	 future	 opportunities.	 Recently,	 a	 framework	was	 published	
for	between-drug	extrapolation	of	covariate	models54 which was used by Brussee et al 
to study whether scaling with a pediatric covariate function from midazolam will lead 
to	 accurate	 clearance	 values	 of	 other	 CYP3A-substrates.55	 Clearances	 of	 drugs	 were	
accurately	scaled	when	they	were	mainly	eliminated	by	CYP3A-mediated	metabolism	
with,	for	example,	high	protein	binding	to	albumine	(>	90%)	and	a	low-to-intermediate	
extraction	 ratio	 of	 <	0.55	 in	 adults.	 However,	 the	 covariate	 relationship	 for	 clearance	
was	based	on	data	from	children	>1	year	of	age.	As	our	population	consists	of	infants	
mainly	<1	years	of	age,	our	data	now	present	a	unique	opportunity	to	test	the	proposed	









children may be at an increased risk of subtherapeutic or toxic exposure of midazolam 
and	potentially	also	of	other	CYP3A-substrates	when	dosed	orally.	The	study	design	with	
an	oral	[14C]microtracer	was	shown	successful	for	safely	studying	the	oral	bioavailability	
of midazolam in children. To ultimately improve the safety and efficacy of pediatric drug 
therapy,	we	recommend	to	consider	study	designs	with	microdoses	for	minimal	risk	PK	
studies	and	[14C]microtracer	studies	to	elucidate	oral	bioavailability.
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SUPPLEMENTARY INFORMATION





was	 considered	 statistically	 significant,	which	 corresponds	 to	p<0.05	 assuming	 a	 chi-
square distribution.56	For	the	structural	model,	one,	two,	and	three	compartment	models	
were	tested.	For	the	error	model	an	additive	error	model	in	the	log-domain	was	used.	
Inclusion	of	 log-normally	distributed	 inter-individual	variability	 (IIV)	was	 tested	on	all	
model	parameters.	For	bioavailability,	a	logit	transformation	with	a	normal	distribution	
for	 inter-individual	 variability	 was	 used	 to	 avoid	 individual	 bioavailability	 estimates	
outside	the	0%-100%	range.	The	absorption	rate	constant	(ka)	for	midazolam	was	fixed	
at	4.16	h−1,	which	yields	peak	concentrations	to	be	reached	round	30	min,	which	 is	 in	
agreement with the observed tmax in our data and with values reported for children in 
previous literature.13
Covariate analysis
The	 correlation	 with	 PK	 parameters	 was	 evaluated	 for	 the	 following	 continuous	




covariates	 included	 gender,	 Pediatric	 Logistic	 Organ	 Dysfunction	 (PELOD)	 score,	 and	
organ	failure	as	determined	by	the	PELOD	score.
Potential covariates were evaluated using forward inclusion and backward elimination 





(PsN),	 for	 which	 five	 hundred	 datasets	 were	 resampled	 with	 replacement	 from	 the	
original datasets and refitted to the model. The obtained parameter values from these 
500	model	fits	were	summarized	as	median	values	and	95%	confidence	intervals,	which	
were compared to the values obtained in the original model fit.
224 Chapter	8
Normalized	 prediction	 distribution	 errors	 (NPDE)	 were	 calculated	 with	 the	 NPDE	
package in R.59	For	this	method,	the	data	set	used	for	model	development	was	simulated	
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Figure S1 Goodness-of-fit	 plots	 of	 the	 oral	 [14C]midazolam	 data	 for	 the	 final	 model.	 A.	 Log-value	 of	
observed	plasma	 concentrations	 vs.	 log-value	of	population	predicted	 concentrations.	 B.	 Log	observed	





vs.	 log	 individual	 predicted	 concentrations.	 C.	 Conditional	 weighted	 residuals	 (CWRES)	 versus	 log	
population	predictions.	D.	CWRES	versus	time	after	first	dose.
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Figure S3 Normalized	prediction	distribution	error	(NPDE)	of	the	final	model	for	oral	 [14C]midazolam.	A.	
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could alter the metabolic profile of a drug. Traditional metabolite in safety testing (MIST) 
studies are used to create metabolite profiles and study the routes of excretion but are 
unethical	 in	children	due	to	the	high	radioactive	burden.	To	overcome	this	challenge,	
we	aimed	to	show	the	feasibility	of	a	MIST	study	using	a	[14C]midazolam	microtracer	as	
proof of concept in children.
Methods:	Twelve	stable,	critically	ill	children	received	an	oral	[14C]midazolam	microtracer	







Results: The approach resulted in sufficient sensitivity to quantify individual metabolites 
in	chromatograms.	[14C]1-OH-midazolam-glucuronide	was	most	abundant	in	all	but	one	
age	group,	followed	by	unchanged	[14C]midazolam	and	[14C]1-OH-midazolam.	The	small	
proportion	of	unspecified	metabolites	<10%	of	 the	 total	drug	 related	exposure	most	
probably	 includes	 [14C]midazolam-glucuronide	 and	 [14C]4-OH-midazolam.	 Excretion	
was	mainly	in	urine;	the	total	recovery	in	urine	and	feces	was	77-94%.
Conclusion: This	first	pediatric	MIST	pilot	study	makes	clear	that	using	a	[14C]midazolam	
microtracer is feasible and safe to generate metabolite profiles and study recovery in 






Drug	 development	 consists	 of	 several	 stages,	 including	 establishing	 the	 absorption,	
distribution,	metabolism	and	excretion	(ADME),	as	well	as	the	efficacy	and	safety	of	the	
drug.	 Importantly,	metabolites	of	the	parent	drug	may	also	contribute	to	efficacy	and	
safety.1 A general approach to study these aspects is by performing a mass balance and 
metabolite in safety testing (MIST) study to obtain information on the routes and extent 
of excretion and to create metabolite profiles.
In	 2008,	 the	 U.S.	 Food	 and	 Drug	 Administration	 recommended	 that	 regarding	 the	
non-clinical	 safety	of	drug	metabolites	 the	exposure	 threshold	 for	 further	metabolite	
characterization	for	an	individual	metabolite	must	be	>10%	of	the	estimated	parent-drug 
exposure.	 In	2009,	 the	 International	Conference	on	Harmonisation	(ICH)	M3	guideline	
(R2)	altered	this	threshold	significantly	to	>10%	of	the	estimated	total-drug	exposure,	
which	was	included	in	the	FDA	guideline	in	2016.2,3
The	 disposition	 of	 a	 drug	 is	 driven	 by	 processes	 such	 as	 drug	 metabolism,	 drug	
transport,	glomerular	filtration	and	body	composition.	These	processes	are	subject	 to	
age-related	changes	reflecting	growth	and	maturation	along	the	pediatric	continuum.4,5 
Most drug metabolizing enzymes and drug transporters act differently in neonates than 
in	older	children	or	adults,	and	 the	maturational	patterns	are	 isoform-dependent.4,6-10 
Children’s	metabolism	may	not	only	be	slower	or	faster	than	that	of	adults	but	may	also	
use different compensatory pathways. The resulting metabolite profiles could contain 
metabolites	that	have	not	yet	been	identified	or	are	≤10%	of	the	total	drug	exposure	in	
adults,	yet	are	present,	disproportionately	present	or	even	represent	>10%	of	the	total	
drug	 exposure	 in	 children.	 This	 mechanism	 is	 most	 obvious	 for	 paracetamol,	 whose	
metabolism switches from mainly sulfation to glucuronidation from birth to 12 years 
of age.11	Glucuronidation	 is	underdeveloped	 in	newborns;	hence,	 sulfation	 is	used	as	







while in adults caffeine is many metabolically cleared.14,15 As in general the metabolites 
differ in terms of efficacy and toxicity16,	knowledge	on	metabolite	profiles	in	children	is	
crucial for applying effective and safe pediatric drug therapy.
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Metabolite	profiles	are	typically	generated	by	human	radiolabeled	ADME	studies,	one	
of	 the	possible	MIST	 studies,	by	 analyzing	plasma,	urine	or	 feces	 samples	with	 liquid	
chromatography	 with	 fraction	 collectors,	 followed	 by	 offline	 radioactivity	 detection	
using liquid scintillation counting.16	 For	 this	 latter	 technique,	 a	high	 radioactive	dose	
of	100	µCi	in	humans	is	needed.	Just	recently,	advances	mainly	in	analytical	technology	
have enabled new approaches to MIST studies with less radioactivity exposure.16,17 By 
using	[14C]microtracers	concurrently	administered	with	a	therapeutic	dose,	metabolites	
can be identified and quantified by accelerator mass spectrometry (AMS) with a 
radioactivity	exposure	of	even	less	than	0.1	µCi.18,19
The amount of radiolabeled dose that is ethically justified to be administered to human 
volunteers participating in clinical trials has been risk classified by the International 
Commission	 on	 Radiological	 Protection	 (ICRP)	 (Table 1).20	 The	 use	 of	 [14C]labeled	




the	 PK	 of	 [14C]labelled	 compounds	 have	 already	 been	 successfully	 conducted.11,21-24 
Yet,	to	the	best	of	our	knowledge,	pediatric	MIST	microtracer	studies	with	[14C]labelled	
compounds to create complete metabolite profiles have not yet been performed.
Midazolam	is	a	drug	with	well-known	metabolism	in	adults	and	is	widely	used	as	a	marker	
for	CYP3A4/5	activity,	a	developmentally	regulated	phase	1	metabolizing	enzyme,	with	
lower activity in neonates than in adults.25	We	 hypothesized	 that	 using	 an	 oral	 [14C]
midazolam	 microtracer	 as	 an	 example-compound	 in	 children	 receiving	 therapeutic	
intravenous	midazolam	for	clinical	needs,	would	permit	to	generate	metabolite	profiles	
of	midazolam	in	children	and	study	routes	of	excretion.	Therefore,	we	aimed	to	explore,	
as	 a	 proof	 of	 concept,	 the	 feasibility	 of	 a	 MIST	 microtracer	 study	 with	 an	 oral	 [14C]
midazolam	microtracer	in	children	in	the	0-6	years	age	range.
Table 1 The	International	Commission	on	Radiological	Protection	(ICRP)	classification	and	justification	of	
radiolabeled doses to be administered to human volunteers participating in clinical trials20
ICRP risk
category






An increase of 
knowledge
At any stage in drug development Yes





after radiological dosimetry using tissue 
distribution data from animals and 







This	 study	 (EudraCT	 2014-003269-46)	 was	 part	 of	 the	 ZonMw	 Priority	 Medicines	




any	study-specific	procedures	written	 informed	consent	 for	 their	child	 to	be	 included.	
The	Dutch	Nuclear	 Research	 and	 Service	Group	 estimated	 the	 radiation	 exposure	 for	
a	 single	microtracer	of	 60	Bq/kg	 (equivalent	 to	 an	adult	 study	of	 0.1	µCi)	 and	<1	µSv	
and	 are	 allowed	 in	 this	 population	 according	 to	 the	 ICRP	 (Table 1).20,27 We explained 





Hospital were considered for inclusion. The following inclusion criteria applied: age from 
birth	(post	menstrual	age	>36	weeks)	up	to	6	years	of	age,	bodyweight	>2.5kg,	clinical	
need	 for	 intravenous	 midazolam,	 and	 an	 indwelling	 arterial	 line	 in	 place	 enabling	
blood	 sampling.	 Exclusion	 criteria	were	 the	 following:	 anticipated	death	 in	 48	 hours,	
extra	corporeal	membrane	oxygenation	(ECMO)	treatment,	circulatory	failure	(defined	
by	the	administration	of	≥1	vasopressor	drug,	or	increase	of	a	vasopressor	drug	in	the	










(hrMS).	The	 IV	 therapeutic	midazolam	dose	was	 prescribed	 by	 the	 treating	 physician	
for clinical purposes and was adjusted on the guidance of validated sedation scores 
and	according	to	a	standardized	sedation	titration	protocol.	According	to	this	protocol,	







is	 estimated	 at	 80-90	ml/kg).30 The blood samples were centrifuged and plasma was 
stored	at	-80ºC	until	analysis.	Urine	was	collected	from	patients	with	a	urinary	catheter	in	
place	for	clinical	reasons.	It	was	collected	with	a	maximum	of	72h	after	[14C]midazolam	







mmol	 (equal	 to	 2.85	 MBq/mg).	 The	 chemical	 name	 is	 8-chloro-6-(2-fluorophenyl)-1-







Subjects and plasma samples
We	created	 four	age	groups:	0-28	days;	1-6	months;	6	months-2	years;	2-6	years.	First	
a	 time-averaged	pool	per	patient	 (AUC0-t	where t is the last sampling time point) was 
prepared according to the Hamilton method 31,32,	 after	 which	 age	 group	 pools	 were	
generated	by	equi-volumetric	pooling.	A	time-averaged	pool	consists	of	aliquots	from	
individual samples that form one composite sample. The volume of the aliquot taken 
from each individual plasma sample was determined by the time interval between 
drawing	of	the	samples.	The	final	time-averaged	pool	reflects	the	mean	plasma	level	of	
the	testing	period	(0-≈24h).
Identification of metabolites and quantification [14C]levels
In	 total,	 150	 µl	 of	 the	 plasma	 pool	 was	 added	 to	 600	 µL	methanol	 and	 centrifuged.	







to	 a	Q-Exactive	 hrMS	 (in-line)	 for	metabolite	 identification	 and	 one	 line	 to	 a	 fraction	




Quantification [14C]levels with AMS
[14C]levels	 were	 quantified	 as	 described	 before.32	 In	 brief,	 the	 tin	 foil	 cups	 were	
combusted	on	an	elemental	analyzer	(Vario	Micro;	Elementar,	Langenselbold,	Germany).	
Generated	 CO2	 was	 transferred	 to	 a	 home-built	 gas	 interface,	 composed	 of	 a	 zeolite	





the	 measured	 [14C]/[12C]	 ratios	 were	 multiplied	 by	 the	 corresponding	 total	 carbon	






voltage	was	 set	at	35	eV.	For	mass	measurement	of	metabolites,	 the	mass	 range	was	





in urine were measured by AMS as described in chapter Quantification [14C]levels with 
AMS.	Recovery	in	urine	was	calculated	by	multiplying	the	[14C]levels	by	the	total	urine	
volume.	 Diapers	 were	 extracted	 using	 ethanol:water	 (25:75).	 To	 optimize	 extraction,	
the diapers were first inverted with the inside facing out. The diapers were individually 
transferred	to	a	bucket	and	one	liter	of	the	extraction	solvent	was	added.	With	lid	closed,	
the bucket was placed on a horizontal shaker for 7 days during which the analytes were 
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extracted.	After	completion,	the	samples	were	homogenized	with	an	Ultra-Turrax	and	a	




criteria,	of	which	parents	of	46	patients	consented	to	 let	 their	child	participate	 in	 the	
study.	For	 this	 sub-study,	 the	 samples	of	 the	first	12	 included	patients	were	 selected,	
which	had	a	median	(range)	age	of	13.1	(1.3	–	218.6)	weeks	and	bodyweight	of	5.6	(3.1	






Number of patients (n) 12
Postnatal age (weeks) 13.1	(1.3	–	218.6)
Weight (kg) 5.6	(3.1	–	17.0)
Gender	(M/F) 8/4




·	 Pulmonary hypertension 1




Number of organs failing on study day 1	(0-2)
PRISM 18	(11-28)
PIM -3.1	(-4.7	–	-0.6)





PELOD=Pediatric Logistic Organ Dysfunction; PRISM=Pediatric Risk of Mortality; PIM=Pediatric Index of 








We were able to identify metabolite profiles for each age group (Figure	 1 and Table 
3). Two prominent peaks and some smaller peaks were present in the AMS radio 






The population was divided in four age groups/Hamilton pools: 0-1 month, 1-6 months, 6 months-2 year and 2-6 
year. [14C]levels were quantified with Accelerator Mass Spectrometry. 1-OHMG=1-OH-midazolam-glucuronide; 
1-OHM=1-OH-midazolam. The corresponding high resolution mass spectrometry retention times can be found 
in Table 4.
Table 3 The parent and metabolite exposures in percentage of the total drug related exposure of an oral 
[14C]midazolam	microtracer	in	four	age	groups
Midazolam 1-OHM 1-OHMG Unspecified
0	–	1	month 40.7% 5.0% 42.7% 11.5%
1	–	6	months 26.2% 2.5% 63.0% 8.3%
6	months	–	2	years 27.0% 2.5% 59.2% 11.3%
2	–	6	years 56.1% 5.6% 32.0% 6.3%
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the	unchanged	 [14C]midazolam	was	most	abundant,	 followed	by	 [14C]1-OHMG.	For	all	




Table	4 presents the mass balance results of urine samples and diapers of four patients. 
The	 main	 route	 of	 excretion	 was	 renal,	 resulting	 in	 a	 recovery	 of	 49-72%.	 The	 total	
recovery	of	the	[14C]midazolam	dose	in	urine	and	feces	was	77-94%.
DISCUSSION




excretion by the use of AMS and hrMS. The metabolite profiles differed per age group 
and	consisted	of	the	parent	drug,	two	major	metabolites	1-OHM	and	1-OHMG,	and	small	
proportions	 of	 unspecified	 fraction	 of	metabolites	 that	were	 <10%	 of	 the	 total	 drug	
related	exposure.	The	recovery	of	the	administered	dose	in	urine	and	feces	was	77-94%.
Our	finding	that	 in	the	three	youngest	age	groups	the	systemic	exposure	to	1-OHMG	
was	most	abundant,	 followed	by	midazolam	and	1-OHM,	 is	 in	 line	with	 literature	and	
supports the feasibility of our microtracer MIST approach. De Wildt et al have shown 
that	after	up	to	6	hours	after	oral	administration	of	midazolam	in	preterm	neonates	the	
fraction	of	urinary	excreted	midazolam,	1-OHM	and	1-OHMG	was	median	(range)	0.11%	
(0.02–0.59%),	0.02%	(0.00–0.10%)	and	1.69%	(0.58–7.31%),	 ,	 respectively.34 Those data 




Urine Feces Total fraction of the 
administered dose 














1 20h 155 0.74 6.21 0.03 0.77
2 48h 124 0.74 31.5 0.19 0.93
3 48h 81 0.49 64.1 0.39 0.88












20h. A longer sampling time could have resulted in a higher recovery as the excretion 
may not yet have been complete. While the relative distribution of systemic exposure to 
metabolite	and	parent	drug	was	similar	in	the	three	youngest	age	groups,	the	absolute	
distribution	 was	 not	 similar.	 The	 sample	 size	 of	 this	 pilot/proof-of-concept	 study	 is	
too	 small,	 however,	 to	 draw	 conclusions	 about	 age-related	 changes	 in	 the	 absolute	
metabolite	profiles,	as	for	example	the	age	group	6	months-2	year	is	underrepresented	
with only one patient.
The	 introduction	 of	 MIST	 studies	 with	 [14C]microtracers	 in	 drug	 development	 has	
resulted	 in	 an	 improvement	 in	 drug	 development	 for	 adults,	 with	 earlier	 human	
metabolism studies increasing the safety as well as efficacy of drugs.16	 Finding	 a	
unique	human	metabolite	at	a	late	stage	in	drug	development,	that	had	not	at	all	or	at	
a	 disproportional	 level	 been	detected	 in	 animals	 during	non-clinical	 drug	 evaluation	
introduces	 safety	 and	 toxicity	 concerns,	 as	 human	 volunteers	 may	 be	 exposed	 to	
this metabolite whose characteristics are not known.17	 In	 addition,	 this	 may	 cause	
considerable delay in drug registration because addition of toxicological assessments 
might	be	required.	Current	regulatory	guidelines	for	drug	development	also	mandate	
scientists to submit a pediatric drug development program to the regulators.39 Although 
for	midazolam	no	unique	metabolite	was	found	in	children,	we	can	speculate	that	this	
may	not	be	true	for	other	drugs.	Thus,	conducting	a	MIST	study	with	a	[14C]microtracer	
is a potentially valuable addition to pediatric drug development that may secure drug 
safety	and	efficacy,	and	avoiding	delay	in	drug	registration.	Also,	MIST	studies	may	lead	
to a reduction in animal radiolabel studies.16	Currently,	juvenile	animals	are	often	used	
to predict drug disposition and metabolism in children. Besides the fact that findings in 
juvenile animals cannot be directly translated human children as they differ widely in 
terms of drug disposition40,	pediatric	MIST	studies	may	also	reduce	the	need	of	animal	
studies.	Subsequently,	metabolic	profiles	 in	other	vulnerable	populations	whose	drug	




approach in pediatrics. By simultaneous identification of metabolites and quantification 
of	 [14C]levels,	 we	were	 able	 to	 safely	 generate	metabolite	 profiles	 of	midazolam	 and	
study the routes of excretion in children. This approach is promising to improve safety 
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Table S1 Individual characteristics of patients included in the analysis
Subject Postnatal age 
(weeks)






1 1.7 3.1 M 178.4 55.95
2 3.7 4.1 M 257 80.6
3 3.6 4.7 M 308.4 96.71
4 1.3 4.3 F 264 82.79
5 9.2 5.4 M 301 94.39
6 14.2 6.6 M 368 115.4
7 14.1 6.0 M 385.5 120.89
8 12.1 4.2 F 257 80.6
9 22.9 5.8 M 360 112.9
10 100.7 10 F 580 181.89
11 209.3 15 M 870 272.83












distribution,	metabolism	and	excretion.	This	mandates	 the	need	 for	dosing	 regimens	
specifically	 tailored	 to	 children.	 Yet,	 there	 are	 gaps	 in	 the	 knowledge	 on	 these	
developmental	changes,	 for	example	 regarding	hepatic	and	 renal	drug	 transport	and	
cytochrome	P450	(CYP)3A	metabolism,	putting	children	at	risk	for	subtherapeutic	or	toxic	
drug exposure. Pediatric drug research is faced with ethical and analytical challenges. 
This thesis addresses these knowledge gaps and challenges by using innovative study 
designs.
Chapter 1 provides the background and aims of the studies presented in this thesis. 
It contains a general introduction to ontogeny of drug metabolism and transport and 
describes the current knowledge gaps.
Part I From literature research –
The	current	stage	of	knowledge	for	ontogeny	of	hepatic	transporters,	phase	1	and	phase	
2 metabolism is reviewed in Chapter 2.	 More	 specifically	 for	 transporters,	 Chapter 
3 shows our current knowledge on developmental changes in transporters in the 
liver,	 kidney	 and	 intestine	 in	 human.	 It	 also	 illustrates	 the	 utility	 of	 incorporating	 this	
information in predicting drug exposure of tazobactam in children. These reviews add 
to	understanding	the	age-related	changes	 in	transporter	expression,	but	also	revealed	
important	knowledge	gaps	and	challenges.	These	include,	but	are	not	limited	to,	the	fact	
that	non-hepatic	 transporter	expression	 in	newborns	 is	understudied,	 that	 the	clinical	
relevance	of	developmental	changes	in	transporter	expression	remain	unknown,	and	that	
practices in study designs and methods differ from lab to lab and should be harmonized.
Part II – to bench –
Developmental	 changes	 in	 mRNA	 and	 protein	 expression	 of	 hepatic	 and	 renal	
transporters are studied in Chapter 4 and Chapter 5. In Table 1 and Table 2,	 the	
developmental	 patterns	 are	 presented	 for	 liver	 and	 kidney	 respectively,	 showing	
transporter-	and	organ	dependent	rates	and	patterns	of	maturation.	Furthermore,	we	
found maturational differences between mRNA expression and protein expression as 
well	as	correlations	between	the	expression	levels	of	various	transporters.	For	hepatic	
transporters	 specifically,	 the	 impacts	 of	 single	 nucleotide	 polymorphisms	 (SNPs)	 on	
transporter	expression	were	studied,	but	no	genotype-protein	expression	relationship	
was	detected.	For	renal	tissue	we	found	that,	using	 immunohistochemistry,	 the	MRP4	
localization at the apical side of the proximal tubule in pediatric samples was similar to 
that in adult samples.
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One	of	 the	underlying	mechanisms	of	 age-related	 changes	 in	 transporter	 expression	
and/or	activity	may	be	by	developmentally	regulated	alternative	splicing.	The	hepatic	
influx	 transporter	 OATP1B1	 (gene	 name	 SLCO1B1)	 plays	 an	 important	 role	 in	 the	
disposition of endogenous substrates and drugs prescribed to children. In Chapter 6, 
alternative splicing of this transporter in pediatric liver tissue is studied. We found that 
two	splice	variants	code	 for	 reference	OATP1B1	protein,	and	eight	code	 for	 truncated	
proteins. The expression of eight isoforms was associated with age. It was concluded that 
alternative	splicing	of	SLCO1B1	occurs	frequently	 in	children.	Although	the	functional	
consequences	 remain	unknown,	 the	data	 raise	 the	possibility	of	 a	 regulatory	 role	 for	
alternative splicing in mediating developmental changes in drug disposition.
In	conclusion,	 these	 transporter-	and	organ	specific	maturation	patterns	suggest	 that	
hepatic and renal handling of substrates likely change with age.
Part III – to clinical research
Most drugs are administered to children orally; hence oral bioavailability is an important 
determinant	 for	 systemic	 exposure.	 CYP3A4	 is	 abundant	 in	 both	 the	 intestine	 and	
liver	 and	contributes	 to	 the	first-pass	metabolism	of	many	orally	 administered	drugs,	
including	 the	 well-validated	 CYP3A4	 probe	midazolam.	 Traditional	 study	 designs	 for	



















*  Determined in post-mortem hepatic tissue of fetuses (n=36), preterm newborns (n=12), term newborns 
(n=10), pediatrics (n=4) and adults (n=8)
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pediatric	 drug	 research	 are	 ethically	 and	practically	 challenging.	Using	 an	 innovative	
microdosing/microtracing	study	design	with	 [14C]labelled	substrates	overcomes	these	
challenges. In Chapter 7,	the	dose-linearity	of	the	PK	of	an	intravenous	[14C]midazolam	
microdose	 was	 studied	 in	 15	 infants	 (median	 gestational	 age	 39.4	 [range	 23.9-41.4]	
weeks,	 postnatal	 age	 11.4	 [0.6-49.1]	weeks).	 By	 comparing	 the	PK	of	 a	microtracer	 (a	
microdose	 given	 simultaneously	with	 a	 therapeutic	midazolam	dose),	with	 the	 PK	 of	
a	single	isolated	microdose,	dose-linearity	from	microdose	to	therapeutic	dose	can	be	
supported. Chapter 8	presents	the	results	of	a	[14C]midazolam	microtracer	population	
PK	 study	 aimed	 to	 determine	 the	bioavailability	 of	midazolam.	 In	 46	 stable,	 critically	
ill	 children	 (median	age	9.8	 [range	0.3	–	276.4]	weeks),	 the	 typical	oral	bioavailability	
varied	widely	with	a	median	of	66%	and	a	range	of	25-85%.	The	exposures	of	the	major	
metabolites	 1-OH-midazolam	 (OHM)	 and	1-OH-midazolam-glucuronide	 (OHMG)	were	
Table 2 Developmental	changes	in	renal	mRNA	and	protein	expression	(Chapter 5)
Transporter
gene/protein

















newborns than in childrenβ




newborns than in childrenβ





*  Determined in post-mortem renal tissue of term newborns (n=1), infants (n=30), children (n=16), adolescents 
(n=5) and adults (n=10);
α  Determined in post-mortem renal tissue of term newborns (n=11), infants (n=60), children (n=31), adolescents 
(n=10) and adults (n=10);
β  Determined in post-mortem renal tissue of preterm newborns (n=9), term newborns (n=19), infants (n=81), 
children (n=38), adolescents (n=10) and adults (n=27);
γ  Determined in post-mortem renal tissue of preterm newborns (n=9), term newborns (n=8), infants (n=21), 
children (n=7) and adults (n=17); TM50: age at which half of the adult value is reached
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also studied to give further insight in the ontogeny of glucuronidation and kidney 
function	involved	in	the	metabolism	to	OHM	and	OHMG,	respectively.	OHM	and	OHMG	





Due	 to	developmental	 changes	 in	drug	metabolism,	metabolic	profiles	of	a	drug	can	
change.	 Metabolite	 in	 safety	 testing	 (MIST)	 studies	 using	 [14C]microtracers	 are	 used	
to	 create	 metabolite	 profiles	 and	 study	 the	 routes	 of	 excretion,	 but	 had	 not	 been	
conducted before in children. Chapter 9	presents	the	first	pediatric	MIST	study.	Using	
a	 [14C]midazolam	microtracer	 approach	 as	 a	 sub-study	 of	 chapter	 8,	we	 showed	 that	
it is feasible and safe to generate metabolite profiles and study recovery in children. 
This	approach	 is	promising	 for	first-in-child	studies	 in	drug	development	to	delineate	
age-related	variation	in	drug	metabolite	profiles.
Part IV General discussion
In Chapter 10	we	discuss	our	main	findings,	compare	them	with	current	literature	and	
provide recommendations for future research to further improve pediatric drug therapy.




•	 Ex vivo transporter data should be validated by e.g. in vivo pharmacokinetic data
•	 Practices	for	proteomic	studies	need	to	be	harmonized
•	 Pediatric	[14C]microtracer	and	MIST	studies	are	an	interesting	opportunity	to	increase	
efficacy and safety in pediatric drug development and for drugs already used in 
clinical practice
•	 The	intestinal	and	hepatic	intrinsic	CYP3A-mediated	clearance	of	midazolam	should	
be studied using the data generated in this thesis
•	 It	 should	be	 studied	whether	 the	midazolam-data	presented	 in	 this	 thesis	 can	be	
extrapolated	to	other	CYP3A-substrates
These recommendations are supplemented with the following more general 
recommendations	 on	 future	 studies/approaches	 and	 on	 how	 to	 use	 our	 current	







•	 Physiologically	 based	 PK	 (PBPK)	modeling	 helps	 us	 understand	 drug	metabolism	
and	transport	pathways,	and	the	impact	of	a	change	in	a	certain	pathway
•	 As	knowledge	gaps	on	ontogeny	remain,	routine	use	of	PBPK	modeling	in	prediction	
of pediatric drug disposition should be done carefully until these knowledge gaps 
are filled
•	 Integrating	population	PK	and	PBPK	models	in	clinical	practice	can	be	accelerated	by	
creating electronic systems to use complex dosing regimens in clinical care parallel 





De	 dispositie	 van	 een	 geneesmiddel	 wordt	 beïnvloed	 door	 leeftijdsafhankelijke	
veranderingen	 in	 de	 absorptie,	 verdeling,	 metabolisme	 en	 excretie	 van	 het	
geneesmiddel.	 Daarom	 dienen	 doseringsschema’s	 voor	 kinderen	 op	 maat	 te	
zijn	 gemaakt.	 Echter,	 er	 zijn	 hiaten	 in	 onze	 kennis	 over	 de	 leeftijdsafhankelijke	
veranderingen van onder andere geneesmiddeltransport in de lever en de nieren en 
geneesmiddelmetabolisme	door	cytochroom	P450	(CYP)3A.	Hierdoor	hebben	kinderen	
een grote kans op subtherapeutische of toxische blootstelling aan geneesmiddelen. 
Geneesmiddelonderzoek	 bij	 kinderen	wordt	 bemoeilijkt	 door	 ethische	 en	 praktische	
uitdagingen. Met behulp van innovatieve onderzoeksmethoden hebben we 
onderzocht welke de leeftijdsafhankelijke veranderingen in geneesmiddeltransport en 
geneesmiddelmetabolisme zijn
Hoofdstuk 1 beschrijft de achtergrond en de doelen van de diverse onderzoeken. Er 
wordt een introductie gegeven over de ontogenie van geneesmiddelmetabolisme en 
-transport,	en	een	beschrijving	van	de	huidige	hiaten	in	onze	kennis.
Deel I Van literatuur –
Door	middel	van	literatuuronderzoek	is	 in	hoofdstuk 2 de huidige kennis beschreven over 
de	ontogenie	van	hepatische	transporters,	fase	1	en	fase	2	metabolisme.	Hoofdstuk 3 geeft 
een	overzicht	van	de	leeftijdsafhankelijke	veranderingen	in	transporters	in	de	lever,	nieren	en	
darmen in de mens. Ook is er een casus opgenomen waarin informatie over ontogenie van 
transporters is gebruikt om blootstelling van het geneesmiddel tazobactam in kinderen te 
voorspellen.	Deze	twee	hoofdstukken	dragen	bij	aan	het	begrijpen	van	leeftijdsafhankelijke	
veranderingen in transporterexpressie. Het literatuuronderzoek heeft belangrijke hiaten 
en	uitdagingen	 in	onze	huidige	kennis	geïdentificeerd.	Dit	omvat	onder	andere	dat	extra-
hepatische	 transporterexpressie	 in	 pasgeborenen	nog	niet	 voldoende	 is	 opgehelderd,	 dat	
de klinische relevantie van leeftijdsafhankelijke veranderingen in transporterexpressie nog 
onduidelijk	 blijft,	 en	 dat	 er	 tussen	 laboratoria	 grote	 verschillen	 zijn	 in	 studieopzetten	 en	
methoden.
Deel II – tot het lab –
Leeftijdsafhankelijke	 veranderingen	 in	 mRNA	 en	 eiwit	 expressie	 van	 transporters	 in	 de	
lever en nieren zijn onderzocht in hoofdstuk 4 en hoofdstuk 5. In Tabel 1 en Tabel 2 zijn 
de	 maturatiepatronen	 terug	 te	 vinden	 voor	 respectievelijk	 de	 lever	 en	 de	 nieren.	 Deze	
patronen	 zijn	 zowel	 transporter-	 als	 orgaanafhankelijk.	 Daarnaast	 hebben	we	 verschillen	
in	 maturatie	 gevonden	 tussen	 mRNA-expressie	 en	 eiwitexpressie,	 maar	 ook	 verbanden	





Eén onderliggend mechanisme van leeftijdsafhankelijke veranderingen in transporter 
expressie	en/of	activiteit	zou	kunnen	zijn	dat	alternative splicing wordt gereguleerd door 
groei	en	ontwikkeling.	De	levertransporter	OATP1B1	(gen	naam	SLCO1B1) is belangrijk in 
de dispositie van endogene substraten en geneesmiddelen die voor kinderen worden 
voorgeschreven. In hoofdstuk 6 is alternative splicing	 van	 SLCO1B1	 onderzocht	 in	
leverweefsel van kinderen. We vonden dat twee splice variants coderen voor de gehele 
OATP1B1	transporter,	en	dat	er	acht	coderen	voor	kortere	eiwitten.	De	expressie	van	acht	
splice variants was geassocieerd met leeftijd. We hebben geconcludeerd dat alternative 
splicing	van	SLCO1B1	vaak	voorkomt	in	kinderen;	we	weten	nog	niet	wat	de	functionele	
consequenties	hiervan	zijn,	maar	stellen	dat	alternative splicing wellicht bijdraagt aan 
leeftijdsgerelateerde veranderingen in geneesmiddeldispositie.
Concluderend,	deze	transporter-	en	orgaanafhankelijke	maturatiepatronen	suggereren	
dat de verwerking van substraten in de lever en de nieren kan veranderen met leeftijd.














vroeg geboren neonaten dan bij volwassenen.




*  Bepaald in post-mortem leverweefsel van foetussen (n=36), te vroeg geboren neonaten (n=12), a terme 
neonaten (n=10), kinderen (n=4) en volwassenen (n=8)
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Deel III – tot klinisch onderzoek
De	meeste	geneesmiddelen	worden	oraal	toegediend	aan	kinderen.	Orale	biologische	
beschikbaarheid	 is	 daarom	 belangrijk	 voor	 de	 systemische	 blootstelling.	 CYP3A	 is	
aanwezig	in	de	darmen	en	lever	en	draagt	significant	bij	aan	het	first-pass	metabolisme	
van	veel	orale	geneesmiddelen,	waaronder	de	gevalideerde	CYP3A-marker	midazolam.	
Geneesmiddelonderzoek	 bij	 kinderen	 kent	 ethische	 en	 praktische	 uitdagingen.	 Deze	
uitdagingen	kunnen	overwonnen	worden	via	een	innovatieve	microdosing/microtracing	
studieopzet	met	een	[14C]gelabelde	substraat.	In	hoofdstuk 7	is	de	dosis-lineariteit	van	
de	PK	van	een	 intraveneuze	 [14C]midazolam	microdosis	bestudeerd	 in	15	zuigelingen	
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lager bij a terme neonaten dan bij 
kinderenβ




lager bij a terme neonaten dan bij 
kinderenβ






*  Bepaald in post-mortem nierweefsel van a terme neonaten (n=1), zuigelingen (n=30), kinderen (n=16), 
adolescenten (n=5) en volwassenen (n=10);
α  Bepaald in post-mortem nierweefsel van a terme neonaten (n=11), zuigelingen (n=60), kinderen (n=31), 
adolescenten (n=10) en volwassenen (n=10);
β  Bepaald in post-mortem nierweefsel van te vroeg geboren neonaten (n=9), a terme neonaten (n=19), 
zuigelingen (n=81), kinderen (n=38), adolescenten (n=10) en volwassenen (n=27);
γ  Bepaald in post-mortem nierweefsel van te vroeg geboren neonaten (n=9), a terme neonaten (n=8), zuigelingen 
(n=21), kinderen (n=7) en volwassenen (n=17); TM50: leeftijd waarop de helft van de volwassenhoeveelheid is 
bereikt.
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(mediaan	 zwangerschapsduur	 39.4	 [range	 23.9-41.4]	 weeks,	 postnatale	 leeftijd	 11.4	
[0.6-49.1]	 weken).	 De	 PK	 van	 een	 microtracer	 (een	 microdosis	 tegelijk	 gegeven	 met	
een	therapeutische	midazolam	dosis)	werd	vergeleken	met	de	PK	van	een	eenmalige	
geïsoleerde	microdosis;	het	resultaat	van	de	studie	lijkt	het	bestaan	van	dosis-lineariteit	
bij kinderen te ondersteunen. Hoofdstuk 8	 presenteert	 de	 resultaten	 van	 een	 [14C]
midazolam	 microtracer	 populatie	 PK	 studie	 die	 als	 doel	 had	 de	 orale	 biologische	
beschikbaarheid	van	midazolam	te	bepalen.	In	46	stabiel	kritisch	zieke	jonge	kinderen	
(mediaan	 leeftijd	 9.8	 [spreiding	 0.3	 –	 276.4]	weeks)	was	 er	 een	grote	 spreiding	 in	 de	






met	 stijgende	 leeftijd.	 Dit	 is	 hoogstwaarschijnlijk	 een	 gecombineerd	 resultaat	 van	
ontogenie	van	CYP3A,	glucuronidering	en	nierfunctie.	De	grote	 spreiding	 in	de	orale	
biologische beschikbaarheid van midazolam maakt de systemische blootstelling aan 
CYP3A-substraten	en	de	metabolieten	na	orale	 toediening	onvoorspelbaar,	met	risico	
op falen van geneesmiddeltherapie of op toxiciteit.
Door	 leeftijdsafhankelijke	 veranderingen	 in	 geneesmiddelmetabolisme,	 zoals	 in	
CYP3A4,	 kunnen	 metabolietprofielen	 van	 een	 geneesmiddel	 veranderen.	 Metabolite 
in safety testing	 (MIST)	 studies	 met	 [14C]microtracers	 kunnen	 gebruikt	 worden	 om	
metabolietprofielen	te	maken	en	de	routes	van	excretie	 te	bestuderen,	maar	zijn	niet	
eerder uitgevoerd bij kinderen. Hoofdstuk 9 laat de eerste MIST studie in kinderen 
zien.	 Door	 toepassing	 van	 een	 [14C]midazolam	microtracer	 konden	we	 aantonen	 dat	
het haalbaar en veilig is om metabolietprofielen te genereren en na te gaan hoeveel 
er	van	de	dosis	terug	te	vinden	is	in	urine	en	feces.	Deze	aanpak	is	veelbelovend	voor	
first-in-child studies.
Deel IV Algemene discussie
In hoofdstuk 10	bespreken	we	onze	belangrijkste	bevindingen,	vergelijken	deze	met	
de huidige literatuur en doen de volgende aanbevelingen om farmacotherapie bij 
kinderen verder te optimaliseren.
Specifiek	voor	de	onderzoeksmethoden	en	de	data	verkregen	in	dit	proefschrift,	bevelen	
we het volgende aan:
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•	 De	 invloed	 van	 andere	 potentiele	 covariaten	 op	 de	 transporterexpressie	 moet	
bestudeerd	 worden,	 zoals	 het	 gebruik	 van	 co-medicatie,	 het	 optreden	 van	
ontsteking,	en	genotype
•	 Ex vivo transporter data moet gevalideerd worden met behulp van bijvoorbeeld in 
vivo farmacokinetiek data
•	 De	huidige	aanpak	voor	proteomic studies moet geharmoniseerd worden
•	 	 [14C]microtracer	 en	MIST	 studies	 bij	 kinderen	 zijn	 een	 interessante	mogelijkheid	
om effectiviteit en veiligheid in de geneesmiddelontwikkeling en huidige 
farmacotherapie voor kinderen te verbeteren
•	 De	 intrinsieke	CYP3A-gemedieerde	 klaring	 van	midazolam	 in	de	darmen	en	 lever	





worden in de klinische praktijk:
•	 Internationale	biobanken,	samenwerkingsverbanden,	platforms	voor	het	delen	van	
data,	 en	netwerken/infrastructuren	 voor	 klinische	onderzoek	bij	 kinderen	 kunnen	
geneesmiddelonderzoek bij kinderen helpen versnellen
•	 Studies	met	exosomen,	organoïden,	endogene	substraten	en	metabolomics kunnen 
een belangrijke bijdrage leveren aan het valideren van transporter ontogenie
•	 Physiologically based PK	(PBPK)	modelleren	helpt	ons	om	geneesmiddelmetabolisme	
en	-transport	te	begrijpen,	evenals	de	impact	van	een	verandering	in	deze	processen
•	 Totdat	de	hiaten	in	de	kennis	over	ontogenie	zijn	weggenomen,	moet	men	voorzichtig	
zijn	 met	 routinegebruik	 van	 PBPK	 modelleren	 om	 geneesmiddelblootstelling	 in	
kinderen te voorspellen
•	 Populatie	 PK	 en	 PBPK	 modellen	 kunnen	 in	 de	 klinische	 praktijk	 sneller	 worden	
geïntegreerd	 door	 het	 ontwikkelen	 van	 elektronische	 systemen	 die	 complexe	
doseringsschema’s	kunnen	integreren.	Deze	systemen	kunnen	dan	parallel	aan	het	
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MeSH Medical Subject Headings
MIDD	 Model	informed	drug	development






























PREA Pediatric Research Equity Act
PRISM Pediatric Risk of Mortality
PXR	 Pregnane	X	Receptor
qRT-PCR	 Quantitative	Reverse	Transcription	Polymerase	Chain	Reaction















TM50	 The age at which half of adult level is reached
Tmax Time at maximum concentration
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met velen heb ik als zeer waardevol ervaren; zonder deze samenwerkingen had dit 
proefschrift niet tot stand kunnen komen. Naast dat ik het grootste gedeelte van mijn 
tijd	 als	 PhD-student	 in	 het	 Erasmus	MC-Sophia	 (Rotterdam)	 ben	 geweest,	 heb	 ik	 de	
kans	gehad	om	een	aantal	maanden	door	te	brengen	in	het	Children’s	Mercy	Hospital	
(Kansas	City,	MO,	USA),	 LACDR	 (Leiden)	en	Radboudumc	 (Nijmegen).	Ofwel;	 een	hele	
hoop mensen hebben bijgedragen aan dit proefschrift of aan mijn tijd als promovenda. 
En die wil ik graag allemaal bedanken!
Allereerst heel veel dank aan de patiënten en ouders die aan de PedMic studie hebben 
meegedaan,	ondanks	de	onzekere	tijden	tijdens	opname	op	de	Intensive	Care	Kinderen	
(ICK).	Het	vertrouwen	en	de	bereidheid	om	belangeloos	bij	te	dragen	aan	verbetering	
van geneesmiddeltherapie bij kinderen is bewonderenswaardig. Ook alle medewerkers 
van	de	ICK	wil	ik	bedanken	voor	hun	inzet	bij	het	uitvoeren	van	de	PedMic	studie.
Beste	prof.dr.	Tibboel,	beste	Dick,	dank	voor	uw	waardevolle	begeleiding	de	afgelopen	
jaren.	 Uw	 bijzondere	 gave	 om	 het	 hoofddoel	 van	 een	 project	 of	 een	 paper	 niet	 uit	
het	oog	te	verliezen,	heeft	een	hoop	pagina’s	tekst	voor	dit	proefschrift	bespaard.	Uw	
gedrevenheid voor onderzoek heb ik erg gewaardeerd. Ik hoop dan ook dat u nog mooi 
onderzoek kunt blijven doen; zowel in de kindergeneeskunde als wellicht nog een 
zijstap richting de geschiedenis van geneeskunde of zelfs in de kunst.
Lieve	 prof.dr.	 de	 Wildt,	 lieve	 Saskia,	 wat	 mag	 ik	 in	 mijn	 handjes	 knijpen	 met	 een	
begeleider	 zoals	 jij.	 Je	 hebt	 met	 ongelooflijk	 veel	 geleerd	 op	 gebied	 van	 het	 doen	
van	 onderzoek,	 klinische	 farmacologie,	 kindergeneeskunde	 en	 CV	 building.	 Het	 was	
even	schrikken	dat	je	vrij	snel	na	mijn	start	naar	het	Nijmeegse	vertrok,	maar	dit	heeft	




mooie garderobe als jij te mogen bezitten. En je moet me toch echt nog eens uitleggen 
hoe die Harry Potter koffer van je werkt;)
Beste	prof.dr.	Allegaert,	beste	Karel,	 ik	kan	mij	blijven	verbazen	over	je	enorme	parate	
kennis	die	je	met	een	snufje	Vlaamse	humor	op	een	onvergetelijke	wijze	weet	over	te	
brengen. Ook de snelheid waarmee je stukken voorziet van kritisch commentaar is 
indrukwekkend.	Wat	 ik	erg	gewaardeerd	heb,	 is	dat	 je	deur	heeft	altijd	open	gestaan	
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voor	overleg	ondanks	je	overvolle	agenda;	of	het	nou	ging	over	mijn	promotietraject,	







en dr. Evita van de Steeg. Maar liefst de helft van de manuscripten in dit proefschrift zijn 
door deze samenwerking tot stand gekomen. Het gaf mij altijd veel energie om langs te 
komen	in	Zeist	of	met	elkaar	te	brainstormen	op	congressen	over	hoe	we	de	pediatrische	
microdosing kunnen integreren in de huidige praktijk. Hopelijk hebben we nu genoeg 
bewijs	geleverd	dat	het	 veilig	 en	 zinvol	 is	 om	pediatrische	microdosing/MIST	 studies	
te	doen!	Our	colleagues	at	UCSF;	prof.dr.	Giacomini,	thank	you	so	much	for	giving	me	
the	opportunity	to	collaborate	with	you	and	Kathy.	Your	drive	to	work	together	rather	
than	to	compete	 is	very	 inspiring.	Dear	Kathy,	you	have	been	my	partner	 in	crime	for	
exploring career options. I am so happy that we are (sort of ) direct colleagues now that 
you	work	at	Genentech	and	 I	work	at	Roche.	Please	promise	me	 to	 stay	 loyal	 to	your	
Sunday funday! The HESI consortium; we never thought that this manuscript would end 






in	words	what	an	 incredible	mentor	you	are.	You	have	 taught	me	to	 take	 the	 time	 to	
think	about	and	interpret	data,	and	to	see	opportunities	in	literally	everything	without	
losing the clinical relevance out of sight. Once again thank you for travelling all the 
way	 to	 the	 Netherlands	 to	 be	 part	 of	 my	 PhD-committee.	 Charlie,	 our	 collaboration	
was the perfect example of two people with an entirely different background being 
complimentary to make a project work. Thank you for supervising me and teaching 
me	all	 the	bio-informatic	knowledge.	Dear	 Jean	and	Chelsea,	you	have	made	me	 feel	
like	home	 in	Kansas	City.	Thank	 you	 for	 taking	me	out	 to	 lunch,	 inviting	me	over	 for	




you for picking me up to go to the hospital and introducing me to your neighborhood. 
Also,	thanks	for	warning	to	not	go	to	Save a Lot	after	8pm,	which	has	probably	saved	me	
a	lot,	e.g.	my	life;)
Heb je het over modelling and simulation van	 pediatrische	 PK	 data	 dan	 kun	 je	 niet	
anders	 dan	 aan	 de	 onderzoeksgroep	 van	 prof.dr.	 Catherijne	 Knibbe	 denken!	 Grote	
dank aan de gehele groep voor de hulp en gezelligheid tijdens mijn uitwisseling. Beste 
Catherijne,	 ik	 ben	 erg	 dankbaar	 dat	 ik	 heb	mogen	 leren	modelleren	 in	 jouw	 groep.	
Bedankt voor je begeleiding van en het brainstormen over de microdosing data. Het is 
bewonderenswaardig	hoe	jij	de	tijd	neemt	elk	project	tot	een	goed	einde	te	brengen,	
ondanks	je	drukke	agenda	als	professor	en	ziekenhuisapotheker.	Lieve	Elke,	van	jou	heb	
ik het echte modelleren geleerd op technisch vlak maar nog meer over hoe de data 
geïnterpreteerd	kan	worden.	Zat	ik	al	een	week	te	ploeteren	op	een	fout	in	het	model,	
wist jij het in één oogopslag op te lossen. Je betrokkenheid op zowel inhoudelijk als 
persoonlijk	 vlak	 zullen	mij	 altijd	 bij	 blijven.	 Jantine,	midazolam	en	 kids;	 daar	weet	 jij	
meer	dan	genoeg	vanaf!	Dank	voor	je	hulp	vanuit	Zwitserland.	Dear	Danica,	we	started	
around	 the	 same	 time	 with	 our	 ‘modelling-career’	 and	 shared	 the	 fun	 but	 also	 the	
frustration on learning to work with the complex software. Thank you so much for all the 
good	talks,	you	have	made	my	Leiden-time	unforgettable!	Sinzi,	thank	you	for	teaching	
me how to perform dose simulations. I am sure we will run into each other in the drug 
development world.
Lieve	 Joke,	 al	meerdere	 keren	heb	 ik	 verzucht	wat	 ik	 toch	 zonder	 jou	had	gemoeten	
afgelopen	jaren.	Je	hebt	me	het	reilen	en	zeilen	van	klinisch	onderzoek	laten	zien,	stond	
altijd	klaar	met	een	kop	koffie	en	een	luisterend	oor,	en	hebt	me	laten	gieren	van	het	





verliezen in data en programma’s maar een overzichtelijk eindproduct weet te creëren. 
Blijf vooral je creatieve brein gebruiken!
Mijn	 medepromovendi	 uit	 Erasmus	 MC	 hebben	 de	 afgelopen	 4	 jaar	 onvergetelijk	
gemaakt.	 Lieve	 Annelieke,	 we	 begonnen	 als	 de	 twee	 dwarrels	 in	 het	 feutenhoekje.	
Ondertussen ben jij getrouwd én gepromoveerd en zijn we toch echt volwassen! 
Lieve	Tanja,	 àltijd	bereid	om	 te	helpen,	 koffie	 te	drinken	of	 te	borrelen.	Brisbane	was	
fantastisch!	 Lieve	 Shelley,	 het	 laatste	 half	 jaar	 hebben	we	 veel	 frustraties	 gedeeld.	 Er	
komt	echt	een	einde	aan	en	dan	kan	je	weer	lekker	fulltime	de	kliniek	in.	Manuel,	wat	
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een	eer	dat	 ik	 je	paranimf	heb	mogen	zijn.	 Jammer	dat	onze	Nijmegen-tijd	net	 langs	
elkaar	liep	maar	hopelijk	heb	je	je	plekje	daar	gevonden.	Frank	en	Willem,	bedankt	voor	
alle gezellige borrels. Ben erg benieuwd waar jullie over een aantal jaar terecht gaan 
komen!	Norani,	altijd	 in	voor	gezelligheid,	succes	met	 je	1000	projecten!	Chantal,	wat	
een	harde	werker	ben	 je	 toch	met	het	combineren	van	onderzoek	en	kliniek.	Renate,	
eindelijk	 komt	 je	 terug	 op	 de	 kamer	 en	 nu	 ben	 ik	 weg!:(	 Miriam,	 bedankt	 dat	 je	 je	
projecten vol vertrouwen aan me over hebt gedragen. Wie weet kunnen we nog eens 













wat een drive hebben jullie voor onderzoek! Jullie zijn ontzettend goede mentors. 
Bedankt voor alle inspirerende en motiverende gesprekken over o.a. carrièrekeuzes. 
Mijn	mede-klinisch	 farmacologen	 i.o.:	Rixt,	 zo	 leuk	om	Brisbane	met	 je	 te	ontdekken;	
Sanne,	jij	als	arts	in	de	apotheek	en	ik	als	apotheker	in	de	kliniek!	Je	wordt	ongetwijfeld	
een	fantastische	kinderpsychiater;	Laura	en	Fleur,	het	was	 leuk	om	op	de	valreep	nog	
een	 ACE	 pharmacology	 &	 therapeutics	 symposium	 met	 jullie	 te	 organiseren;	 Paola,	
hopelijk	heb	je	het	naar	je	zin	als	AIOS	ziekenhuisfarmacie	in	het	oosten!;	Florine,	wat	















wist te vinden om afspraken met haar in te plannen.












Noor,	 ruim	 10	 jaar	 geleden	 is	 onze	 vriendschap	 ontstaan	 in	Utrecht.	 In	 de	 tussentijd	
hebben	 wij	 beiden	 veel	 tijd	 in	 het	 buitenland	 doorgebracht,	 wat	 onze	 vriendschap	
alleen maar hechter heeft gemaakt. Ook al zijn we totaal verschillend; we begrijpen 
elkaar en kunnen daardoor uren praten over alles wat in de wereld en in ons eigen leven 





we elkaar niet laten uitpraten en alles aan elkaar kwijt kunnen. Hopelijk kom je ècht op 
den	duur	in	Zwitserland	wonen	zodat	we	samen	de	bergen	kunnen	ontdekken!
Lieve	pap	en	mam,	ik	weet	niet	waar	ik	moet	beginnen	met	jullie	bedanken.	Jullie	zijn	




in	Frankrijk	en	 jouw	onvoorwaardelijke	 loyaliteit	 aan	o.a.	de	brandweer	 is	ontzettend	
bijzonder.	 Hopelijk	 kun	 je	 binnenkort	 settelen	 boven	 op	de	 berg!	 Anne-lyke,	 jij	 staat	
altijd	 klaar	 om	 te	 helpen.	 Jongste	 zusje	maar	 als	 eerste	 een	 huis	 gekocht,	 wat	 jullie	
314 Dankwoord
prachtig	hebben	opgeknapt.	Geniet	van	de	ruimte	om	je	heen!	Lieve	Tony	en	Monika,	
bedankt voor alle weekenden die we bij jullie hebben doorgebracht. Ik kan me geen 
fijnere schoonfamilie wensen!
Lieve	Rikkert,	mijn	rots	in	de	branding.	Wat	zal	jij	blij	zijn	als	er	PhD	achter	mijn	naam	
staat en dit traject eindelijk is afgerond! Met jouw positieve en optimistische kijk heb 
jij me afgelopen jaren met beiden benen op de grond gehouden. Ik weet dat dit niet 
altijd	makkelijk	was,	maar	hier	ben	ik	je	wel	eeuwig	dankbaar	voor!	We	hebben	al	zoveel	
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